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SNP  - Single Nucleotide Polymorphism 
SPSS  - Statistical Package for Social Sciences 
STG  - Superior Temporal Gyrus 
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TEMPS-A - Temperament Evaluation of the Memphis, Pisa, Paris and San-Diego- 
   Autoquestionnaire 
T/L  - Translocation 
WAIS  - Wechsler Adult Intelligence Scale 
WASI  - Wechsler Abbreviated Scale of Intelligence 
WCST  - Wisconsin Card Sorting Task 
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Organisation of Thesis 
 
 
This thesis examines a large multiply affected family with the strongest known genetic risk 
factor for psychosis, to compare the cognitive profiles in those with and without the risk factor, 
as well as in those with the risk factor, with and without psychoses.  Similar comparisons were 
made between individuals with schizophrenia and individuals with bipolar disorder as well as 
a control group of healthy participants.  Neuropsychological measures were then related to 
symptom severity and polygenic risk profile scores.  Recruiting individuals with schizophrenia 
and bipolar disorder also provided a positive control group to enable the comparison of results 
from the DISC1 t(1;11) kindred in addition to establishing any differences between the two 
conditions. 
 
As direct comparisons between the DISC1 t(1;11) kindred and the combined patients group 
were not warranted due to confounders such as shared heredity and environmental factors, this 
thesis has been structured in two parts.  Firstly to investigate how the cognitive profiles differ 
between those with and without the known genetic risk factor - DISC1 t(1;11) translocation – 
and how they differ from healthy controls and patients with psychiatric illness (of similar 
severity) without the genetic risk factor, and secondly to examine how the cognitive profiles 
differ between those with schizophrenia and bipolar disorder. 
 
Chapter 1 provides a brief overview of the major non-organic psychiatric disorders, i.e. 
schizophrenia, bipolar disorder and major depressive disorder.  This chapter also provides 
information on diagnosis, epidemiology, course of illness, family and genetics, and cognition.  
A narrative summary of the neuropsychology of DISC1 in humans forms Chapter 2 and 
describes the research findings to date for associations between the DISC1 gene and measures 
of cognition.   
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Findings to date support the current dominant neurodevelopmental hypothesis and question 
why the DISC1 t(1;11) translocation is of interest, what we know so far and what is not there. 
 
The data for this thesis was collected as part of a larger multi-modal imaging study - The 
Scottish Family Mental Health Study (SFMHS) - which formed the third major follow-up of 
this unique family. The history and background of the previous two follow up studies, together 
with details of the original Scottish pedigree are provided in Chapter 1.  The SFMH study 
provided the first opportunity to investigate the rare DISC1 t(1;11) translocation with brain 
structure, function and chemistry, particularly glutamate.  My primary role in the SFMH study 
was to recruit members of the DISC1 t(1;11) kindred, together with patients and control 
participants; arrange for participants to undertake a multi-modal MRI scan, provide a blood 
sample and undertake a full clinical interview.  As the effect (if any) of the rare DISC1 t(1;11) 
translocation on cognition has not been fully investigated, I conducted a full 
neuropsychological test battery which provided the initial data for this thesis. 
 
As all participants were recruited as part of the wider SFMH study, all five groups (DISC1 
t(1;11) carriers, DISC1 t(1;11) non-carriers, individuals with schizophrenia, individuals with 
bipolar disorder and healthy control participants) followed the same protocol and procedure, 
therefore methodology covering recruitment, assessments and procedure, aims, hypotheses and 
analysis are detailed in one chapter (Chapter 3), however there are two separate results chapters.  
Chapter 4 provides results for DISC1 t(1;11) carriers and non-carriers and Chapter 5 provides 
results for the patient samples and healthy control participants. 
 
A synthesis summarising the aims and overall results of this thesis, together with suggested 
directions for future work, limitations of the study and final conclusions are provided in 
Chapter 6. 






Deficits in a number of cognitive domains have been associated with core symptoms of 
schizophrenia, including working memory, attention, motor skills, reaction time, episodic 
memory and executive function. Bipolar Disorder is also associated with cognitive impairment; 
however the level of impairment appears to be less severe than that seen in schizophrenia. 
 
A translocation (t(1;11)) containing the Disrupted-in-Schizophrenia 1 (DISC1) gene has been 
found to be highly associated with schizophrenia, bipolar disorder and major depressive 
disorder. As such, this gene has been the focus of much research and to date DISC1 has been 
found to be associated with brain development, brain structure and the glutamate system - all 
key factors in current models of schizophrenia and affective disorders. 
 
The aim of this PhD is to identify cognitive domains that are differentially impaired or 
unimpaired in a large Scottish family, some of whom carry this rare DISC1 variant, a balanced 
translocation (t (1;11) (q 42; q14.3)), that segregates with schizophrenia and affective disorders, 
as well as psychiatric patients with schizophrenia and bipolar disorder and healthy control 
subjects. 
 
All participants have undergone standardised cognitive assessments to measure premorbid I.Q. 
(NART), current I.Q. (WASI) verbal memory, working memory, verbal fluency, processing 
speed, motor skills, executive function (BACS) and selected CANTAB tasks to assess simple 
and five-choice reaction time. Polygenic risk profile scores and self-report questionnaire data 
have also been investigated. 
 
Results indicate an impact of the DISC1 t(1;11) translocation on general intelligence and 
attention and processing speed.   
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Significant differences were also identified between DISC1 t(1;11) carriers and non-carriers on 
self-report questionnaire data. Mean scores for polygenic risk for bipolar disorder were 
significantly different between DISC1 t(1;11) carriers and non-carriers and polygenic risk for 
schizophrenia was significantly associated with symptom severity, as measured by the Positive 
and Negative Symptom Scale (PANSS). 
 
Within the patient groups, a measure of processing speed (the token motor task) was found to 
be significantly different between those with schizophrenia and bipolar disorder and there was 
also a trend for attention and processing speed. As expected, I.Q. was significantly different 
between patients and control participants. Clinical ratings were significantly associated with 
neuropsychological and self-report measures.  Polygenic risk for major depressive disorder was 
found to be significantly associated with impaired general intelligence (current IQ) and slowed 
reaction time in patients who were not currently depressed, suggesting there may be genetic 
risk markers in this population which impact on cognition.  This is a novel finding and further 
suggests the possibility of a biological component related to the genetics of depression. 
 
In conclusion, and in line with the literature, psychosis has a negative impact on cognition with 
reduced performance across several neuropsychological tasks between patient groups, with 
schizophrenia patients performing worse than patients with bipolar disorder and both patient 
groups performing worse than healthy control participants. Cognition is markedly more 
impaired in DISC1 t(1;11) translocation carriers and especially in those with psychosis. The 
DISC1 t(1;11) translocation and psychosis may therefore confer a “double hit” on cognition - 
in addition to psychosis itself - which is known to impair cognitive function, significantly 
increasing the level of cognitive impairment and increasing the risk for psychosis in general. 
 






Cognition is essential for making sense of and understanding the world around us.  It includes 
thinking, learning, understanding and remembering.  These abilities help people to perform and 
enjoy their daily routines, develop employment skills, socialise, be motivated to set and achieve 
goals, enjoy sports and/or other hobbies etc.  If these abilities are damaged however, it can 
often have a devastating impact, and in the case of schizophrenia, and to a lesser extent, bipolar 
disorder, activities which are taken for granted by most, can become difficult if not impossible.  
In the most severe cases, it can even determine people’s living status, occupation and social 
abilities.  Understanding more about the reasons why cognition becomes impaired in mental 
illness and being able to improve it would lead to much better outcomes and quality of life for 
people who suffer from these disorders.  It is hoped it would also go some way to addressing 
important humanitarian and public health concerns. 
 
This thesis has two parts – firstly it investigated cognition in people who have a higher than 
usual risk of developing a major mental illness due to a big difference in their genetic make-
up.  This difference is very rare but important to study, as it may tell us more about how 
problems with thinking and memory differ between people with and without this genetic 
difference, and about how these problems develop.  This thesis also found that the genetic 
difference does impact on general intelligence and on attention and processing speed, and that 
this difference points to the problems being developmental in nature.  People with the genetic 
difference were also found to have a higher polygenic risk (lots of genes each with a very small 
effect, but a much larger effect together) of developing a major mental illness such as 
schizophrenia, bipolar disorder and/or major depression and this is something that can be 
investigated in more detail in the future. 
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The second part of this thesis investigated cognition in people with schizophrenia and people 
with bipolar disorder, as well as in people who have no history of mental ill-health.  This 
allowed the results from the first group with the genetic difference to be compared with the 
results from people with a psychiatric illness in general, to find out if there were differences 
that could be caused by differences in their genetic make-up.  It found a difference in motor 
speed between people with schizophrenia and people with bipolar disorder and a group 
difference was identified in the people with the genetic risk that wasn’t found in the people 
with psychiatric illness in general, pointing to an effect of their genetic make-up.  As before, 
polygenic risk was again found to be related to a number of cognitive abilities in these groups 
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The name ‘schizophrenia’ was coined 100 years ago by Eugen Bleuler, originating from the 
Greek ‘schizein’ – meaning ‘to split’ and ‘phren’, meaning ‘mind’ (Kuhn, 2004).  Bleuler 
considered the term ‘splitting of the mind’ to relate to the separation of function between 
thinking, memory, perception and personality (Bleuler & Bleuler, 1986). Schizophrenia refers 
to a disease concept generally considered to have been defined by Emil Kraepelin (1856 – 
1927) who stated that “appropriate investigations would eventually reveal the nature of this 
brain disease” (Lawrie et al., 2004), and although an exact aetiology has yet to be discovered, 
advances in medical science and technology are successfully deciphering the complex coding 




Schizophrenia usually emerges in late adolescence or early adult life, often striking people 
down in their prime (Johnstone et al., 2010).  The symptomology of schizophrenia is 
characterised by ‘positive’ symptoms, ‘negative’ symptoms and impaired cognitive function. 
Positive symptoms most commonly consist of auditory and/or visual hallucinations – for 
example, hearing voices that no-one else can hear, and/or seeing people or objects that are not 
there. 
 
Hallucinations can involve all of the senses and although not as common, olfactory, tactile and 
gustatory hallucinations – i.e. smelling odours that others cannot; feeling things that are not 
there and/or experiencing a bad taste may also be experienced (Johnstone et al., 2010). 
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Positive symptomology also refers to delusions, i.e. false beliefs, and include paranoia – for 
example, individuals believing they are being spied on; their conversations are being listened 
to; and/or they believe people are always talking about them.  Most characteristically, delusions 
involve various passivity phenomena, for example, people report the feeling that they are being 
controlled or influenced by a mysterious force and/or alien force.  Others report thought 
insertion, thought withdrawal or thought broadcasting.  (Johnstone et al., 2010). Hallucinations 
are typically referred to as the manifestation of psychosis; with individuals often requiring 
immediate psychiatric help. 
 
Negative symptoms are not as obvious as positive symptoms, which are abnormal by their 
presence; however negative symptoms are equally disabling and difficult to manage.  While 
positive symptoms can usually be successfully managed by pharmaceutical interventions, the 
same cannot be said for negative symptoms, resulting in an adverse effect on prognosis and 
eventual functional outcome.  Negative symptoms include social withdrawal, poverty of speech 
and lack of motivation – symptoms recognised by their absence. Individuals stricken with 
schizophrenia often transform from previously active, social and independent people into 
inactive, withdrawn and often completely dependent people. Employment can often become 

















To meet a diagnosis of schizophrenia in line with the Diagnostic and Statistical Manual of 
Mental Disorders 5th Edition (DSM-5) (American Psychiatric Association, 2013) individuals 
will have had the illness for at least six months and have experienced at least two of the 
following symptoms which should have been present for a prolonged period of time during a 
one month period - one of which must include either delusions, hallucinations or disorganised 
speech, together with grossly disorganized or catatonic behaviour and/or negative symptoms 
(i.e., diminished emotional expression or avolition).  These criteria are slightly different to 
earlier editions which previously required only one of the specified symptoms from Criterion 
‘A’ to be present, however the American Psychiatric Association (APA) who are the publishers 
of the Diagnostic and Statistical Manual of Mental Disorders, made this change based on the 





According to the World Health Organisation, (1998) schizophrenia is one of the largest 
contributors to the global burden of disease, ranking in the top ten illnesses.  Schizophrenia has 
a lifetime risk of around 1% of the population worldwide, affecting more than 21 million 
people.  Prevalence (i.e. the number of cases in a population at any one time point) 
internationally is approximately 5 in every 1000 and incidence (i.e. the number of new cases 
annually) is approximately 0.2 in every 1000. 
 
As previously mentioned, age of first onset of psychosis is usually late teens to early adulthood; 
however females can have a later age of first onset. Schizophrenia affects both males and 
females; however more males are affected than females.   
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Although the exact cause(s) of schizophrenia remains unknown, there are a number of genetic 
and environmental risk factors associated with the development of schizophrenia including 
heritability and familial risk, obstetric complications, living in an urban area, time of year of 
birth – significantly winter and early spring, immigration and older paternal age all contributing 
(World Health Organisation, 1998).  Cannabis and other drug use, as well as alcohol, are also 
believed to play a part in the later development (or prolonged duration) of major mental illness 
(NHS Choices, 2015). 
 
Schizophrenia has been found to reduce life expectancy by approximately 10 – 25 years 
(Laursen et al., 2012), as a result of its association with poor lifestyle - for example, obesity, 
poor diet, smoking and lack of exercise.  Suicide rates are also higher than average in 
schizophrenia (Palmer et al., 2005; Hor et al., 2010).  Schizophrenia has a large economic cost 
as well as a large human cost as it is a major cause of disability – ranked 3rd after paraplegia 
and blindness (World Health Organisation, 2007) therefore being able to identify new targets 
for treatment to improve the functional outcome and quality of life for sufferers is priority. 
 
1.1.4 Course of Illness and Treatment 
 
Schizophrenia is most commonly diagnosed after an individual experiences their first psychotic 
episode, at which point they will usually be seen by a psychiatrist.  It’s possible however, that 
up until this point, symptoms may still have been present, although these wouldn’t necessarily 
have met the threshold for a diagnosis of schizophrenia.  This phase of illness is known as the 
prodromal period, in which negative symptoms, including social withdrawal, loss of 
motivation, flat affect and loss of experiencing pleasure may also have been present (Johnstone 
et al., 2010).  
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Prognosis after this point depends a lot on response to treatment and the severity of any 
cognitive impairment.  Chronic schizophrenia can often be successfully managed with 
medication, and some individuals are able to return to work and live independent and 
productive lives, however for those who do not respond well to treatment, or who are more 
severely impaired, the outlook is less favourable.  These individuals may require family support 
and/or help from community housing and/or a support worker visiting daily to assist with 
personal care, meals and activities.  As cognitive function can continue to decline throughout 
the course of the illness (Johnstone et al., 2010), some individuals could eventually become 
completely reliant on family and/or community support to assist them with every aspect of their 
lives. 
 
Positive symptoms of schizophrenia are usually managed successfully by the use of 
antipsychotic medication. Chlorpromazine was discovered circa 1952 and revolutionised 
patient care (Turner, 2007).  Chlorpromazine is still used today; however there are now an 
additional number of effective antipsychotics which can be used solely, or in combination with 
other mood stabilizers and/or antidepressant medications. As the effects of schizophrenia can 
sometimes be prolonged and incapacitating (Turner, 2007), antipsychotic medication can 
provide patients with the ability to reconnect with their loved ones and carers, making it hard 
not to see chlorpromazine (and other antipsychotics) as almost a psychic penicillin (Turner, 
2007). 
 
Non-pharmacological interventions such as cognitive behavioural therapy (CBT) and psycho-
education are also promising therapeutic treatment options which may be able to offer respite 
from some of the harder to treat negative symptoms (Cooke, 2014). 
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1.1.5 Familial and Genetic Factors 
 
Schizophrenia is familial (O’Donovan et al., 2009) and highly heritable (Harrison & Owen, 
2003; O’Donovan et al., 2009).  Specific genetic markers have been identified in patients with 
schizophrenia (Sullivan et al., 2003; Kieseppa et al., 2004; Harrison & Weinberger, 2005; 
Stefansson et al., 2009) and there is also compelling evidence from a number of family, twin 
and adoption studies which report that genetic factors are important in how schizophrenia is 
transmitted (Johnstone et al., 1999; Harrison & Weinberger, 2005). 
 
Genetic research of schizophrenia has moved to finer mapping techniques in the search for 
likely candidate interactors such as single nucleotide polymorphisms (SNPs) which are 
responsible for transmitting the correct coding instructions during development, while 
collaborative genome-wide association studies (GWAS) and linkage studies have begun to 
identify rare mutations, deletions and duplications of genetic structures and translocations. 
Until now, GWAS had identified around 30 schizophrenia-associated loci, however the 
Schizophrenia Working Group of the Psychiatric Genomics Consortium (PGC) have recently 
identified 108 independent schizophrenia-associated genomic loci (Ripke et al., 2014). 
 
As can be seen from Table 1.1 however, this does not explain all of the variance in liability to 












Morbid Risk of Schizophrenia (Definite and Probable) for Relatives of Schizophrenic Patients 
Relationship       % Shared genes Risk (%) 
General population                       N.A.        1 
Spouses of patients                       N.A.        2 
Third-degree relatives                       12.5  
First cousins         2 
Second-degree relatives                       25  
Uncles/aunts         2 
Nieces/nephews         4 
Grandchildren         5 
Half-siblings         6 
First-degree relatives                       50  
Parents         6 
Siblings         9 
Children        13 
Siblings with 1 schizophrenic parent        17 
Dizygotic twin        17 
Monozygotic twin                   100       48 
Children with 2 schizophrenic parents                   100       46 
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1.2 Bipolar Affective Disorder 
 
Bipolar affective disorder, previously known as ‘manic depressive disorder’, is a complex 
major mental disease.  Originally introduced as an illness by Falret in 1851 as ‘folie circulaire’, 
this translated to ‘circular madness’ and described manic and melancholic episodes which were 
separated by symptom-free periods (Angst & Sellaro, 2000).  ‘Folie à double forme’ was a 
term used by Baillarger (1854) to describe cyclic episodes (manic-melancholic) and these were 
also referred to by Kraepelin as ‘double attacks’.  Mixed states were also known in the early 
19th century and were referred to as ‘mixtures’ by Heinroth (1818) as well as ‘middle forms’ 
by Griesinger (1845).  Three specific mixed states – ‘manic stupor’, ‘unproductive mania’ 
(elated mood, inhibition of thinking and increased motor activity) and ‘agitated melancholia’ 
(depression with flight of ideas and agitation) were defined by Weygandt (1899) and were later 
used as the basis for Kraepelin’s textbook descriptions (1899) (Kraepelin, E. 1971). 
 
By the late 19th century, Kraepelin (1913) had unified mood disorders and, as a result, bipolar 
disorders were considered to be part of a broad group known as ‘manic depressive insanity’ 
(MDI) which incorporated single episodes as well as recurrent depression.  As a result of the 
unification of affective disorders, research studies often failed to distinguish between mania, 
bipolar disorder and depression (Angst & Sellaro, 2000).  The distinction between these 
disorders (mania, depression and bipolar disorder), however, was disputed by some, and the 
categories were maintained in several studies including Pilcz (1901) and Ballet (1903) (Angst 
& Sellaro, 2000). 
 
 





Bipolar Affective Disorder is highly recurrent (Angst & Sellaro, 2000) and usually occurs 
during the later teenage years or during early adulthood and is likely to persist throughout the 
lifespan (National Institute of Mental Health, 2015).  Symptoms of bipolar disorder include 
periods of mania in which individuals experience feelings of elation. 
 
Mania is usually (but not always) followed by depressive episodes in which individuals 
experience feelings of intense despair.  ‘Mixed’ episodes can also be experienced in which, for 
example, individuals may be suffering from a depressive episode but they also have manic 
feelings of over-activity or restlessness.  Mixed episodes are also the most problematic, having 
a poorer prognosis, higher risk for chronicity and slower remissions (Angst & Sellaro, 2000). 
 
The Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) (American 
Psychiatric Association, 2013) categorises Bipolar Affective Disorder as either: Bipolar 1 
Disorder; Bipolar II Disorder; Cyclothymic Disorder; Substance/Medication-Induced Bipolar 
and Related Disorder; Bipolar and Related Disorder due to another Medical Condition; Other 
Specified Bipolar and Related Disorder or Unspecified Bipolar and Related Disorder.  Bipolar 
1 is characterised by at least one manic episode lasting longer than 1 week.  Usually, individuals 
with Bipolar 1 will also experience episodes of depression, although it is possible to have only 
manic episodes. If the illness is left untreated, manic episodes could last as long as 3 – 6 months 
and depressive episodes could last as long as 12 months. 
 
Bipolar II is characterised by several episodes of severe depression, however manic episodes 
are milder. Rapid cycling can occur with both types I and II and is characterised by individuals 
suffering from more than 4 mood swings in a 12 month period.  
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Cyclothymic Disorder is characterised by milder mood swings than those experienced with full 
bipolar disorder, however although milder, they can last longer and can sometimes develop 
into full bipolar disorder (American Psychiatric Association, 2013). 
 
Mania and depression affect an individual’s emotions, thinking, physiology and behaviour.  
During a manic episode, sufferers can feel ecstatically happy; can have lots of new ideas and 
also make some bad decisions; go without sleep and feel full of energy; talk and move around 
very quickly, display odd behaviour, spend money recklessly etc. 
 
During a depressive episode, individuals can feel extreme sadness, the feeling they want to 
burst into tears for no apparent reason; they struggle to make basic decisions and struggle to 
see any positives; struggle to sleep, lose their appetite.  Individuals could also have difficulty 
completing basic everyday chores and often avoid others (NHS Choices, 2016). 
 
During very severe periods of mania or depression, individuals can also experience psychotic 
symptoms, i.e. delusions and/or hallucinations.  During mania, delusions are usually in the 
form of grandiose beliefs about themselves, i.e. that they are special, they are better than 
everyone else, their ways are best, they know better, etc.  Individuals can often also believe 
they have super powers – for example, they believe they can heal the sick.  Psychotic symptoms 
during a severe period of depression can result in very negative delusions, i.e. individuals can 
become extremely self-critical, self-blaming and self-punishing and can experience feelings of 
worthlessness and guilt (Mental Health Care, 2012). People suffering from psychotic 
depression in bipolar disorder also have a higher risk of suicide, as much as 20 - 30 times that 
of the general population (Pompili et al, 2013). 
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Hallucinations could manifest in the form of seeing; hearing; smelling, tasting or feeling 
something that isn’t actually there (Johnstone et al., 2010).  In between periods of mania and 
depression, sufferers were thought to be symptom free; however research has found this isn’t 
strictly the case.  Although severe symptoms seem to disappear, studies have discovered that 
in some cases, mild symptoms actually persist, causing problems with thinking, and the 




To meet a diagnosis of Bipolar Affective Disorder, the Diagnostic and Statistical Manual 5th 
Edition (DSM-5) (American Psychiatric Association, 2013) criteria for mania and depression 
are as follows: 
 
Mania is characterised by: 
 
A. “A distinct period of abnormally and persistently elevated, expansive, or irritable 
mood, lasting at least 1 week (or any duration if hospitalization is necessary)”. 
 
B. During this period, at least 3 from a list of specified symptoms must have persisted       
(4 if the mood is only irritable) and have been present to a significant degree. 
 
Major Depressive Disorder is characterised by: 
“Depressed mood and/or loss of interest or pleasure in life activities for at least 2 weeks” and 
at least 5 of 9 specified symptoms that “cause clinically significant impairment in social, work, 
or other important areas of functioning almost every day”.  
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In addition to the above, diagnosis for a Major Depressive Disorder requires two or more major 
depressive episodes and the severity of episodes for both mania and depression is rated by the 





In the general population, lifetime prevalence rates of bipolar disorder are estimated between 
1 - 5% and between 0.5 - 3% for bipolar II.  The estimate rises to between 2.8% - 6.5% when 
the full spectrum of bipolar conditions are considered.  Bipolar disorder appears to affect men 
and women equally, however more women are diagnosed with Bipolar II, and women are more 
likely to suffer rapid-cycling and mixed states than men.  Age of onset is usually late teens or 
early adulthood, however the timescale between the experience of a first episode and actually 
receiving treatment can be anywhere between 5 – 10 years (Bauer & Pfennig, 2005). 
 
Suicide is a high risk for bipolar patients with up to 20% dying this way (Pompili et al., 2013).  
Severity of illness, genetic and familial factors, together with loss of support (medical or 
social), adverse childhood and/or environmental experiences and psychiatric comorbidity were 
all factors found by the Stanley Foundation Bipolar Network which contributed to the risk of 
suicide (Bauer & Pfennig, 2005). 
 
1.2.4 Course of Illness and Treatment 
 
It is likely that affected individuals will have experienced bipolarity symptoms for some time 
prior to receiving a diagnosis (Bauer & Pfennig, 2005).  Studies have found that sufferers can 
often go untreated for lengthy periods of time, estimated to be between 5 – 10 years after 
experiencing their first episode (Bauer & Pfennig, 2005). 
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Symptoms can usually be successfully managed with mood stabilisers; however because 
bipolar disorder is a lifelong illness, it is also likely that this will be lifelong (National Institute 
of Mental Health, 2015). 
 
Bipolar disorder develops approximately 10 years earlier than recurrent depression (usually in 
adolescence) with mania typically manifesting in the early 20’s (Angst & Sellaro, 2000). 
 
Studies have found that over the lifetime, females with bipolar disorder experience more 
depressive episodes than men, and the proportion of depressive and manic episodes remains 
stable (Angst & Sellaro, 2000).  There is a higher risk of chronicity with mixed episodes in 
which remissions are also slower (Bauer & Pfennig, 2005). 
 
The mean length of episodes has been reported to be between 3 and 6 months in clinical studies, 
however this reduces to between 2 to 3 months in epidemiological studies.  Bipolar disorder is 
relentless in its recurrence and during its course, affective episodes continue throughout the 
lifespan in an irregular pattern.  As previously stated, during periods of remission which were 
essentially believed to be symptom-free, it is now known that sufferers often continue to 
experience residual hypomanic or depressive symptoms and continued functional impairment.  
Overall, bipolar disorder has a poor prognosis as a result of its high recurrence, chronicity of 
episodes, residual depressive or hypomanic symptoms and early death due to suicide (Angst & 
Sellaro, 2000). 
 
Antidepressant medication is an effective treatment; however those who respond well to 
antidepressants may still require maintenance treatment during affective episodes (Angst & 
Sellaro, 2000).  Maintenance treatments usually require a mood stabiliser, for example lithium, 
and in the case of psychosis, antipsychotic medication may also be required. 
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Psycho-education is also an effective tool for prevention as it teaches sufferers how to 
recognise the early signs that they may be about to experience another affective episode.  
Psychological therapies, for example, cognitive behavioural therapy (CBT) is also helpful in 
the management of bipolar spectrum disorders (Lam et al., 2000).  Individuals with Bipolar 
disorder are often able to continue to work and live independently in the community, maintain 
relationships and lead very successful productive lives; however for those whose episodes are 
more severe, family and/or community support may be required in addition to periods of 
hospitalisation (Mind, 2015). 
 
1.2.5 Familial and Genetic Factors 
 
From a familial and genetic view, bipolar disorder is one of the most extensively studied 
psychiatric disorders (Smoller & Finn, 2003).  There is a consistent body of evidence from 
family, twin and adoption studies which supports the existence of genes which predispose 
people to the risk of developing bipolar disorder.  As the level of relatedness to an individual 
with bipolar disorder diminishes, so does the level of risk a related family member has of 
developing a mood disorder (Craddock et al., 2005).  Heritability estimates are high, with one 
study reporting 89% in a UK twin pairs study (McGuffin et al., 2003) and 93% in a Finnish 
study of same-sex twin pairs (Kieseppa et al., 2004). 
 
Although not as well studied as schizophrenia, there is growing evidence that consistently 
highlights specific genetic regions which are believed to be involved in the pathophysiology of 
bipolar disorder (Craddock et al., 2005).  Recent association studies have identified specific 
genes, significantly CACNA1C and ANK3 which provide strong evidence for association with 
bipolar disorder (Ferreira et al., 2008; Sklar et al., 2011).   
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Sklar et al., (2011) have also identified a new variant in ODZ4 which also achieved genome-
wide significance for association with bipolar disorder.  These recent findings highlight the 
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1.3 Major Depressive Disorder 
 
Major Depressive Disorder (MDD) is one of the most common psychiatric disorders seen in 
primary care (Sharp et al., 2002) and was originally described by Hippocrates as a distinct 
disease which had both physical and mental symptoms (Hippocrates, Aphorisms, Section: 
6.23).  During the 17th to 19th centuries, the term ‘depression’ from the Latin verb ‘deprimere’, 
meaning ‘to press down’ (McMullen & Conway, 2002) was introduced. 
 
Symptoms of depression have been described as far back as classical times, resulting in 
numerous theories including humoral theory, i.e. the four humours (black bile, yellow bile, 
blood and phlegm) (US National Library of Medicine, 2012), moral and spiritual theories, for 
example ‘acedia’ (absence of caring or sloth) (Daly, 2007) and depression was also likened to 
mourning by Freud (Carhart-Harris et al., 2008).  Mixed social and biological theories have 
been proposed (Lewis, 1934), as well as theories from cognitive psychologists such as Aaron 
Beck who proposed that depression was caused by a ‘cognitive triad’ (Beck, 1979).  
Psychodynamic theories - i.e. existential and humanistic - were also offered (Freeman et al., 
1986), and by the mid twentieth century, researchers had proposed that depression was caused 
by a chemical imbalance in neurotransmitters in the brain (Schildkraut, 1965).  In the mid 
1970’s, as part of proposals for diagnostic criteria based on patterns of symptoms, the term 
‘Major Depressive Disorder’ was introduced by US clinicians (Spitzer et al., 1975), and was 
incorporated into the Diagnostic and Statistical Manual, 3rd edition in 1980 (DSM-III) 
(American Psychiatric Association, 1980). 
 
DSM-III diagnostic thresholds included mild depressive episodes, with higher categories for 
moderate to severe episodes (Gruenberg et al., 2005).   
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As very severe episodes of depression could result in psychotic features, DSM-IV (American 
Psychiatric Association, 2000) classified psychotic major depression as a subtype or variant of 
major depressive disorder (Park et al., 2014). Psychotic major depression denotes the presence 
of psychotic symptoms, such as delusions and hallucinations as well as the depressive disorder 




As the term ‘depression’ literally means ‘to press down’, it was introduced as a means of 
describing the change in a person’s emotions and affect, as if these were being pressed down 
(McMullen & Conway, 2002).  Depression is a mood disorder and its symptoms are complex 
and vary widely from person to person.  Symptoms range from mild to very severe and can 
happen once in a lifetime, known as a single episode, or symptoms can recur throughout the 
lifetime, known as recurrent episodes (World Health Organisation, 2012).  Previously well 
individuals often begin to find themselves crying for no apparent reason, having persistent low 
mood and feeling great sadness.  Symptoms also include the person losing interest and/or 
pleasure in activities they previously used to enjoy, losing motivation, feelings of guilt, talking 
and/or moving slower, unexplained aches and pains and having suicidal thoughts (NHS 
Choices, 2014).  Depression can also affect work and family life, and symptoms can last from 
a few weeks or months to years.  Depression affects people psychologically, physically and 
socially, depending on the severity and duration of the symptoms being experienced (World 
Health Organisation, 2012). 
 
A mild episode will have some impact on a person’s daily life, a moderate episode will have a 
significant impact on daily life and a severe episode will result in the person finding it almost 
impossible to manage their daily routines. 
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Severe depression can also result in the person experiencing psychotic symptoms which will 
almost certainly require the individual to be hospitalised for treatment (Mental Health Care, 
2012). 
 
Depression is often mistaken for grief, which does have similar symptoms, however if a person 
is suffering from grief - which is a natural response to loss (usually of a loved one) – their 
sadness will come and go, rather than be continual, and they will still usually be able to enjoy 
certain things and be able to look forward to the future.  If a person is suffering from depression 
however - which is an illness – their low mood will be continual and they will not be able to 




To meet a diagnosis of a major depressive episode, an individual will have experienced at least 
five core criterion symptoms from Criterion ‘A’, one of which will be either depressed mood 
or loss of pleasure/interest for a period of at least two weeks - representing a change in the 
individuals’ usual functioning.  In addition, the symptoms will have caused clinically 
significant impairment or distress in their occupational, social or other important areas of 
functioning e.g. family life, hobbies, etc. (Diagnostic and Statistical Manual of Mental 
Disorders Fifth Edition (DSM-5), (American Psychiatric Association, 2013).  
 
For recurrent major depression, the individual will have experienced two or more episodes 
separated by a period of at least two months, during which their symptoms do not meet criteria 
to be classed as a major depressive episode. Severity of symptoms will determine the 
classification, i.e. whether the episode is mild, moderate or severe.   
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Severe episodes will be further determined by the presence or absence of psychotic symptoms 
(American Psychiatric Association, 2013). 
 
Psychotic major depression is the most severe with sufferers experiencing delusions and/or 
hallucinations, most commonly auditory and/or visual, in addition to the depressive episode 
itself (American Psychiatric Association, 2013).  Critically, the content of these 




According to the World Health Organisation in October 2012, depression was stated as a 
leading cause of disability worldwide, globally affecting over 350 million people of all ages 
(World Health Organisation, 2016). There are many potential risk factors for the development 
of depression, for example, stressful life events such as the loss of a loved one, divorce, drugs, 
alcohol, redundancy, head injury, ageing and money problems.  These can be single events or 
a combination of events that together could trigger the onset of a major depressive episode.  
Certain personality traits such as being very critical of oneself or having low self-esteem are 
also associated with depression.  Having a family history of depression, i.e. a parent, brother 
or sister who has/has had the illness is also likely to increase a persons’ risk of developing 
depression (NHS Choices, 2014).   Lifetime prevalence rates vary per country, with Japan 
reported as being 3% and the U.S. being 19% (Andrade et al., 2003).  
 
Depression can occur at any age, from childhood to old age, and depression has been found to 
affect twice as many women than men.  At its’ worst, depression is responsible for an estimated 
800,000 suicides every year (World Health Organisation, 2016). 
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Although depression can strike at any age, population studies have found that major depression 
usually has a later age of onset than most other major mental illnesses which typically begin 
during adolescence – early adulthood. Population studies also reported that individuals 
suffering from major depression were most likely to experience their first episode in their early 
twenties, with an estimated peak risk period for onset between mid - late adolescence and the 
mid-forties (Kessler & Bromet, 2013). 
 
Available data for the U.K. in 2009 reported age of onset for a major depressive episode to be 
between the ages of 25 – 44 with a second smaller incidence between the ages of 45 – 64 (Rait 
et al., 2009).  More recently, the British Psychological Society published findings from the 
Office for National Statistics which surveyed 40,000 households and found the highest 
incidence of mild mental illness occurred in those aged 50 – 54 years.  In those aged 16 or over, 
19% reported symptoms, and there were higher incidences (27%) in those who were separated 
or divorced (British Psychological Society, 2013) which is in line with findings from 
population studies (Kessler & Bromet, 2013).  Socioeconomic status and level of education 
have also been found to be associated with depression and depression is more likely to occur 
in urban rather than rural areas (Paykel et al., 2003). 
 
1.3.4 Course of Illness and Treatment 
 
Depression develops gradually which makes it more difficult for sufferers to realise that they 
are actually ill – very often people will try their best to continue with their daily lives and 
routines as normal, and sometimes the change in them will be noticed and pointed out by a 
family member, friend or work colleague (NHS Choices, 2014).   
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Individuals may experience feelings of anxiousness before the onset of a depressive episode as 
panic and generalized anxiety disorder were found to be strong predictors for secondary major 
depressive episodes (Hirschfeld et al., 2001).  Some of the psychological core criterion 
symptoms that will likely be experienced include persistent low mood, loss of pleasure and/or 
loss of interest in activities that used to be enjoyed, lack of concentration, inability to make 
decisions, hopelessness, feeling worthless, feelings of guilt, irritability, intolerance and 
thoughts of self-harming or suicide. Physical symptoms include slower speech and/or slower 
movements, disturbed sleep, fatigue, unexplained aches and pains, weight loss when not dieting 
or weight gain due to loss or increase of appetite.  Socially, sufferers often will often struggle 
with employment, withdraw from hobbies and events and generally become isolated. Very 
severe cases can result in psychosis with delusions and/or hallucinations. 
 
Typically, these might be delusions of guilt, sin or nihilism, and any auditory or visual 
hallucinations are usually critical and/or negative in tone.  Individuals will not usually 
experience all of the above symptoms, however at least five will result in a diagnosis of a major 
depressive episode (American Psychiatric Association, 2013). 
 
Symptoms can last a few weeks to a few months but can last a lot longer (Kessler & Bromet, 
2013).  A single episode will see the individual recovering with no further episodes, however 
for some people, symptoms will return after a period of at least two months during which time 
their symptoms did not meet the core criterion. A number of people suffer from chronic-
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Depression is treatable pharmacologically and non-pharmacologically with moderate to severe 
cases treated by the use of anti-depressant (and if necessary, anti-psychotic) medication(s) and 
talking therapies such as cognitive behavioural therapy (CBT).  For very severe cases, 
including psychotic major depression, ECT (electroconvulsive therapy) is also an effective 
option, in combination with psychotherapy, anti-depressant and anti-psychotic medications 
(American Psychiatric Association, 2013). Anti-depressants are not recommended as a first 
line of treatment for cases of mild depression and the preferred initial treatment is psychosocial 
which could include self-help groups, self-help books and/or exercise which has been found to 
be effective in relieving the symptoms of mild depressive episodes (NHS Choices, 2014). 
Treatments are usually very effective; however chronic-recurrent cases and those with 
psychotic major depression usually require a maintenance therapy i.e. constantly monitored by 
way of follow-up appointments (Diagnostic and Statistical Manual for Mental Disorders-5 
(DSM-5), American Psychiatric Association, 2013; NHS Choices, 2014). 
 
1.3.5 Familial and Genetic Factors 
 
Family and genetic research of major depression have provided good evidence that this disorder 
is highly heritable (Whalley et al., 2013).  Twin and adoption studies are a classic means of 
distinguishing between genetic and environmental factors in families where there are a larger 
number of members affected by illness than would be expected by chance (McGuffin & Katz, 
1989). 
 
From early twin studies, genetic factors were found to play an important role, with concordance 
rates found to be two to five times higher in monozygotic twins compared to dizygotic twins 
(McGuffin & Katz, 1989).  Although heritability plays a part, the genetic architecture of 
depression remains complex and not fully understood (Thomson et al., 2014).   
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Association studies have reported that genetic susceptibility to major depression overlaps with 
that for both bipolar disorder and schizophrenia (Schosser et al., 2010) and to date, no single 
gene has been identified which can be said to be causal in the development of depression 
(Nestler et al., 2002; Lewis et al., 2010) although the unique DISC1 t(1;11) translocation has 
shown genome-wide significant linkage for recurrent major depressive disorder (Thomson et 
al., 2014).  Major depression is familial - with heritability estimated to be 0.37 (Wray et al., 
2012), however, evidence suggests it is not caused by genetics alone but more likely by a 
combination of genetic and environmental influences (Sullivan et al., 2000). 
 
Childhood maltreatment (physical and/or emotional) is one of the strongest risk factors for the 
later development of major mental illness including recurrent major depressive disorder and 
importantly, psychotic major depression (Holshausen et al., 2014).  Other potential 
environmental risk factors include stress, viral infections, anxiety, drugs and/or alcohol use 
(Nestler et al., 2002) as well as chronic strains with family relationships and less support 
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Cognitive impairment precedes the onset of schizophrenia (Aylward et al., 1984; Woodberry 
et al., 2008) however having a lower I.Q. by no means guarantees that an individual will go on 
to develop a severe mental illness in later life.  The issues around impaired cognition as a 
symptom of schizophrenia are still being debated, however it is recognised that schizophrenia 
has a negative impact on cognitive function, especially general intelligence (I.Q.), memory and 
executive function (Heinrichs et al., 1998; Johnstone et al., 1999). 
 
Individuals with schizophrenia demonstrate global intellectual impairments pre-dating 
psychosis onset. Studies have reported significantly poorer performances in general 
intelligence in people who have later developed schizophrenia as far back as primary school 
(Caspi et al., 2003; Osler et al., 2007) with children who later developed schizophrenia 
performing worse in school tests and/or IQ tests than their healthy peers (Joyce, 2013).  
Information processing speed is also of importance as it is known to account for 25% of the 
variance in the general ability of healthy populations (Joyce, 2013).  As evidenced from 
replicated studies that underperformance is evident as far back as childhood, Khan & Keefe, 
(2013) postulate the possibility that this impairment is present at birth.  It is equally possible, 
however, that impairment occurs at some point during development, but prior to the onset of 
psychosis, and this lag in brain development may be a crucial early manifestation of the illness 
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Importantly, family studies have revealed neurocognitive deficits in the unaffected relatives of 
individuals with schizophrenia who performed significantly poorer than healthy control 
subjects in tests of general intelligence, memory and psychomotor performance (McIntosh et 
al., 2005) executive functions and attention (Snitz et al., 2006).  
 
Family studies have also shown that symptoms and cognition are dissociable domains which 
follow different developmental paths, and in doing so they point to impaired cognition as a risk 
factor for the later development of schizophrenia (Gold, 2004).  Following this, genetic model 
fitting was applied in a twin study which reported that genetic influences substantially 
contributed to all cognitive domains tested, with the highest heritability found for general 
intelligence and working memory (Toulopoulou et al., 2007). Recently, cognitive ability was 
reported as being a true endophenotype for susceptibility to schizophrenia by Lencz et al., 
(2014) who provided empirical evidence at a molecular level of genetic overlap between 
cognitive ability and schizophrenia. 
 
Using polygenic risk profiling, McIntosh et al., (2013) also reported association between 
schizophrenia and cognitive ability.  In particular, they reported that an increased polygenic 
risk of schizophrenia was associated with reduced cognitive ability at age 70 and further, that 
greater relative decline in cognitive function was also associated with greater polygenic risk 
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1.4.2 Bipolar Disorder 
 
Impaired cognition in bipolar disorder is recognised as a core feature of the illness; however 
the level of impairment is not as severe or as permanent as that seen in schizophrenia (Bora et 
al., 2009; Barch & Sheffield, 2014). General intelligence appears to remain intact; however 
impairment is evident in areas of memory, executive function and processing speed 
(Lewandowski et al., 2011). It was generally believed that impaired cognition could often 
return to premorbid levels during euthymic periods, however as previously mentioned 
elsewhere, evidence suggests that even during periods of euthymia, sufferers continue to 
experience residual symptoms of hypomania and/or depression (Angst & Sellaro, 2000). 
 
There is also converging evidence of persistent cognitive impairment during euthymic periods 
which may, in part, be caused by these residual symptoms.  Kurtz & Gerraty (2009) found that 
cognitive impairment persisted in individuals with bipolar disorder during all phases of the 
illness (euthymic, manic or mixed and depressed episodes) and similar results were reported 
by Bora et al., (2010) who conducted a meta-analysis of cognitive impairment in affective 
psychoses and also found cognitive dysfunction in remitted bipolar patients.  These findings 
were supported by Thompson et al., (2005) who studied a large group of verified euthymic 
bipolar patients and revealed deficits across a broad range of cognitive domains. 
 
In addition to the negative impact on cognition evidenced in individuals with bipolar disorder, 
research has also identified neuropsychological dysfunction in the unaffected relatives of 
patients with bipolar disorder resulting in areas of executive control and declarative memory 
postulated as potential endophenotype markers (Nicol Ferrier et al., 2004; McIntosh et al., 
2005).  
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A meta-analysis of neuropsychological deficits in euthymic bipolar patients identified impaired 
response inhibition as the most prominent potential cognitive endophenotype for bipolar 
disorder which was impaired in both euthymic bipolar patients and their unaffected relatives. 
This study also identified set-shifting ability and verbal memory as further potential cognitive 
endophenotypes for bipolar disorder (Bora et al., 2009). 
 
Cognition appears to remain intact in bipolar disorder, at least until the experience of a first 
episode, which differs from schizophrenia, in which cognitive deficits are present prior to 
illness onset (Lewandowski et al., 2011). 
 
Impairment can deteriorate further, depending on length of illness and severity of episodes, and 
cognitive ability is most impaired in individuals who experience psychosis (Glahn et al., 2007). 
Effect of medication may impact on cognitive ability, however cognitive impairment has also 
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1.4.3 Major Depressive Disorder 
 
Cognitive function in major depressive disorder and psychotic major depression has not been 
studied to the same extent as other major mental illness such as schizophrenia and bipolar 
disorder (Fleming et al., 2004).  However as cognitive function is known to be a critical 
determinant of outcome, both in everyday functioning and quality of life (Barch & Sheffield, 
2014), there is now accumulating evidence that major depression is also accompanied by 
neuropsychological deficits (Basso, 1999; Baune et al., 2010; Lee et al., 2012).   Although 
cognitive impairment is worse in schizophrenia compared to bipolar disorder and psychotic 
major depression; the profile of impairment in major depressive disorder has been found to be 
similar, which is consistent with the idea that this may reflect common neural mechanisms 
(Barch & Sheffield, 2014). 
 
Studies of patients with psychotic major depression have reported significant impairments in 
verbal and visual memory, as well as executive functions, attention and language functions 
(Reichenberg et al., 2009).  Cognitive deficits are also a feature of non-psychotic major 
depression, albeit less severe than those experienced with psychosis (Fleming et al., 2004).  A 
recent longitudinal study reported that in clinical remission, unipolar depressed patients 
showed deficits in visual memory and processing speed and suggested that executive 
dysfunction may be a trait marker (Xu et al. 2012).  
 
Genetic studies of cognition for major depression have not as yet identified specific risk genes, 
however, Thomson et al., (2014) identified DISC1 putative functional variants that were 
nominally associated with recurrent major depressive disorder and cognition at the locus wide 
level of significance, a finding which requires further study. 
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1.5 History and Background of the DISC1 t(1;11) Kindred 
 
The t(1;11) translocation was first identified in 1970 in a large Scottish family by Jacobs et al., 
(1970), however it took some 30 years before the DISC1 gene was identified and provisionally 
christened Disrupted-in-Schizophrenia 1 (Miller et al., 2000), a title which has remained, and 
which is now commonplace worldwide.  The DISC1 gene, located on chromosome 1q42, 
together with its’ novel counterpart DISC2, were so called as a result of much cytogenetic 
research, resulting in the discovery that gene function was directly disrupted by the DISC1 
gene. It was further hypothesized to be a causative event in the development of schizophrenia 
and other psychiatric disorders such as bipolar disorder and major depressive disorder (Miller 
et al., 2000). 
 
The origins of DISC1 trace back to a large Scottish pedigree with an unusually high number of 
cases covering a range of psychiatric disorders including schizophrenia, bipolar disorder and 
major depressive disorder.  During a cytogenetic survey of juvenile delinquent boys awaiting 
admission to a Scottish borstal in 1968, the proband was found to have a balanced translocation 
between chromosome 1 and a chromosome in group ‘C’ - later identified as chromosome 11 
(1;11)(q42.1;q14.3) (St. Clair et al., 1990). 
 
Jacobs et al., (1970) were able to pinpoint the proband after examining clinical data held by the 
MRC Cytogenetics Registry in Edinburgh on 282 pedigrees with familial autosomal anomalies 
(St. Clair et al., 1990).  To identify the presence of associated psychiatric illness, each of the 
282 pedigrees were examined, and although several isolated associations were found, the 
proband was the only case of mental ill health within a single pedigree which co-segregated 
with a chromosomal anomaly (St Clair et al., 1990). 
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After further investigation, the abnormality was traced through several branches of the family 
and found to be present in four generations.  Additionally, cumulative data gathered by general 
practitioners from annual follow-ups revealed that many of the other family members had been 
referred to psychiatrists and/or admitted to psychiatric hospitals during the intervening years 
(St. Clair et al., 1990). 
 
Around the same time, another family had been identified as having major mental illness         
co-segregating with a balanced translocation around the same region on chromosome 11 (Smith 
et al., 1989).  The reciprocal breakpoint in this family, however, was found to be at 
chromosome 9.  In view of these findings, it was hypothesized that chromosome 11 (in 
particular, the region q21-22) warranted further examination in the search for genes that could 
potentially predispose people to psychiatric illness (St. Clair et al., 1990). 
 
1.5.1 Clinical Phenotypes 
 
From the original cytogenetic study by Jacobs et al., (1970) (Figure 1) no abnormal phenotypes 
were reported.  The family were subsequently followed up by St. Clair et al., (1990) who were 
able to clinically assess 77 family members (58 living and 19 deceased) (Figure 2).  The follow 
up study was conducted as a result of the additional information from GPs who had continued 
to provide updates to the MRC Cytogenetics Registry, Edinburgh and reported that a high 
number of the original family had been admitted to mental hospitals and/or referred to 
psychiatric services.  In total, 34 family members were found to carry the t(1;11) translocation 
and from these, 23 individuals were diagnosed with a psychiatric illness. Eleven individuals 
had a major mental illness – either schizophrenia, schizoaffective disorder or major depressive 
disorder (recurrent unipolar) - 2 had died as a result of suicide, 5 had a minor psychiatric illness 
– either generalised anxiety disorder, minor depressive disorder or alcoholism and a further 5 
were receiving specialist treatment for adolescent psychiatric disorders. 
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From the 43 non-carriers, 5 family members had a psychiatric diagnosis, none of which was a 
major mental illness (generalised anxiety disorder, minor depressive disorder, alcoholism) (St. 
Claire et al., 1990). 
 
A further follow-up study was carried out with this family in 2000 by Blackwood et al., (2001) 
who were able to include 87 family members for karyotype analysis.  They also clinically 
assessed a total of 69 individuals and reported nine new cases of psychiatric illness which had 
occurred during the previous 10 years.  Thirty-seven individuals were found to carry the 
balanced translocation from which 29 family members received a psychiatric diagnosis.  
Illnesses included schizophrenia (N=7), bipolar disorder (N=1), major depressive disorder 
(recurrent) (N=10), adolescent conduct disorder (N=2) and major depressive disorder (single 
episode) (N=1).  Thirty-eight non-carriers were karyotyped from which 5 individuals received 
a minor diagnosis of either adolescent conduct-and-emotional disorder (N=1), single episode 
depression (N=3) or alcoholism (N=1) (Figure 3). 
 
The study by Blackwood et al., (2001) was the first to examine cognition and intelligence 
quotient (I.Q.) in a sub-group of these family members and reported that premorbid I.Q. 
(measured by the NART) was within the normal range.  Further, no difference was found in 
mean I.Q. scores between translocation carriers and non-carriers.  P300 Event Related Potential 
(ERP) was also recorded in family members (carriers and non-carriers) as well as a group of 
patients with schizophrenia and a group of healthy control participants.  P300 was found to be 
abnormal in family members – translocation carriers had significantly reduced P300 amplitude 
compared to non-carriers and further, it became evident that changes in P300 were not 
exclusive to those individuals with a psychiatric diagnosis.   
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These are interesting results as changes in P300 amplitude and latency are believed to indicate 
deficits in short-term memory required for the speed and efficient processing of information 
and are also considered to be trait markers of risk for the later development of major mental 
illness. 
 
The t(1;11) family remains unique, as to date the t(1;11) translocation has not been found in 
any other individual or family, and their continued willingness to participate in a longitudinal 
study of this nature affords us the opportunity to conduct further investigations and make use 
of new technologies that were either not available or as advanced as they are today.  Additional 
investigations may shed more light on the DISC1 gene itself and further, being able to identify 
phenotypes that are differentially impaired or unimpaired between translocation carriers and 


























Figure 1.1: Original pedigree, reported as part of a cytogenetic study by Jacobs et al., 1970 
 





Figure 1.2: Family members followed up - from St. Clair et al., 1990. 
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1.6 The DISC1 t(1;11) Translocation Phenomenon 
 
The DISC1 gene is one of the strongest known risk factors for psychosis; however the effect(s) 
of the t(1;11) balanced translocation (Figure 1.4), if any, is not fully understood.  To date, 
cognitive findings specific to the t(1;11) translocation are limited and do not appear to suggest 
any direct impact of the translocation (Blackwood et al., 2001). 
 
 
Figure 1.4 DISC1 t(1;11) Balanced Translocation 
 
DISC1 itself is known to be associated with brain development, brain structure and the 
glutamate system - all key factors in current models of schizophrenia and affective disorders 
(Harrison & Weinberger, 2005; Chubb et al., 2008). 
 
Studies investigating neurocognitive function and either DISC1 or the 1q42 region, have 
reported significant findings across a range of cognitive domains (Gasperoni et al., 2003; 
Paunio et al., 2004; Burdick et al., 2005; Hennah et al., 2005; Cannon et al., 2005; Thomson et 
al., 2005; Liu et al., 2006; Palo et al., 2007) (Chapter 2). 
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Several human neuroimaging studies have also made use of a variety of genetic imaging 
techniques to investigate DISC1 together with brain structure and function (see Duff et al., 
2013 for a full review). 
 
The breakpoint of the DISC1 translocation lies within the DISC1 and DISC1FP1/Boymaw 
genes.  Recent work discovered that the breakpoint on chromosome 11 contains biologically 
relevant DNA (Zhou et al., 2008) and was named both DISC1 fusion partner 1 (DISC1FP1) 
and Boymaw (Zhou et al., 2008; Eykelenboom et al., 2012).   
 
The DISC1 t(1;11) balanced translocation has recently been investigated using a variety of 
imaging modalities which found that DISC1 translocation carriers have reduced cortical 
thickness correlating with positive symptom severity and general psychopathology as well as 
reduced gyrification in the prefrontal cortex which also correlated with the severity of general 
psychopathology.  Glutamate concentrations in the right dorsolateral prefontal cortex were also 
found to be significantly reduced (Thomson, Duff et al., 2016).   A multi-functional scaffold 
protein known to mediate several processes implicated in major psychiatric disorders is 
encoded by DISC1, and DISC1 has also been shown to influence brain function and 
neurodevelopment in rodent models, in which behaviours believed to model depression and 
schizophrenia were also found (Thomson, Duff et al., 2016).  In a study of DISC1 transgenic 
mice, Shen et al., (2008) reported that alterations in the DISC1 gene lead to reduced neurite 
outgrowth and the failure of normal neuronal proliferation which lead to large ventricles, 
reduced cortical size and behavioural changes similar to schizophrenia-like phenotypes. 
 
DISC1 has unexpectedly been linked with Alzheimer’s disease by way of a previously 
unrecognised interaction between APP (Amyloid Precursor Protein) and DISC1 (Young-Pearse 
et al., 2010; Shahani et al., 2015; Tomoda et al., 2017).   
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Although schizophrenia and Alzheimer’s disease are clinically distinct conditions, they both 
result in cognitive impairment and deficits in information processing.  As such, future work 
investigating the molecular aspects of the DISC1-APP interaction may provide more clues and 
improve our understanding of cognitive processes in neurodegenerative disorders (Young-
Pearse et al., 2010; Shahani et al., 2015: Tomoda et al., 2017). 
 
Very recent work by Teng et al., (2016) reported that low cognitive ability was associated with 
rare disruptive variants in the DISC1 Interactome (a large set of proteins that interact with the 
DISC1 protein) and also very recently, supporting the earlier P300 ERP work by Blackwood 
et al., (2001) a SNP-based analysis identified significant associations between startle latency 
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1.6.1 Polygenic Risk Profiling 
 
The DISC1 locus has been reported as being involved in a broad range of disorders including 
schizophrenia, schizoaffective disorder, bipolar disorder, recurrent major depression and most 
recently, in autism spectrum disorders.  These reports are supported by independent genetic 
linkage and association data from multiple populations (Chubb et al., 2008; Bradshaw et al., 
2012).  
 
It is becoming increasingly apparent that major psychiatric disorders such as schizophrenia, 
bipolar disorder and major depressive disorder have at least some genetic risk factors in 
common (Thomson, Duff et al., 2016).   
 
As no single gene is known to be directly causative in the aetiology of major mental illness, 
linkage and association studies have been helpful by way of widening the search. 
 
Large collaborative genome-wide association studies (GWAS) have shown a polygenic 
component to the risk of schizophrenia (McIntosh et al., 2013) and have begun to reveal the 
complex genetic architecture involved in psychiatric disorders.  New findings from these 
studies have also identified an element of genetic overlap between schizophrenia, bipolar 
disorder and major depressive disorder (Thomson et al, 2014). 
 
Polygenic theory (numerous genes of small effect) however, is not new.  In 1967 Gottesman 
and Shields stated that polygenic theory had not been given enough attention, and they 
hypothesised that a number of genes of small effect interacting with each other, together with 
environmental ‘milieu’ pre-disposed people to the risk of developing major mental illness.  
Their work proposed a ‘liability to schizophrenia threshold’ that once reached, would most 
likely lead to illness. 
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Taking polygenic theory forward, polygenic risk scores can be calculated and therefore 
compared to determine whether the polygene approach could be used as a valid predictor for 
the later development of major mental illness (Purcell et al., 2009).   
 
Polygenic risk for schizophrenia was investigated with a specific focus on general intelligence 
in a large cohort of older non-psychiatric participants by McIntosh et al., (2013) who reported 
an association between an increased polygenic risk for schizophrenia with lower cognitive 
ability at age 70.  McIntosh et al., also reported that between the ages of 11 and 70 there was a 
greater relative decline in general cognitive ability. They concluded that common genetic 
variants could underlie the risk of schizophrenia as well as cognitive ageing. 
 
Whalley et al., (2016) investigated polygenic risk for schizophrenia in depression and reported 
a significant relationship between neuroticism in unaffected control participants and polygenic 
risk for schizophrenia. 
 
Their study did not find the same relationship in those with major depressive disorder and 
suggested this could be due to heterogeneity, however their findings are in line with a model 
in which traits for depression in the general population are predicted by genetic risk for 
schizophrenia.  Previous studies have also reported a negative relationship between polygenic 
risk for schizophrenia and cognitive function, pointing to a shared genetic risk between 
impaired cognition and schizophrenia (Lencz et al., 2014, Liebers et al., 2016).  
 
Polygenic risk for schizophrenia is a risk factor for schizophrenia, bipolar disorder and 
depression.  As the DISC1 t(1;11) balanced translocation is not always associated with illness, 
let alone schizophrenia, it may be the case that polygenic risk interacts with translocation status 
to influence diagnosis. 
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1.6.2 Why is the DISC1 t(1;11) balanced translocation of interest and what do we know so 
far? 
 
The balanced translocation itself - which identified DISC1 – remains very much unstudied as 
this particular translocation has only been found in one large Scottish kindred.  Single family 
studies are important for identification of the group of psychoses in which single-gene loci may 
have a major effect on illness risk (Blackwood et al., 2001).  From the early work by Jacobs et 
al., (1970) and St. Clair et al., (1990) there is evidence that the translocation is highly heritable, 
at the time being found in four generations of the family. 
 
From a study by Blackwood et al., (2001) pre-morbid I.Q. was found to be within normal 
ranges in both translocation carriers and non-carriers. P300 amplitude and latency, however, 
were found to be abnormal in family members with psychoses and their asymptomatic 
relatives, compared to patients with schizophrenia and healthy controls.   
 
These findings indicate the possibility that the translocation may play a role in the development 
of grey matter volume in the left posterior superior temporal gyrus (STG) which has previously 
been found to be reduced in schizophrenic patients with auditory P300 abnormalities 
(McCarley et al., 1993). 
 
Abnormal P300 amplitude and latency is also believed to indicate impairment in the speed and 
processing of stimuli which has been clearly demonstrated in significantly reduced information 
processing speed tasks in patients with schizophrenia (Braff, 1993). The t(1;11) translocation 
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1.6.3 DISC1 t(1;11) Translocation – What is not there? 
 
Measures of attention and pre-morbid I.Q. were obtained circa 1990 (see Chapter 2 for a full 
review), however a full battery of neuropsychological measures has not as yet been undertaken.  
Similarly, there is potential to learn more about the translocation from the wide range of 
imaging modalities now available (see Thomson, Duff et al., 2016). 
 
Investigating the polygenic risk profiles of t(1;11) family members by directly comparing those 
with and without the translocation is also a promising area for future research as is the 
longitudinal comparison of cognitive ability, especially with regard to cognition across the 
lifespan, which could offer new insights. 
 
Specific comparisons of the cognitive profiles, clinical symptoms, polygenic risk profile scores 
and self-reported personality/mood data between those with schizophrenia with/without the 
translocation; those with bipolar disorder with/without the translocation and those with major 
depressive disorder with/without the translocation could all be very informative. 
 
Finally, it would also be interesting to investigate whether any cognitive domains, clinical 
symptoms, polygenic risk profiles and/or any self-reported questionnaire data correlate with 
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1.7 Overall Aims and Hypotheses 
 
1.7.1 DISC1 t(1;11) Translocation Carriers and Non-Carriers 
 
The aim of this study - as part of a larger study undertaken to conduct complementary 
investigations in individuals from the t(1;11) family (Thomson, Duff et al., 2016), is to compare 
the cognitive profiles (including clinical ratings, polygenic risk profile scores and self-reported 
personality/mood data) of those with the genetic risk factor - DISC1 translocation - with and 
without psychiatric illness and assess the effects of possible confounding factors including, in 
particular, illness and medication, to establish how the cognitive profiles differ and the impact, 
if any, of the unique balanced translocation. Group comparisons will therefore be conducted 
between those with and without the known genetic risk factor.  Translocation carriers will then 
be examined by sub-group (grouped by diagnosis - with and without psychotic/affective/any 
psychiatric illness) with a view to determining whether any differences within this kindred 
could be postulated as being a translocation effect or an effect of illness. 
 
As a result of previous findings (Blackwood et al., 2001), we hypothesise a reduction in current 
IQ and information processing speed in those carrying the DISC1 t(1;11) translocation and 
particularly in those with psychosis.   
 
As positive symptom severity was found to correlate with reduced cortical thickness (Thomson, 
Duff et al., 2016), symptom severity, in particular positive symptoms, were also hypothesised 
to be associated with a reduction in IQ and measures of processing speed, again particularly in 
translocation carriers – especially those with psychosis. 
 
The t(1;11) translocation is not always associated with illness, let alone schizophrenia, and 
polygenic risk for schizophrenia is a risk factor for schizophrenia, bipolar disorder and 
depression, it may, therefore, interact with translocation status to influence diagnosis. 
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As a result of this and the previous findings by McIntosh et al., (2013) and Whalley et al., 
(2016) it was further hypothesised that associations would be found between polygenic risk for 
schizophrenia in t(1;11) family members - especially in translocation carriers with psychosis - 
and measures of general intelligence (I.Q).  It was also hypothesised that associations would 
be found between polygenic risk for schizophrenia, especially in translocation carriers with 
psychosis, and symptom severity - in particular positive symptomology. 
 
The analysis plan includes examining the effects of the translocation in t(1;11) carriers and 
non-carriers and relating any findings to unaffected controls versus participants with 
schizophrenia and bipolar disorder. A direct comparison between translocation carriers and 
unrelated individuals with schizophrenia, bipolar disorder or unaffected control participants 
was not warranted given differences in degrees of relatedness and shared environmental effects 
between these groups. 
 
Research into how similar family members' brains are has suggested that certain areas are 
highly heritable (Glahn et al., 2007b).  This means that direct comparisons between members 
of one family with a group of unrelated individuals would be significantly confounded by the 
shared heredity within the family, therefore, direct comparisons between the t(1:11) kindred 
and those with schizophrenia, bipolar disorder or unaffected control participants were not 
performed.  
 
The recruitment of schizophrenia, bipolar disorder and unaffected control participant groups 
allows for the comparison of the effects of having a psychiatric disorder in general, to the 
effects of the t(1;11) translocation within the family, while minimising key confounds and 
without the need for direct comparisons between family members and patients. 
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1.7.2 Aims and Hypotheses – Patients and Control Participants 
 
In line with the investigations between DISC1 t(1;11) family members, the clinical, cognitive, 
polygenic risk profiles and self-reported personality/mood data of participants with 
schizophrenia, participants with bipolar disorder and unaffected control participants, will also 
be compared.  These samples were recruited with a view to identifying any potential patterns 
in the results from the t(1;11) kindred that are absent in the patient/control groups which may 
be explained as being unique and potentially directly attributable to the translocation. 
 
It was hypothesised that there would be a significant reduction in IQ and measures of 
processing speed between participants with schizophrenia and bipolar disorder compared to 
unaffected control participants and that there would be reductions in IQ and measures of 
processing speed between the schizophrenia/bipolar disorder participant groups with the 
greatest impairment in individuals with schizophrenia compared to individuals with bipolar 
disorder. It was similarly hypothesised that IQ in participants with bipolar disorder would be 
more impaired than that evidenced in unaffected control participants. 
 
In line with the t(1;11) family, it was further hypothesised that associations would be found 
between polygenic risk for schizophrenia and general intelligence (IQ) and/or symptom 





































Schizophrenia is a complex mental illness first conceptualised over 100 years ago, the cause(s) 
of which remains unknown.  There is still no direct diagnostic test for the illness and 
importantly there is still no overall cure.  There is, however, convincing evidence that 
schizophrenia is a genetic and neurodevelopmental disorder (Sawa and Snyder, 2002; Stahl, 
2007). 
 
Schizophrenia is defined by its’ ‘positive’ symptoms (e.g. hallucinations, delusions, disordered 
speech and thoughts, etc.) and ‘negative’ symptoms (e.g. poverty of speech, inability to 
experience pleasure, lack of motivation, etc.) (Sawa and Snyder, 2002; Camargo et al., 2007) 
- positive symptoms being abnormal by their presence and negative symptoms notable by their 
absence. Impaired cognition is also a core symptom of schizophrenia, especially general 
intelligence, memory and executive functions (Johnstone et al., 2010).  Research to identify 
new therapeutic targets for treatment, as well as to pinpoint specific indicators allowing early 
intervention would be beneficial in improving outcomes and helping to shield people from 
having to experience psychosis. 
 
2.1.1 Schizophrenia – highly heritable and cognitive 
 
Specific genetic markers have been identified in patients with schizophrenia and bipolar 
disorder.  Importantly, these markers have also been identified in the non-affected relatives of 
patients, providing strong evidence that these illnesses are both heritable conditions (Sullivan 




Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
66 
  
Compelling evidence from a number of family; twin and adoption studies also report that 
genetic factors are important in how schizophrenia is transmitted (Johnstone et al., 1999; 
Harrison & Weinberger, 2005), however, this does not explain all of the variance in liability to 
the illness; therefore environmental factors must also be considered (Gottesman, 1991). 
 
Cognitive bio-markers of risk have also been reported in people with schizophrenia and bipolar 
disorder (Keri et al., 2001; McIntosh et al., 2005; Arts et al., 2008, Drysdale et al., 2013).  
General intelligence (I.Q.) and working memory were found to have the highest heritability in 
a twin study which used genetic model fitting (Toulopoulou et al., 2007).  The study also 
reported that genetic influences substantially contributed to all cognitive domains tested.  Much 
work remains to be done in this area which is very promising for future studies. 
 
2.1.2 Cognition as a possible intermediate phenotype? 
 
Cognition, or mental processing, is essential for gaining and understanding knowledge from 
the world around us. Executive function, learning and memory, working memory, attention 
and concentration, motivation, general intellectual ability and emotions are all basic cognitive 
functions of the brain which can be disrupted in psychiatric illness by many factors including 
genetic; developmental and environmental (Lönnqvist, 2010).  Intact cognition affords people 
the opportunity to perform and enjoy their daily routines, develop employment skills, enjoy 
socialising with family and friends, become motivated to set and achieve goals, enjoy sports 
and/or other hobbies and generally become a productive member of society.  Impaired 
cognition can drastically impact on these abilities, however in the case of schizophrenia, and 
to a lesser extent, bipolar disorder, activities which are taken for granted by most, can become 
impossible.  The level of cognitive impairment in schizophrenia can be predictive of functional 
abilities in areas such as living status, occupational and social abilities (Barch & Keefe, 2010; 
Lönnqvist, 2010).   
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Improving cognitive function would potentially improve the functional outcomes and quality 
of life for sufferers of this very debilitating illness, and go some way to addressing important 
humanitarian and public health concerns (Barch & Keefe, 2010). 
 
Studies investigating cognition are gradually teasing out links between brain and behaviour 
with a particular focus on how to measure cognitive function in schizophrenia (Nielsen et al., 
2011). 
 
Although cognitive functions have been measured as part of many earlier studies, no standard 
battery of neuropsychological tests existed, meaning a wide variety of tests were used and 
results were therefore difficult to compare (Nielsen et al., 2011).  Overall, test scores of patients 
with schizophrenia are likely to be one to two standard deviations below those of control 
subjects and those with schizophrenia have also been found to be more severely impaired than 
those with bipolar disorder or recurrent major depression across a wider range of cognitive 
domains (Nielsen et al., 2011).  Imaging techniques have added valuable knowledge to the 
evidence base and functional imaging has consistently revealed a reduction in prefrontal cortex 
activity in schizophrenia - consistent with cerebral circuitry being impaired - disrupting normal 
cognitive functioning (Nielsen et al., 2011). 
 
Impaired cognitive performance is recognised as a core feature of schizophrenia, so much so 
that there has recently been a call for schizophrenia to be reclassified as a cognitive illness 
(Khan & Keefe, 2013). Patients with schizophrenia demonstrate global intellectual 
impairments which pre-date psychosis onset, and impairment is also found in other areas of 
cognition, especially attention and processing speed, executive function and memory 
(Johnstone et al., 1999).   
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Information processing speed is of particular importance as it is known to account for 25% of 
the variance in the general ability of healthy populations (Joyce, 2013).  It is evident from 
replicated studies that prior to the onset of psychosis, individuals who developed schizophrenia 
performed worse in school tests and/or IQ tests than their healthy peers, and their 
underperformance was evident as far back as childhood (Joyce, 2013). 
 
As cognitive underperformance has been evidenced in schizophrenic patients as far back as 
childhood it is possible that this impairment is present at birth (Khan & Keefe, 2013).  It is 
equally possible, however, that impairment occurs at some point during development, but prior 
to the onset of psychosis, and this lag in brain development may be a crucial early manifestation 
of the illness (Khan & Keefe, 2013). 
 
Cognitive ability has been reported as being a true endophenotype for susceptibility to 
schizophrenia (Lencz et al., 2014), however to date, there is no defining ‘cognitive signature’ 
of schizophrenia and future research to further characterise this is promising for future work 
(Joyce, 2013). 
 
2.1.3 Why might DISC1 impact on neuropsychological function? 
 
To date, it has been established that the DISC1 gene is expressed in glia and neurons and is 
translated to a protein that has an impact on neurochemical and neurodevelopmental processes 
including neuronal migration, glutamatergic transmission, neuritic outgrowth and 
synaptogenesis, which are believed to be involved in the pathophysiology of schizophrenia 
(Cannon et al., 2005).  DISC1 is also an intracellular scaffold protein with many protein 
interactors (Sawa & Snyder, 2005, Ishizuka et al., 2006, Porteous & Thomson, 2006) heavily 
involved in critical neurodevelopmental roles.   
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Two of its’ major roles are thought to include the regulation of key processes in early brain 
development and synapse formation and maintenance (Brandon & Sawa, 2011).  DISC1 has 
also been found to be expressed in several brain regions including the hippocampus, 
hypothalamus, olfactory bulb, cerebellum, cortex and in the brainstem after birth.  Importantly, 
DISC1 has been found to be highly expressed in the developing brain (Schurov et al., 2004).  
Although this gene appears to play a critical role in early development and adolescence, it is 
also highly expressed in the adult brain, in particular in the dentate gyrus of the hippocampus 
(Austin et al., 2004). 
 
Genomic imaging studies examining the effects of DISC1 variants on brain structure and 
neurocognitive function (see Duff et al., 2013 for a comprehensive review) have also provided 
some evidence that intact cognition is dependent on normal undisrupted development.  
Research over the past decade has established many critical brain mechanisms involving 
DISC1 that could potentially result in abnormalities of the neurodevelopmental process, which 
in turn could lead to altered brain structures and/or impairment in brain function (Rampino et 
al., 2014). 
 
Genetic research of DISC1 has moved to finer mapping techniques in the search for likely 
single nucleotide polymorphisms (SNPs) which are responsible for transmitting the correct 
coding instructions in development.  Two common SNPs have been studied extensively with 
regard to the DISC1 gene and major psychiatric disorders, namely Ser704Cys (rs821616) and 












Copy number variants (CNVs) and rare variants are also of interest, as they are believed to play 
a crucial role in neurodevelopment, while collaborative genome-wide association studies 
(GWAS) and linkage studies have identified rare mutations and deletions in individuals, as 
well as duplications of genetic structures and translocations, all of which play a critical role in 
development, which may shed more light on the complex systems involved in normal human 
development free from psychiatric disorder (Bradshaw & Porteous, 2012). 
 
Interest in the neuropsychological study of major mental illness as the link between brain and 
behaviour is increasing.  This chapter will review the literature on the neuropsychology of 
DISC1 in humans, and summarise studies that investigate cognitive function and variants of 
the DISC1 gene to identify associations between DISC1 and any specific cognitive domains 









Studies were sought on healthy participants and/or those with psychiatric illness presenting 
original data on the effects of any DISC1 gene variant and cognition. A systematic search was 
conducted for papers published until the end of December 2014 using Embase, PsychINFO, 
OVID and Pubmed. Key-words used were: Disrupted-in-Schizophrenia 1, DISC1, 
Neuropsychology, Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Cognition 
and Human.  A manual search of the reference lists of identified review articles and 
bibliographic cross-referencing was also performed, together with a search of relevant 
conference abstracts for the period January 2010 – December 2014. From included studies, 
data was extracted on subject demographics, diagnosis, illness variables and 
neuropsychological assessments – details are provided in Tables 2.1 and 2.2. 
  
2.2.1 Description of studies 
 
Twenty-six human neuropsychological studies of DISC1 or the DISC1 location were found: 
(Blackwood et al., 2001 ; Gasperoni et al., 2003 ; Paunio et al., 2004 ; Hennah et al., 2005 ; 
Cannon et al., 2005 ; Callicott et al., 2005 ; Burdick et al., 2005 ; Thomson et al., 2005 ; Liu et 
al., 2006 ; Hashimoto et al., 2006 ; Palo et al., 2007 ; Di Giorgio et al., 2008 ; Raznahan et al., 
2010 ; Prata et al., 2010 ; Nicodemus et al., 2010 ; Brauns et al., 2011 ; Sprooten et al., 2011 ; 
Chakirova et al., 2011 ; Carless et al., 2011 ; Chakravarty et al., 2012 ; Li et al., 2012 ; Kahler 
et al., 2012 ; Whalley et al., 2012 ; Thomson et al., 2013 ; Thomson et al., 2014 ; Nicodemus 
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Fourteen studies specifically investigated DISC1 variants with neuropsychological function at 
an observable behavioural level: (Blackwood et al., 2001; Gasperoni et al., 2003; Paunio et al., 
2004; Hennah et al., 2005; Cannon et al., 2005; Callicott et al., 2005; Burdick et al., 2005; 
Thomson et al., 2005; Liu et al., 2006; Palo et al., 2007; Carless et al., 2011; Thomson et al., 
2013; Thomson et al., 2014; Nicodemus et al., 2014). 
 
These studies examined the effects of either the 1q42 region, the common DISC1 SNP 
Ser704Cys (rs821616), other common or rare variants and gene-gene interactions with a variety 
of cognitive functions and are included for review (Table 2.1).  Twelve studies were conducted 
using functional magnetic resonance imaging and were not included for review.  Studies that 
included a measure of either current IQ, premorbid IQ and/or reading comprehension are 
summarised in Table 2.2. 
 
2.2.2 Subject characteristics 
 
From included studies, three examined healthy/non-psychiatric participants (Thomson et al., 
2005; Carless et al., 2011; Thomson et al., 2013) while the majority of studies examined 
patients with schizophrenia and/or affective disorders (n=10).  Group sizes for studies 
specifically examining cognition at an observable behavioural level varied from 12 to over 700 
participants. Two studies specifically examined patients with schizophrenia and/or affective 
disorders; (Burdick et al., 2005; Liu et al., 2006) and nine studies included a comparison group 
of healthy control subjects (Blackwood et al., 2001; Gasperoni et al., 2003; Paunio et al., 2004; 
Hennah et al., 2005; Cannon et al., 2005; Callicott et al., 2005; Palo et al., 2007; Thomson et 
al., 2014; Nicodemus et al., 2014). 
 
Twelve studies did not specifically examine cognition at an observable behavioural level but 
gathered a measure of general intelligence.   
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Group sizes varied from 53 to over 1000 participants (Hashimoto et al., 2006; Di Giorgio et 
al., 2008; Raznahan et al., 2010; Nicodemus et al., 2010; Prata et al., 2010; Sprooten et al., 
2011; Brauns et al., 2011; Chakirova et al., 2011; Chakravarty et al., 2012; Li et al., 2012; 
Whalley et al., 2012; Kahler et al., 2012). 
 
In general, diagnosis was confirmed by structured clinical interview for DMS-III-R and/or 
DSM-IV.  In most cases, assessments of contemporaneous mental state were presented using 
observer rating scales for positive and negative symptoms of schizophrenia and some also 
included observer mood rating scales.  Although details of antipsychotic medications were not 
provided, one study explicitly excluded subjects with substance misuse (Nicodemus et al., 





















2.3.1 DISC1 and Neuropsychological Function 
 
To date, fourteen human neuropsychological studies of DISC1- using a range of assessments - 
include a specific measure of cognitive assessment (see Table 2.1). Twelve studies did not 
specifically investigate cognitive function at an observable behavioural level but did obtain a 
measure of either current/pre-morbid I.Q. or reading comprehension from their study samples 
(see Table 2.2 which includes 3 studies from Table 2.1 who also reported a measure of either 
current or premorbid I.Q. and/or reading comprehension).  I.Q. data were not comparable due 
to the variability of the measures used and the methods of acquiring and reporting results. 
 
Results have been ordered by cognitive domain as agreed by the MATRICS (Measurement and 
Treatment Research to Improve Cognition in Schizophrenia) (Nuechterlein et al., 2008). 
 
Table 2.1 
Studies investigating associations between DISC1 variants and specific measures of cognitive function/studies that include a 
specific measure of cognitive assessment. 
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* WAIS-R (Wechsler Adult Intelligence Scale Revised), WMS (Wechsler Memory Scale), WMS-R (Wechsler Memory Scale 
Revised), CPT (Continuous Performance Test), CVLT (California Verbal Learning Task), WCST (Wisconsin Card Sorting Task), 
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 2.3.2 General intellectual ability (I.Q.) 
 
Blackwood et al., (2001) measured general intellectual ability in all participating members of 
a large extended Scottish kindred, some of whom carried a unique t(1;11) translocation. Using 
the National Adult Reading Test (NART), pre-morbid intelligence scores were found to be 
within the normal range and no differences were found in mean pre-morbid I.Q. scores between 
translocation carriers (n=12, M=100.3) and non-carriers (n=8, M=100.5).  A measure of current 
I.Q. in this study would have allowed pre-morbid I.Q. to be compared to current I.Q. which 
may have revealed an effect of the translocation.  
 
As a result of its association with impaired learning and memory, variation in DISC1 became 
the focus of normal cognitive aging. Thomson et al., (2005) used the same general mental 
ability test undertaken by participants of the Lothian Birth Cohort in 1921 at age 11 and tested 
them again at age 79 to examine the effect of genotype at SNP rs821616 and normal cognitive 
function (n=425).  Although there were no significant effects of DISC1 genotype on cognition, 
a significant genotype by sex interaction was revealed for females homozygous for the Cys 
allele. Female (n=17) cognitive ability scores were significantly lower than males (n=13); 
indicating the possibility that variation in DISC1 may affect normal cognitive aging, especially 
in females. This was the first study to report an association between cognitive function and a 
DISC1 polymorphism in a non-psychotic population. Due to the small sample sizes these 
findings will require to be replicated in a larger sample before being confirmed. 
 
In a more recent study, Thomson et al., (2014) investigated 889 control participants from the 
Lothian Birth Cohort (LBC) (1936) with 653 patients (schizophrenia (n=240), bipolar disorder 
(n=221) and recurrent major depressive disorder (n=192)). 
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Functional and putative regulatory variants were found to be nominally associated with 
recurrent major depressive disorder and/or cognitive ability at the locus-wide level of 
significance. Burden analysis for putative functional variants observed a nominally significant 
increase in burden of minor alleles for coding SNPs or SNPs in CpG islands and Moray House 
Test score measures of cognitive ability.  As the reported association between recurrent major 
depressive disorder in the discovery cohort and an intronic SNP (rs16856199) had a ‘modestly 
significant P-value’ which could be due to chance, these findings require to be replicated in 
independent samples. 
 
In a separate population based study of participants with recurrent major depression 
(Generation Scotland) no significant results were found for any of the cognitive variables 
investigated, however Thomson et al., (2013) did report association of the DISC1 SNP 
rs6541281 with a reduced age of onset. 
 
2.3.3 Speed of Processing 
 
The previously mentioned study by Blackwood et al., (2001) also investigated auditory P300 
Event Related Potential (ERP) recordings in their study of a Scottish kindred known to carry a 
unique DISC1 t(1;11) translocation (n=12).  Recordings were compared with a group of non-
carriers from the same family (n=10); a group of unrelated patients with schizophrenia (n=20) 
and a group of healthy controls (n=26).  The study detected abnormal P300 amplitude and 
latency in translocation carriers with psychoses and their asymptomatic relatives. 
 
Auditory P300 is believed to indicate deficits in the speed and efficiency of the processing of 
stimuli in short-term memory and has consistently shown prolonged latency of, and reduced 
amplitude of P300 ERP in patients with schizophrenia as well as in their relatives. 
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Studying single large families with multiple affected family members is advantageous in 
mental health research, especially the major psychoses, however there is also a disadvantage 
in that the results could be unique and/or rare to that particular family and not, in fact, to the 
illness itself. 
 
Burdick et al., (2005) provided preliminary evidence that the DISC1 gene may affect 
information processing in patients with schizophrenia. In their study of 250 patients with 
schizophrenia, a significant association was found between the DISC1 SNP hCV1650649 and 
rapid visual search using the Trail Making Test-A. 
 
Patients carrying two copies of this risk allele were found to perform significantly worse than 
patients carrying only one or no copies, and these results remained significant after they limited 
their comparisons to patients carrying two copies of the risk allele (n=152) to patients carrying 
only one copy (n=87).  Patients were split into two groups - African Americans and Caucasians 
- however after conducting analyses for these groups separately, only the results for the African 
American patients remained significant. It was noted that there were demographic differences 
between the groups, specifically in terms of illness duration and education which may have had 
a bearing on these results. 
 
In a large study of Finnish families, Palo et al., (2007) collected neuropsychological data on 
158 individuals with a range of diagnoses including Bipolar Disorder I, Bipolar Disorder II, 
Bipolar Disorder NOS, Cyclothymia, Bipolar Disorder 1 with intermittent psychotic features, 
psychotic depression, schizophrenia, schizoaffective disorder and psychosis NOS as well as 
unaffected family members.  Using the Category Fluency task from the Controlled Oral Word 
Association Test, designed to assess verbal fluency, Palo et al., reported an association between 
category fluency and the DISC1 SNP rs821616.   
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Their study also reported an association between the DISC1 SNP rs980989 and psychomotor 
processing speed using the Digit Symbol task, again taken from the Wechsler Adult 
Intelligence Scale-revised.  It should be noted that the significant results reported here were not 
corrected for multiple testing to afford a full interpretation using the non-corrected values. 
 
In a recent study, Nicodemus et al., (2014) combined a candidate gene approach with a 
computational linguistic approach (latent semantic analysis (LSA)). Using a category fluency 
task (animals) the DISC1 SNP rs12133766 was found to be negatively associated with average 
vector length in male controls – a finding which was replicated in male probands but not male 
siblings, likely due to the small sample. This finding indicates that males who carried a copy 
of the minor allele at rs12133766 used less complex terms in response to the cue ‘animal’ than 
those who did not carry a copy of the minor allele, regardless of the number of words generated. 
 
Their study also found that this SNP was not significantly associated with traditional measures 
of verbal learning and recall which suggests the novel computational linguistic approach may 
be tapping into different components of category fluency than those measured by the more 
traditionally-used tasks, and may therefore be able to provide a more specific phenotype. 
 
2.3.4 Attention and Vigilance 
 
In their study of 215 Finnish families, of which 746 individuals completed comprehensive 
neuropsychological assessments, Hennah et al., (2005) reported an association between the 
DISC1 haplotype HEP3 and visual attention and visual working memory.   
 
Using the visual span forward task from the Wechsler Memory Scale-Revised, Hennah et al., 
noted a poorer performance in the affected offspring but not in the unaffected offspring for 
visual attention.  
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The included individuals had a range of diagnoses and were grouped according to increasingly 
inclusive liability classes (LC).  LC1 comprised individuals with schizophrenia only; LC2 
included individuals with schizophrenia and schizoaffective disorder; LC3 included 
individuals with schizophrenia, schizoaffective disorder and schizophrenia spectrum disorders 
and finally, LC4 represented the whole sample with the addition of individuals with bipolar 
disorder and/or major depressive disorder and 356 unaffected offspring. This finding is slightly 
unexpected as earlier work by Hennah et al., 2003 postulated the HEP3 haplotype as a 
potentially protective variant. 
 
Cannon et al., (2005) examined gene-gene interactions involving DISC1 variants in 7 twin pairs 
concordant for schizophrenia, 52 twin pairs discordant for schizophrenia and 59 healthy control 
twin pairs (n=236). Their work reported associations between a rare 4-SNP DISC1/TRAX 
haplotype, ‘AATG’ (n=17) which was significantly positively associated with visual reaction 
time.  A primary difference was reported between the two samples in the genetic structure of 
the HEP2 haplotype (AC) which was found to have a lower-than-expected rate in the twin 
sample.  This finding could indicate the variation as being due to chance, especially in view of 
the small sample size. 
 
102 schizophrenic nuclear families with at least 2 affected siblings were assessed using a 
Continuous Performance Task (CPT) by Liu et al., (2006).  231 individuals were assessed using 
an un-degraded CPT task and 225 completed a degraded CPT task. Liu et al., reported an 
association between DISC1 and impairment of sustained attention suggesting the DISC1 gene 
may be involved in regulating the working memory aspect of sustained attention in 
schizophrenia.  
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As the significant finding was associated with the un-degraded CPT task and not the degraded 
task, it’s possible that this task makes use of differing neuropsychological functions, i.e. the 
degraded task involves working memory together with a sensory-perceptual component, 
whereas the un-degraded task involves working memory only. 
 
2.3.5 Working Memory 
 
Early work by Gasperoni et al., (2003) reported an association between variation in spatial 
working memory in schizophrenic patients and their unaffected co-twins, with a marker on 
chromosome 1q.  Their study sample consisted of 30 dizygotic and 20 monozygotic same-sex 
twin pairs discordant for schizophrenia, and 27 dizygotic and 28 monozygotic healthy control 
twin pairs. Generalizability of this result may be questionable due to the fact that the data relate 
to a genetic isolate from Finland, therefore additional research using non-Finnish populations 
is required to confirm this finding. 
 
As part of their larger DISC1 imaging study, Callicott et al., (2005) assessed working memory 
separately using the Wisconsin Card Sorting Task.  
 
At an observable behavioural level they reported lower category scores for homozygous Ser 
allele (rs821616) participants across all diagnoses.  Although this result reached significance, 
it did not survive multiple comparisons. It was noted in this study that DISC1 had a larger 
impact on MRI findings as oppose to the observable behavioural cognitive findings and it’s 
possible that DISC1 variation may impact the efficiency of information processing, resulting 
in mild neuronal impairment rather than more pronounced cognitive deficits.  
 
In the previously mentioned study of 250 patients with schizophrenia by Burdick et al., (2005) 
verbal working memory was found to be significantly associated with the DISC1 SNP 
hCV1650649 using the Digits Backward task. 
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
84 
  
Again, patients carrying two copies of this risk allele were found to perform significantly worse 
than patients carrying one or no copies of the allele and again, these results remained significant 
after limiting their comparisons to patients carrying two copies of the risk allele (n=152) to 
patients carrying only one copy (n=87).  Patients were split into two groups - African 
Americans and Caucasians - however after conducting analyses for these groups separately, 
only the results for the African American patients remained significant. Previous studies with 
positive findings were restricted to Caucasian subjects, therefore having distinct ethnic groups 
could have resulted in environmental effects and/or the effects of other genes differentially 
modulating this relationship. 
 
In their population-based cohort study of same-sex twins born in Finland, Cannon et al., (2005) 
tested for associations between schizophrenia and several endophenotypic traits believed to be 
involved in the pathogenesis of this illness.  Using the Wechsler Memory Scale, a 4-SNP 
DISC1/TRAX haplotype (AATG; n=17) was found to be associated with spatial working 
memory.  Again, it was previously noted that there was a primary difference between the two 
samples in the genetic structure of the HEP2 haplotype (AC) which was found to have a lower-
than-expected rate in the twin sample.  This finding could indicate the variation as being due to 
chance, especially in view of the small sample size. 
 
Using the Wechsler Memory Scale-revised (Digit Span Forward), Palo et al., (2007) reported 
an association between a DISC1 protective haplotype: G-T-G of rs1655285, rs751229 and 
rs3738401 and auditory attention as part of a study of 158 individuals from Finnish families 
with Bipolar Disorder. Participants included unaffected family members (n=51), participants 
with other mental disorders (n=26) and an overlapping sample of participants with bipolar 
disorder type 1, type II, NOS and cyclothymia.   
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These participants also overlapped with bipolar disorder participants with intermittent 
psychotic features, psychotic depression, schizophrenia, SA disorder and psychosis NOS (Palo 
et al., 2007).  As previously noted, the significant results reported in this study were not 
corrected for multiple testing and the non-corrected values have been shown to allow for a full 
interpretation of the data. 
 
Carless et al., 2011 conducted a large study utilising non-psychiatric participants from large 
extended families who were part of the San Antonio Family Heart Study and the San Antonio 
Diabetes/Gallbladder Study (n=1232).  Using a spatial delayed response task they reported 
cognitive measures of working memory as being associated with the DISC1 SNP rs2793094 
and spatial working memory. Correction for multiple testing was not performed on all of the 
phenotypes examined in this study, therefore replication of the observed associations will be 
required. 
 
2.3.6 Verbal Learning and Memory 
 
Using the California Verbal Learning Test, chromosome region 1q42 was found to have linkage 
of semantic clustering and verbal learning in an internal isolate of 110 Finnish schizophrenia 
families living in northern Finland, and of intrusive recall errors in 58 Finnish schizophrenia 
families living elsewhere in Finland (Paunio et al., 2004). 
 
 As part of their larger DISC1 imaging study, Callicott et al., (2005) assessed episodic memory 
separately using the Logical Memory II subsection of the Wechsler Memory Scale. At an 
observable behavioural level they reported that participants with schizophrenia, homozygous 
for the Ser allele of SNP rs821616 demonstrated reduced performance on this task.  Although 
this result reached significance, it did not survive multiple comparisons.  
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Ser/Cys has not been implicated as being a causative mutation for diminished cognition and 
there is no direct evidence to this effect, therefore investigating different DISC1 SNPs may 
yield stronger effects. 
 
In their large twin-study (n=236) examining gene-gene interactions of DISC1 variants, Cannon 
et al., (2005) reported associations between certain DISC1/TRAX haplotypes and short-term and 
long-term memory impairment. Using the California Verbal Learning Task, semantic clustering 
was significantly negatively associated with a 3-SNP DISC1 Haplotype - HEP1 (n=115) and 
HEP1 was also associated with verbal learning and memory generally.  A 4-SNP DISC1/TRAX 
Haplotype – AATG (n=17) was also significantly negatively associated with verbal learning 
and memory.   
 
In their large study of Finnish families with Bipolar Disorder, Palo et al., (2007) also 
administered the California Verbal Learning Test to 158 participants (bipolar spectrum disorder 
(n=66); psychotic disorder (n=67); other mental disorders (n=26) and unaffected family 
members (n=51)) and reported an association to perseverative recall errors and long delay recall 
with the DISC1 SNP rs751229.  Long delay recall was also found to be associated with the 
DISC1 SNP, rs1322784. It has already been noted that the significant results from this study 
are non-corrected due to the omission of multiple testing.  
 
2.3.7 Visual Learning and Memory 
 
In their previously mentioned study of 215 Finnish schizophrenia families, Hennah et al., 
(2005) used the visual span backward task from the Wechsler Memory Scale-Revised and 
reported evidence of poorer performance in visual working memory in a sample of 249 affected 
offspring and 273 unaffected offspring.  
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They noted an almost equal contribution from both the affected and unaffected offspring to 
their observed associations between short-term visual memory and the DISC1 haplotype HEP3.  
As stated earlier, the HEP3 haplotype had previously been thought to represent a protective 
variant which is counterintuitive to these findings.  
 
2.3.8 Reasoning and Problem Solving 
 
The Wechsler Adult Intelligence Scale-revised (Block Design) was also administered by Palo 
and colleagues (2007) as part of their previously mentioned Finnish bipolar family study. Using 
this measure they reported an association between visuospatial ability and the DISC1 SNP 
rs821616.  Visuospatial ability was also found to be associated with the DISC1 SNP rs980989. 
It has already been noted that the significant results reported in this study are based on non-
corrected values due to the omission of multiple testing. Multiple testing was not conducted to 




Although general intelligence (I.Q.) could not be statistically compared across studies, 
premorbid I.Q. in the Scottish kindred was found to be within the normal range in both those 
carrying the rare t(1;11) translocation and those without. A measure of current I.Q. was not 
obtained for these family members, and is an area for future examination as it may reveal an 
impact of the translocation on general intelligence.  The DISC1 SNP rs821616 was reported to 
affect general cognition in older non-psychiatric females who had significantly lower scores 
on cognitive ability tests than their male counterparts (Thomson et al., 2005).  Variation in 
DISC1 may be a risk factor for impaired cognition in general, and for cognitive aging, 
especially in females. 
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From the fourteen studies that specifically examined DISC1 and/or the DISC1 region and 
cognitive function at an observable behavioural level, Blackwood et al., focussed on a rare 
t(1;11) translocation, three studies focussed on the DISC1 chromosome region 1q (Gasperoni 
et al., 2003; Paunio et al., 2004; Liu et al., 2006), three studies investigated a common DISC1 
SNP, namely Ser704Cys (rs821616) (Callicott et al., 2005; Thomson et al., 2005; Palo et al., 
2007), two studies examined DISC1/TRAX haplotypes (Hennah et al, 2005; Cannon et al., 
2005) and five studies found associations between cognitive function and a number of other 
DISC1 SNPS (Burdick et al., 2005; Palo et al., 2007; Carless et al., 2011; Thomson et al., 2014; 
Nicodemus et al., 2014). 
 
Spatial working memory, verbal learning and memory and visual attention have all been 
associated with variation at the breakpoint region, 1q42 (Gasperoni et al., 2003; Paunio et al., 
2004; Liu et al., 2006).  Verbal fluency, visual memory, working memory, visuospatial ability 
and the Moray House Test of general cognition have been associated with the common DISC1 
SNP, Ser704Cys (rs821616) (Callicott et al., 2005; Thomson et al., 2005; Palo et al., 2007). 
 
Verbal learning and memory, visual memory, spatial working memory, reaction time and 
attention have all been associated with the DISC1 haplotypes, HEP1, HEP3, a rare 
DISC1/TRAX haplotype, ‘AATG’ and/or a protective haplotype  G-T-G of rs1655285, 
rs751229 and rs3738401, (Cannon et al., 2005; Hennah et al., 2005; Palo et al., 2007).  Spatial 
working memory was also associated with DISC1 SNP rs2793094 (Carless et al., 200), while 
verbal working memory associated with DISC1 SNPs hCV1650649 and hCV12001930 
(Burdick et al., 2005).  In this study, Burdick and colleagues also reported an association 
between processing speed and both of these DISC1 SNPs.   
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Verbal fluency associated with the DISC1 SNP rs12133766 (Nicodemus et al., 2014) and 
psychomotor processing speed was associated with the DISC1 SNP rs980989 (which was also 
significantly associated with visuospatial ability and verbal learning) (Palo et al., 200).  The 
rare t(1;11) translocation was associated with abnormal P300 results in family members which 
is believed to be an indication of impaired processing speed. 
 
2.4.1 Why is the DISC1 t(1;11) Translocation of interest and what do we know so far? 
 
The balanced translocation itself - which identified DISC1 – remains very much unstudied as 
this particular translocation has only been found in one large Scottish kindred.  Single family 
studies are important for identification of the group of psychoses in which single-gene loci may 
have a major effect on illness risk (Blackwood et al., 2001).  From the early work by Jacobs et 
al., (1970) and St. Clair et al., (1990) there is evidence that the translocation is highly heritable, 
being found in four generations of the family.  From the study by Blackwood et al., (2001)   
pre-morbid I.Q. was found to be within normal ranges in both translocation carriers and         
non-carriers, however, P300 amplitude and latency were found to be abnormal in family 
members with psychoses and their asymptomatic relatives compared to patients with 
schizophrenia and healthy controls. 
 
These findings indicate the possibility that the translocation may play a role in the development 
of grey matter volume in the left posterior superior temporal gyrus (STG) which has previously 
been found to be reduced in schizophrenic patients with auditory P300 abnormalities 
(McCarley et al., 1993).  As stated earlier, abnormal P300 amplitude and latency is also 
believed to indicate impairment in the speed and processing of stimuli which has been clearly 
demonstrated in significantly reduced information processing speed tasks in patients with 
schizophrenia (Braff, 1993).  The t(1;11) translocation may also be a significant contributor 
here. 
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2.4.2 DISC1 t(1;11) Translocation – What is not there? 
 
Although measures of attention and pre-morbid I.Q. were obtained circa 1990, a full battery of 
neuropsychological tests has not as yet been undertaken.  Similarly, there is potential to learn 
more about the translocation from the variety of imaging modalities now available. 
 
Direct comparisons between those with and without the translocation are promising areas for 
future research. Longitudinal comparisons of cognitive ability, especially with regard to 
cognition across the lifespan, could also offer new insights. Specific comparisons between 
those with schizophrenia with/without the translocation; those with bipolar disorder 
with/without the translocation and comparisons of those with major depressive disorder 
with/without the translocation could be very informative. Considering the previous work 
conducted by Thomson et al., (2005) which found a significant effect of genotype by gender 
on cognitive ability in older females, future work could potentially investigate the possibility 
of an effect of gender between t(1;11) carriers and non-carriers. It would also be interesting to 
investigate whether clinical symptoms and self-report questionnaire data correlate with t(1;11) 
carrier status and/or diagnosis within these family members. 
 
2.4.3 Methodological Issues 
 
The results from these studies appear inconsistent and the majority are limited by small sample 
sizes.  No study presented power calculations and multiple comparisons were not routinely 
conducted.  False negative results are likely when analysing small sample sizes and can reduce 
the probability of reliable positive findings – especially in association with multiple 
comparisons.  A number of studies investigated similar populations and potential confounding 
factors were not fully accounted for.   
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Non-genetic confounders such as age and gender were most frequently controlled for, however 
antipsychotic medication, lifestyle, substance abuse, illness duration, affection status and years 
of education were not routinely accounted for.  A measure of either pre-morbid or current I.Q. 
may also have been helpful in view of its known effect on cognition.   To remedy the small 
sample sizes, a possible solution might have been to calculate a combined effect size estimate 
through meta-analysis, however this option was not viable due to the methodological 
differences which prevented valid meta-analysis of this data.  Another inconsistency is the lack 
of an accepted standard battery of neuropsychological tests.  Although a number of studies 
made use of the CVLT together with various measures from the WAIS (Wechsler Adult 
Intelligence Scale), there were a number of other tests used, making it difficult to compare the 
data.  The MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) test battery was primarily developed for use in clinical trials in schizophrenia 
to evaluate cognition-enhancing medications, however, universal use of this battery or the Brief 
Assessment of Cognition in Schizophrenia (Keefe, Harvey et al., 2004) would facilitate the 




DISC1 remains one of the most important and most studied genes in psychiatric research – its 
importance confirmed in a recent study by Ayalew et al., (2012) who identified it as one of the 
leading risk genes for the development of schizophrenia, based on the totality of biological 
evidence.  Moreover, Thomson et al., (2014) made clear that many DISC1 variants remain 
undiscovered.  The majority of measures in the studies reviewed here included a component of 
working memory which is known to be impaired in schizophrenia as well as affective disorders. 
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Working memory and working memory subsystems (posited by Baddeley, 1986; 1992) i.e. 
verbal memory (phonological loop), visual memory (visuospatial sketchpad) and possibly a 
subsystem for numerically processed information (Leather & Henry, 1994) are reported to be 
mediated by prefrontal areas of the brain and invoke the dorsolateral prefrontal cortex (Callicott 
et al., 2000; Horn et al., 2003).  It has also been reported that in schizophrenia, DISC1 
expression is altered in the orbitofrontal cortex (Sawamura et al., 2005) which is linked to the 
dorsolateral prefrontal cortex and working memory, prompting Burdick et al., (2005) to suggest 
that the orbitofrontal cortex may mediate DISC1 effects on neurocognition.  This may 
especially relate to the memory system, as working memory underlies a number of verbal and 
visual cognitive abilities (Silver et al., 2003).  
 
Silver et al., reported that verbal working memory was significantly correlated with visual 
orientation, visual retention, executive function, visuomotor coordination and simple motor 
function.  Their study also reported that spatial working memory was significantly correlated 
with visual orientation, visual retention, simple motor function, memory for faces and memory 
for objects (Silver et al., 2003).  In addition to verbal and visual abilities, working memory also 
underlies processing speed (Brebion et al., 1998) and sustained attention (Coull et al., 1996; 
Liu et al., 2006) all of which have been found to associate with either DISC1 or the DISC1 
region. 
 
From the studies reviewed here, DISC1/DISC1 SNPs and/or DISC1 (DISC1/TRAX) haplotypes 
have shown association with a number of cognitive domains, the majority of which utilise a 
working memory component, supporting the current dominant neurodevelopmental hypothesis 
(Owen et al., 2011).   
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Impaired working memory is likely to have a knock-on effect on other cognitive processes such 
as information processing speed, verbal and visual memory functions, verbal fluency and 
sustained attention, all of which will, in turn, have a negative impact on measures of general 
intelligence (I.Q.).  Future work examining the DISC1 gene and cognition, specifically in 
relation to the memory system and general intelligence, are promising areas in the search for 
genetic variants which may underlie cognitive impairment in schizophrenia and affective 
disorders. 
 
Of particular interest is the t(1;11) balanced translocation which may play a role in both 
working memory and therefore general intelligence as a result of the abnormal P300 recordings 
identified in this family (Horn et al., 2003).  Taken together, these findings strengthen the 




















































3.1.1 Inclusion Criteria: DISC1 t(1;11) Carriers and Non-Carriers 
 
Fifty members of this large previously reported Scottish kindred (St Clair, Blackwood et al., 
1990) were approached to participate in the study (Figure 3.1).  Members of the family had 
been in contact with researchers from the University of Edinburgh for many years and through 
them other members of the family were invited to participate.  There were no specific inclusion 
criteria as the study required as many family members as possible to participate.  The only 
exclusion criteria were the ability to provide informed consent and the MRI safety checklist.  
 
All members of the family who were willing to participate (n=42) were recruited.  Four 
married-in participants were excluded from the analysis, leaving a total of 38 and, after 
informed consent was obtained, whether an individual participant carried the t(1;11) balanced 
translocation was confirmed (n=14) with one unable to complete all tasks.  Three subjects were 
diagnosed at structured psychiatric interview with a psychotic disorder (1 x schizophrenia, 1 x 
schizoaffective disorder and 1 x bipolar disorder).   All were treated with valproate and two out 
of three were also treated with antipsychotic drugs (one with clozapine and lithium and one 
with risperidone and sertraline) (Table 3.1). All other subjects were un-medicated at the time 
of testing. 
 
Full clinical diagnoses for all of the translocation carriers are as follows: Schizophrenia (n=1), 
Schizoaffective Disorder (n=1), Bipolar Disorder (n=1), Major Depressive Disorder 
(Recurrent) (n=3), Major Depressive Disorder (Single Episode) (n=3), Cyclothymia (n=3) 
Conduct Disorder (n=1), thus, all 13 received a diagnosis. 
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Clinical diagnoses were also established for three of the non-carriers as follows: Major 
Depressive Disorder (Recurrent) (n=2) and Generalised Anxiety Disorder (n=1). One            
non-carrier was also being treated with Amytriptyline (Table 3.1). 
 
Medication for t(1;11) Carriers and Non-Carriers 
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Figure 3.1 – DISC1 t(1;11) Scottish Kindred 
 
 
DISC1 family tree diagram. Individuals included in current  
analysis are highlighted in red/blue. Image created in Haplopainter. 
Y: t(1;11) carrier 
IQ: Only Current IQ available 
 
Carriers included (n=13)  
 
Non-Carriers included (n=15) 
 
Diagnoses: 
Unknown – unknown psychiatric status 
Psychosis – schizophrenia, schizoaffective or 
psychotic bipolar disorder 
MDD(R) – recurrent major depression 
Other – single episode depression, cyclothymia 
or conduct disorder 
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3.1.2 Inclusion Criteria: Patients (Schizophrenia and Bipolar Disorder) 
 
We also recruited a ‘positive control’ group of patients with affective and psychotic illnesses: 
schizophrenia (n=32) and bipolar affective disorder (n=16).  The aim of recruitment of this 
group was to allow us to establish robust effects of the t(1;11) translocation within the family, 
and to evaluate the possibly confounding effects of having a psychotic disorder.  Patients were 
recruited through consultant psychiatrists in Edinburgh and were then approached by the study 
team to give informed consent to participate in the trial.  The majority of patients with 
schizophrenia were stable and were happy to participate in research having taken part in 
previous studies which may have increased the number of participants in this sample with more 
years of education, greater socio-economic status and higher than expected general intellectual 
ability.  Only those who were able to provide informed consent were recruited. 
 
3.1.3 Inclusion Criteria: Unaffected Control Participants 
 
A group of unaffected control participants were also recruited (n=42).  Where possible, control 
participants were recruited from the same geographical areas as the family and patient groups.  
Unaffected control participants were also recruited directly from the Scottish Mental Health 
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3.1.4 Exclusion Criteria 
 
Exclusion criteria for all patients and unaffected controls included the following: 
 Inability to give informed consent 
 MRI safety exclusion criteria (metal / pacemaker) 
 Dementia or other neurological disorder 
 History of severe head injury (with loss of consciousness) 
 Current substance dependence / a clinical diagnosis of substance-induced psychosis 
(although NB that current substance misuse is not an exclusion criterion) 
In addition, for unaffected control participants, exclusion criteria included a family history of 
psychosis or other mental health disorder. 
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3.2  Clinical Assessments and Procedure 
 
All participants (n = 128) were interviewed by a trained psychiatrist and diagnoses were 
confirmed using the SCID (First, Spitzer et al. 2002) and/or the OPCRIT symptom check-list 
(McGuffin, Farmer et al. 1991).  All diagnoses were reviewed by a second psychiatrist who 
was blind to diagnosis and carrier status.  Participants were further assessed using the Positive 
and Negative Symptoms Scale (PANSS) (Kay et al., 1987), Scale for the Assessment of 
Negative Symptoms (SANS) (Andreasen, 1981), Global Assessment of Functioning (GAF) 
(DSM-III-R, American Psychiatric Association, 1987), Young Mania Rating Scale (YMRS) 
(Young et al., 1978) and the Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960).  
Symptom rating took place within one week of the MRI scan. 
 
Participants were then invited to complete a range of self-report personality and mood 
questionnaires which included the Beck Depression Inventory (BDI) (Beck et al., 1961), the 
Altman Mania Scale (AMS) (Altman et al., 1997), the Eysenck Personality Questionnaire 
(EPQ) (Eysenck & Eysenck, 1975), the TEMPS-A (Akiskal & Mallya, 1986) and the Kings 
Schizotypy Questionnaire (KSQ) (Williams, M. The psychometric assessment of schizotypal 
personality. PhD thesis. Institute of Psychiatry, University of London, 1993).  Tests were 
administered in the same order (as above) to each participant. Full details of the clinical rating 
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3.2.1 Clinical Measures 
 
(a) Structured Clinical Interview for DSM-IV 
 
The Structured Clinical Interview for DSM-IV Axis Disorders Patient Version (First, Spitzer 
et al., 1995) provides a semi - structured scripted approach to evaluate psychopathology and 
establish the current or lifetime presence of psychiatric diagnoses according to DSM - IV 
Criteria (American Psychiatric Association, 1994).  For each specific diagnosis, e.g. 
depression/anxiety, mania, psychosis and/or panic, initial probe questions glean critical criteria 
for each disorder. Positive responses are followed up with additional questions and negative 
responses allow the interviewer to move forward to the next section.  The SCID has good 
reliability, as demonstrated across many types of study (i.e., multi-site vs. single site, joint vs. 
test-retest, and/or with raters who have worked together, etc.).  Determining validity is more 
difficult due to the lack of there being a ‘gold standard’ which could be used to establish 
psychiatric diagnoses (Insel, 2013) therefore the clinical standard is often the ‘best estimate’ 
diagnoses. 
 
(b) Operational Criteria Checklist 
 
The OPCRIT (OPerational CRITeria) is a checklist made up from the operational criteria for 
major psychiatric illnesses and generates diagnoses based on each DSM classification 
(McGuffin et al., 1991). Originally, OPCRIT was designed to be used in molecular genetic 
research to allow a polydiagnostic approach to be used in the diagnosis of psychotic and 
affective disorders (Craddock et al., 1996).  The OPCRIT is made up of 90 items focussing on 
psychopathology together with relevant background information.  The OPCRIT checklist can 
include information gathered from diagnostic interviews and/or case records and can be rated 
on an episodic or lifetime-ever basis. 
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The OPCRIT has good reliability and, as previously with the SCID, as there is no ‘gold 
standard’ to measure the validity of lifetime psychiatric diagnoses, the ‘best-estimate’ 
diagnosis (reached by the consensus of two or more psychiatrists (or trained clinicians) on the 
basis of all available information) is currently accepted as standard procedure (Leckman et al., 
1982). 
 
(c) Positive and Negative Symptoms Scale 
 
Schizophrenia is defined by positive symptoms (hallucinations, delusions, disorganized 
thought) and by negative symptoms (cognitive deficits, blunted affect, impaired social 
functioning) (Kay et al., 1987).  The 30 item Positive and Negative Symptoms Scale (PANSS) 
was developed to assess these symptoms in a quick and reliable manner together with a measure 
of General Psychopathology.  The Positive and Negative scales consist of 7 items in each which 
are scored on a 7 point scale (1 = absent, 7 = severe).  The General scale consists of 16 items, 
again rated on a 7 point scale.  Scores for each scale can range from 7 – 49 for both the Positive 
and Negative scales and from 16 – 112 for the General scale.  All items were derived from two 
established rating scales, namely the Brief Psychiatric Rating Scale (BPRS) (Overall and 
Gorham, 1962) from which 18 items were selected, and the Psychopathology Rating Scale 
(PRS) (Singh & Kay, 1975a) from which 12 items were selected. 
 
The PANSS incorporated a fourth scale, the Bipolar Composite subscale which can be 
calculated by subtracting the Negative subscale score from the Positive subscale score, 
providing a Bipolar index with scores ranging from -42 to +42.  The PANSS is a reliable and 
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(d) Scale for the Assessment of Negative Symptoms 
 
The Scale for the Assessment of Negative Symptoms (SANS) (Andreasen, 1981) is a rating 
scale designed to assess 30 negative symptoms often observed in schizophrenia and 
incorporates five global symptoms (alogia, affective flattening, avolition-apathy, anhedonia 
and attentional impairment).  Ratings are based on a 6 point scale from 0 to 5 (0 = no evidence, 
5 = severe).  Ratings are based on observations during a clinical interview as well as by the 
consideration of information from family members, nurses and ward staff.  The SANS was 
designed to capture a time period of up to one month and is therefore a useful tool for measuring 
changes in clinical status in addition to providing an assessment of the severity of negative 
symptoms.  The SANS provides several types of scores, each of which provides a measure of 
severity, including an overall global rating (by summing all 5 global symptoms scores), global 
ratings for individual negative symptom complexes which provides an index of the level of 
severity for each symptom.  Sub-scale scores can also be calculated for each of the five global 
symptoms as well as calculating an overall score for the full 30 items.  The SANS has been 
found to have good reliability as well as good validity and excellent interrater reliability 
(Andreasen, 1981). 
 
(e) Global Assessment of Function 
 
The severity of psychiatric illness can be scored using the Global Assessment of Functioning 
(GAF) (DSM-III-R, American Psychiatric Association, 1987) which was derived from an 
earlier rating scale - the Global Assessment Scale (GAS) (Endicott, Spitzer, & Fleiss, 1976). 
The GAF is known and used around the world and forms Axis V of the Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR).  The 
GAF rates psychological, social, and occupational functioning and is intended to be a generic 
rating of how a patient is functioning overall, as oppose to a diagnosis-specific scoring system. 
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The GAF is a simple and quick scale to use and covers the full spectrum from severe 
psychopathology to no psychiatric symptoms.  Scores can be either a single overall score from 
1 to 100, or scores can be separated to reflect ‘symptoms’ (GAF-S) and ‘functioning’         
(GAF-F), again with scores from 1 to 100 (Aas, 2011).  In general, the GAF has been found to 
have good reliability and validity (Jones et al., 1995), however its’ validity has been questioned 
due to the subjective nature of rating (Aas, 2011). 
 
(f) Young Mania Rating Scale 
 
The Young Mania Rating Scale (YMRS) (Young et al., 1978) was designed to assess the 
severity of mania, from mild to severe.  Its design is based on the Hamilton Rating Scale for 
Depression (see below) and consists of eleven items which are rated by clinicians and during a 
clinical interview and are based on behavioural observations by the clinician, together with a 
subjective report from the patient on their condition over the previous 2 days.  To compensate 
for poor co-operation in cases where patients are particularly ill, four questions (No’s 5, 6, 8 
and 9) are allocated additional weight.  The Young Mania Rating Scale was considered 
necessary as previous rating scales were felt to be too long to administer and/or lacked the 
necessary scope and sensitivity required to accurately rate the severity of mania.  Each of the 
eleven items has five grades, each of which defines a specific level of severity.  Item choice 
was based on published descriptors of the core symptoms of the manic phase in bipolar 
affective disorder covering all stages of the illness, from mild to severe.  The Young Mania 
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(g) Hamilton Rating Scale for Depression 
 
The Hamilton Rating Scale for Depression (Hamilton, 1960) was created specifically for use 
on patients already diagnosed as suffering from an affective depressive disorder.  The rating 
scale is quick and simple to use, and offers a practical tool in the assessment of treatment 
effects. 
 
The scale consists of 17 items (Depressed Mood, Guilt, Suicide, Insomnia (initial, middle, 
delayed), Work and Interests, Retardation, Agitation, Anxiety (Psychic, Somatic), Somatic 
(gastrointestinal, general, genital), Hypochondriasis, Insight and Loss of Weight.  Each item is 
rated on either a five point scale (0 – 4) or a three point scale (0 – 2) to determine the severity 
of a depressive episode.  The three point scale is used where the item is difficult or impossible 
to rate (No’s 4, 5, 6, 9, 12, 13, 14, 16, 17).  The Hamilton Rating Scale for Depression is the 
most widely used scale by clinicians to rate the severity of clinical depression (O’Hara et al., 
1983) and it has been found to have good reliability and validity between clinician raters, as 












Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
106 
  
3.2.2 Self-Report Questionnaire Measures 
 
(a) Beck Depression Inventory 
 
The Beck Depression Inventory was created to ascertain a quantitative measure of the severity 
of depression (Beck et al., 1960).  The inventory consists of 21 categories of symptoms and 
attitudes that were clinically derived as a result of systematic observations by the author of the 
characteristic symptoms and attitudes of depressed patients.  Each category has 4 or 5 
statements that are graded by severity from 0 – 3 (0 = no symptoms, 3 = severe).  Categories 
were developed to reflect a particular behavioural manifestation of depression and include 
mood, pessimism, sense of failure, lack of satisfaction, guilt, sense of punishment, self-hate, 
self-accusations, self-punitive wishes, crying, irritability, social withdrawal, indecisiveness, 
body image, work inhibition, sleep disturbance, fatigability, loss of appetite, weight loss, 
somatic preoccupation, loss of libido.  The Beck Depression Inventory has been found to have 
good reliability as well as a high degree of validity (Addington et al., 1992). 
 
(b) Altman Self-Rating Mania Rating Scale 
 
The presence of, and severity of manic symptoms can be assessed by the Altman Self-Rating 
Mania Rating Scale (ASRM) (Altman et al., 1997).  The scale is quick to administer, consisting 
of 5 items, each of which has 5 statements which are rated from 0 – 4.  Scores are summed and 
a cut-off point of 6 or higher is considered to indicate a high probability that manic or 
hypomanic symptoms are present.  This assumption is based on a specificity rate of 87.3% and 
a sensitivity rating of 85.5%.   
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The ASRM significantly correlates with the Young Mania Rating Scale (YMRS) as well as the 
Clinician-Administered Rating Scale for Mania (CARS-M) (Altman et al., 1994) and is 
compatible with DSM-IV criteria (American Psychiatric Association, 1994).  It can be used in 
both inpatient and outpatient settings and can also be used as a psycho-educational tool to assist 
patients to recognise and track their own symptoms. 
 
(c) Eysenck Personality Questionnaire 
 
This 90 item questionnaire was developed to ascertain the personality constructs of neuroticism 
(N), extroversion (E), psychoticism (P) and social desirability (L) (Eysenck and Eysenck, 
1975).  Personality measures of neuroticism, extroversion and psychoticism are predicted on a 
‘biologically based theory of personality’ (Barrett et al., 1998).  Across cultures, social 
desirability is also believed to have the same degree of measurement similarity (Barrett et al., 
1998).  Psychometric scales for each construct are derived from forced choice ‘yes’ or ‘no’ 
answers to a number of statements e.g. “Are you a talkative person?” which are summed to 
give a total score for each personality measure. The questionnaire contains 21 statements for 
extroversion, 23 for neuroticism, 25 for psychoticism and 21 for social desirability.  The 
Eysenck Personality Questionnaire (EPQ) has good reliability and validity. 
 
(d) Temperament Evaluation of the Memphis, Pisa, Paris and San Diego 
 Autoquestionnaire 
 
This self-report questionnaire was developed over a number of years and was designed to 
measure affective temperaments in psychiatric patients as well as healthy volunteers. There are 
five temperament sub-scales, namely cyclothymic, depressive, irritable, hyperthymic and 
anxious.   
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The questionnaire comprises a total of 39 forced choice ‘true’ or ‘false’ statements with 12 
statements making up the cyclothymic sub-scale, 8 statements each make up the depressive, 
irritable and hyperthymic sub-scales and the anxious sub-scale consists of 3 statements.  The 
TEMPS-A has good reliability and validity (Akiskal & Mallya, 1986). 
 
(e) Kings Schizotypy Questionnaire 
 
The Kings Schizotypy Questionnaire (KSQ) was devised as part of an unpublished doctoral 
thesis by Maureen Bernadette Williams (1993): "The Psychometric Assessment of Schizotypal 
Personality".   The questionnaire consists of 63 forced choice ‘yes’ or ‘no’ statements with 9 
questions each accounting for seven sub-groups, namely recurrent illusions 1, social isolation, 
social anxiety, recurrent illusions 2, magical thinking, paranoid ideation and ideas of reference.  
These sub-groups can be further reduced to two main sub-groups providing a total for ‘positive 
symptoms’ and ‘negative symptoms’ and/or a total score can be used.  The statements were 
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3.2.3 Neuropsychological Assessments and Procedure 
 
Twenty-six family members (translocation carriers: N=13, non-carriers: N=13), fifty patients 
(schizophrenia: N=32, bipolar disorder: N=16) and forty-two healthy control participants 
completed neuropsychological assessment. Participants were administered standardised 
neuropsychological measures to assess pre-morbid intelligence (National Adult Reading Test, 
NART) and general intelligence (Wechsler Abbreviated Scale of Intelligence WASI).  The 
Brief Assessment of Cognition in Schizophrenia (BACS) was also administered to assess a 
range of cognitive domains including verbal memory (list learning), working memory (digit 
sequencing task), processing speed (verbal fluency, token motor task, symbol coding), and 
executive function/reasoning and problem solving (tower test). Finally, participants were 
assessed using the Simple and Five-Choice Reaction Time measures from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB).  Tests were administered in the same 
order (as above) to each participant. Full details of all neuropsychological tests used are 
detailed below in order of administration: 
 
(a) Verbal Intelligence (Premorbid ability) 
 
Intelligence is known to correlate highly with cognitive ability (O'carroll 1995), and has also 
been shown to deteriorate in schizophrenia and to a lesser extent in bipolar disorder (Mortimer 
1997). The National Adult Reading Test (NART; Nelson, 1982; NART–R; (Nelson and 
Willison 1991) is widely used to estimate premorbid intellectual ability as a result of its’ 
presumed measure of crystallised intelligence. Knowledge based on acquired learning is 
considered less vulnerable to the effects of cognitive decline than tests of fluid intelligence 
(Whyte, McIntosh et al. 2005).  
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Participants are required to read aloud 50 irregular words i.e. words which do not follow the 
usual grapheme-phoneme correspondences (e.g. chord, ache) (Coltheart et al., 1988) therefore 
participants are not able to correctly pronounce words they are not already familiar with. The 
total errors score (words pronounced incorrectly) is then used to calculate an estimate of 
premorbid intelligence (Bright, Jaldow et al. 2002). 
 
(b) General Intelligence 
 
The Wechsler Abbreviated Scale of Intelligence (WASI) is an abbreviated version of 
Wechsler's Adult Intelligence Scale (WAIS) (Wechsler 1955). The WASI provides an overall 
estimate of general intelligence (full-4 or full-2) as well as sub-group estimates of verbal and 
performance intelligence. Verbal intelligence is estimated from tasks of vocabulary and 
similarities in which participants are asked to provide word definitions and verbally explain 
how two words are related. Performance intelligence is estimated from tasks of block design 
and matrix reasoning in which participants are asked to use blocks to create pre-determined 
patterns and select the correct shape from a choice of five shapes to complete an incomplete 
puzzle. The WASI provides an IQ estimate using all 4 of these sub-tests (Full-4) however the 
WASI can be abbreviated further and provide an IQ estimate using only 2 of the sub-tests, 
namely vocabulary and matrix reasoning (Full-2). 
 
(c) Verbal Memory, Working Memory, Processing Speed and Executive Function 
 
The Brief Assessment of Cognition in Schizophrenia (BACS) (Keefe, Harvey et al. 2004) was 
designed to measure treatment-related changes in cognition and includes brief assessments of 
four neurocognitive domains: verbal memory, working memory, processing speed and 
reasoning and problem solving/executive function, details of which are provided below: 
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(d) Verbal memory 
 
Verbal memory is assessed by a list learning task which involves participants being read a list 
of 15 words after which they are asked to recall as many of the words as they can remember. 
This procedure is repeated 5 times. The outcome measure used is the total number of words 
correctly recalled per trial. 
 
(e)  Working memory 
 
Working memory is assessed by using a digit sequencing task in which participants are read 
sets of numbers which start with 2 digits and increase in length to a maximum of 8 digits. The 
numbers are read in a random order and participants are asked to repeat the numbers back in 
order from the lowest number to the highest. The outcome measure used is the number of trials 
in which all sets of numbers were repeated in the correct order. 
 
(f) Motor speed 
 
Motor speed is assessed by using a token motor task in which participants are given 60 seconds 
to place as many tokens as possible into a container. In total there are 100 tokens which are 
split so that there are 50 tokens on the left of the container and 50 on the right. Participants 
must use their right and left hands simultaneously to pick up one token in each hand and place 
them into the container at the same time. The outcome measure used is the total number of 
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(g) Processing speed 
  
Processing speed is assessed by the administration of three verbal fluency tasks, namely two 
letter fluency tasks and a category fluency task.  The Controlled Oral Word Association Test 
is administered to assess letter fluency and is administered twice.  Participants are asked to 
name as many words as they can think of that begin with a specific letter of the alphabet – in 
this study the letters ‘F’ and ‘S’ are used.  For category instances (semantic fluency) 
participants are asked to name as many animals as they can think of in 60 seconds. The outcome 
measure used is the total number of words generated per trial. 
 
(h) Attention and processing speed 
 
Attention and processing speed is assessed by using a symbol coding task in which participants 
have 90 seconds in which to write in the numerals 1 – 9 on a response sheet as matches to 
symbols which appear in a key which is provided on the response sheet. The outcome measure 
used is the total number of correct responses. 
 
(i) Executive function/reasoning and problem solving 
 
Executive function/reasoning and problem solving is assessed using the Tower of London task 
in which participants are asked to work out the least number of moves it would take to make 
one picture (Picture ‘A’) look like another picture (Picture ‘B’). Both pictures are shown 
simultaneously and show 3 different coloured balls arranged on 3 pegs of differing heights. 
The tallest peg can hold all 3 balls, the middle peg can hold 2 balls and the smallest peg can 
only hold one ball.  
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
113 
  
This task employs the standard rules that apply to tower tests in that balls can only be moved 
one at a time and balls which are on top of other balls must be moved to an available space first 
(Keefe et al., 2008). The outcome measure used is the total number of correct responses. 
 
(j) Reaction Time 
 
The Cambridge Neuropsychological Test Automated Battery (CANTAB) is a computer-based 
assessment system that uses a touch screen computer to administer a battery of 
neuropsychological tests designed to assess various cognitive functions (Sahakian, Morris et 
al. 1988). 
 
(k) Psychomotor Co-ordination and Motor Speed 
 
 
Simple Reaction Time measures each participant’s response time when attending to a visual 
target where the stimulus is predictable. The Reaction Time Test (RTI) is able to separate 
response latency from movement time in both the simple and 5-choice stages. Participants are 
required to complete five stages which increase in complexity: in the single-choice stage 
participants must react as soon as they see a yellow dot appear on the screen and in the 5-choice 
stage the dot may appear in any one of five locations. Participants respond either by simply 
touching the screen or using a press-pad, and in the later stages they are required to do both. 
Outcome measures are divided into simple and 5-choice reaction time and simple and            
five-choice movement time. 
 





The primary contrasts of interest were the direct comparisons between members of the t(1;11) 
kindred with the translocation and those members of the family without the translocation,       
co-varying for demographic variables known to impact on neurocognitive measures, i.e. age, 
gender and (where relevant) general intelligence (IQ). Group effects were also of interest, 
specifically t(1;11) translocation carriers compared by diagnosis for impact of the t(1;11) 
translocation. 
 
Raw test data were used in the analyses. Kolmogorov-Smirnov Z tests - using standardised 
residuals - confirmed all test distributions to be normal.  Independent samples t-tests were used 
to conduct main group comparisons. Where data were found to violate assumptions of 
homogeneity of error variance, the equal variances not assumed statistic was used. Sub-group 
comparisons were subjected to a one-way analysis of variance (ANOVA) and a general linear 
model univariate analysis of covariance where appropriate. Measures of effect size are 
provided (Cohen’s d) which have been calculated using the unadjusted means, standard 
deviations and sample sizes. Tests were two-tailed and statistical significance was considered 
at p<0.05.  Pearson Product Moment Correlation Analysis were used to determine whether 
there were any relationships between neuropsychological, clinical, polygenic risk profile 
scores, antipsychotic medication (CPZ equivalents) and self-reported personality/mood data.  
Partial correlations were conducted to control for age, gender and current I.Q. (premorbid I.Q. 
when current I.Q. was the variable of interest).  
 
For polygenic risk analyses, the number of variants scored in each participant was retained and 
used as a covariate in all analyses (CNT). 
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For all analyses, whether any differences between the groups were associated with 
psychopathology was investigated by examining the results for diagnostic sub-groups 
(psychotic disorder, recurrent depression, other diagnosis) of those with the translocation, as 
well as relating cognitive measures to the PANSS general, and positive psychotic symptom 
severity ratings in those with and without the t(1;11) translocation. 
 
Due to the uniqueness of the DISC1 kindred, opportunities to conduct investigations are very 
rare and therefore additional exploratory analyses were conducted which resulted in a relatively 
large number of assessments.  To reduce the possibility of Type II errors, all significant p-
values were corrected using the FDR procedure and considered significant when pFDR ≤ .05. 
 
As a first step, data for t(1;11) carriers and non-carriers were directly compared without co-
varying for any of the known demographic variables likely to impact on neurocognitive 
measures. The analyses were then repeated, co-varying for age, gender and current I.Q. to 
determine if there were any significant differences between translocation status and which of 
the demographic variables, if any, impact on these results. Where homogeneity of variance 
assumptions were violated, non-parametric analyses were conducted and reported. 
 
A similar approach was taken in the analysis of the patient and control data to keep the analyses 
in line and to allow for a visual inspection of the results between DISC1 t(1;11) carriers and 
non-carriers and those from patients with schizophrenia and bipolar disorder, as the primary 
aim of recruiting these samples was to act as a ‘positive’ control group for the DISC1 family.  
This provides an opportunity to establish robust effects of the t(1;11) translocation within the 
family, and to evaluate the possibly confounding effects of having a psychotic disorder. 
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Research into how similar family members’ brains are anatomically has suggested that certain 
areas are highly heritable (Glahn et al., 2007b).  
 
This means that direct comparisons between members of one family with a group of unrelated 
individuals would be significantly confounded by the shared heredity within the family. 
Therefore, direct comparisons between the t(1;11) kindred and patients or controls were not 
performed. The recruitment of the patient and control groups allows for the comparison of the 
effects of having a psychiatric disorder in general to the effects of the t(1;11) translocation 





As genotyping was performed elsewhere as part of a larger study - the ‘Scottish Family Mental 
Health Study’ (SFMHS) – genotyping methods are provided in Appendix 1. 
 
3.3.2 Polygenic Risk Profile Scores 
 
As above, polygenic risk profile scores were generated elsewhere as part of a larger study - ‘the 
‘Scottish Family Mental Health Study’ (SFMHS) therefore methods for polygenic risk 
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4. DISC1 t(1;11) Carriers and Non-Carriers 
 
4.1 Demographic Details 
 
Sample demographics, including clinical ratings for the t(1;11) family are detailed in table 4.1. 
 





    T/L Carriers  
   (N=14) 
 
    Non-Carriers  
   (N=15) 
 
Gender (M/F)           7/7 
 
   Mean (SD) 
        5/10 
 
   Mean (SD) 
Age  55.64 (15.28)  43.73 (20.19) 
Premorbid IQ (NART)  103.07 (7.23)  104.54 (6.36)† 
Current IQ (WASI)  88.15 (16.79)*  93.47(10.68) 








PANSS Total  46.86 (24.31)  33.73 (5.43) 
PANSS Negative Symptoms       9.64 (9.06)       7.00 (0.00) 
PANSS Positive Symptoms  10.14 (6.29)  7.00 (0.00) 
PANSS General Symptoms  27.07 (10.73)  19.73 (5.43) 
SANS  7.07 (26.46)  .40 (1.55) 




 2.93 (5.40) 
5.57 (6.21) 
600.00 (0.00) 
 .00 (0.00) 
3.60 (6.16) 
0.00 (0.00) 
     
Table 4.1 – Sample demographics for DISC1 t(1;11) translocation carriers and non-carriers. * N=13, † N=13. Positive and 
Negative Symptoms Scale (PANSS); Scale for the Assessment of Negative Symptoms (SANS); Global Assessment of Function 
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4.1.1 Age, Gender, Premorbid IQ, Current IQ & IQ Difference 
 
Initial group comparisons were conducted between all t(1;11) carriers (n=14) and non-carriers 
(n=15). Demographic variables of age (Figure 4.1), gender, premorbid IQ, current IQ and 
premorbid to current IQ difference (Table 4.1 and Figure 4.2) were compared using an 
independent samples t-test with group as a factor.  All were found to be non-significant (p>.05) 
and were not controlled for in the preliminary analyses. 
 
t(1;11) Carriers and Non-Carriers: Age 
 
     
            Figure 4.1 - Mean and median ages for DISC1 t(1;11) translocation carriers and non-carriers 
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t(1;11) Carriers and Non-Carriers: Premorbid I.Q., Current I.Q. and I.Q. Difference 
 
 
Figure 4.2 – Premorbid IQ, Current IQ and Premorbid to Current IQ Difference – DISC1 t(1;11) translocation carriers and non-carriers 











IQ Difference t(1;11) Carriers and Non-Carriers
Non-Carriers (N=15) T/L Carriers (N=14)
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4.1.2 Brief Assessment of Cognition in Schizophrenia (BACS) 
 
An initial comparison of the performance data for the six assessments which make up the Brief 
Assessment of Cognition in Schizophrenia (BACS) did not identify any significant results 
between t(1;11) translocation carries (n=13) and non-carriers (n=13) (Figure 4.3).  A general 
linear model univariate analysis of covariance (homogeneity of error variance met) was then 
conducted to control for age, gender and current IQ (all p>.05).  There was, however, a 
moderate to large effect size (Cohen’s d = -0.8) for attention and processing speed as measured 
by a symbol coding task (Figure 4.5). 
 
Means and Standard Deviations for the raw data from t(1;11) carriers and non-carriers’ 
performance for each of the tasks which make up the Brief Assessment of Cognition in 
Schizophrenia, together with both CANTAB reaction time tasks are provided in Table 4.2.  
 
Statistical conclusion validity is concerned with ensuring that any reported relationships 
between variables are reasonable and correct. It may be the case here that there are, in fact, 
some significant relationships between translocation status and specific cognitive domains as 
evidenced by the moderate to large effect sizes seen for motor speed and attention and 
processing speed (see Figure 4.5).  Significant relationships may not have been detected due to 
insufficient power.  Low statistical power can lead to a higher probability of committing a Type 
II error and concluding that there is no effect when there actually is (Cohen, J. 1992).  It is 
encouraging, none the less, that strong associations have been identified which can be 
investigated further in future work. 
 
 





 t(1;11) Carriers and Non-Carriers - Means and Standard Deviations:  
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Table 4.2 – Brief Assessment of Cognition in Schizophrenia (BACS) and the Cambridge Neuropsychological Test Automated 












t(1;11) Carriers and Non-Carriers: Brief Assessment of Cognition in Schizophrenia (BACS) 
Test Battery 
 
Figure 4.3 – Bar chart for six assessments which make up the Brief Assessment of Cognition in Schizophrenia (BACS): DISC1 

























B.A.C.S. t(1;11) Carriers and 
Non-Carriers
T/L Carriers (N=13) Non-Carriers (N=13)
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4.1.3 Cambridge Neuropsychological Test Automated Battery (CANTAB) 
 
An initial main group analysis was conducted between t(1;11) carriers (n=13) and non-carriers 
(n=13) on the performance data from two CANTAB assessments to measure reaction time 
using an independent samples t-test with group as a factor. Mean scores (Table 4.2) met the 
significance threshold (p≤.05) for simple reaction time (equal variances not assumed)                   
(t = -2.126, df = 15.722, p = .050) and five-choice reaction time (equal variances assumed)       
(t = -2.070, df = 24, p = .049) (Figure 4.4), both of which also produced moderate to large 
effect sizes (Cohen’s d = 0.87 and 0.84 respectively) (Figure 4.5). 
Simple and Five-Choice Reaction Time 
  
               Non-Carriers (N=13)                    t (1;11) (N=13)                        Non-Carriers (N=13)                    t (1;11) (N=13) 
                  Translocation Status                                                                     Translocation Status                                                                                                           
 
     t(1;11): Psychotic Disorder          MDD (Recurrent)          Other Diagnoses  
Figure 4.4 – Scatterplots for Simple and Five-Choice Reaction Time between DISC1 t(1;11) Translocation Carriers and Non-
Carriers.  
 
A general linear model univariate analysis of covariance (homogeneity of error variance met) 
was then conducted to control for current IQ, with results remaining significant - simple 
reaction time (F(1,23) 4.948, p = .036); five-choice reaction time (F(1,23) 4.791, p = .039).  
Results were not robust, however, to control for age, gender and current IQ (p = > 0.5 for both).  
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Visual inspection of the scatterplots for simple and five-choice reaction time (Figure 4.4) 
suggest that a degree of difference may be contributed to by outliers.  This is an important 
consideration as two of the three t(1;11) carriers in the ‘Psychotic Disorder’ sub-group were 
receiving antipsychotic medication.  Extrapyramidal symptoms of antipsychotic medication 
can have a powerful effect on fine motor function which is required to perform these tasks 
(Owens, D.C. 2014).  To account for this possibility the outlier from the ‘Psychotic Disorder’ 
sub-group was removed and the analyses were repeated.  Five-Choice Reaction Time was 
robust controlling for age, gender and current IQ (p=.040) however Simple Reaction Time 
marginally failed to reach significance (p=.051). 
 
 





Effect Sizes for Neuropsychological Measures between DISC1 t(1;11) Translocation Carriers and Non-Carriers 
 

































EFFECT SIZE (Cohen's D) between t(1;11) carriers and non-carriers (N=26)
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4.2 Clinical Symptom Rating Scales: DISC1 Carriers and Non-Carriers 
 
In line with the main hypotheses, symptom severity rating scales were investigated within the 
t(1;11) kindred with the additional hypotheses that IQ and processing speed tasks would be 
significantly associated with measures from the Positive and Negative Symptoms Scale 
(PANSS) - particularly positive symptoms.  As this offered a rare opportunity to investigate 
the t(1;11) kindred, additional exploratory analyses were also conducted, including examining 
self-reported measures of personality and mood. 
 
Symptom severity rating scales were compared between all t(1;11) carriers and non-carriers 
using independent samples t-tests. A significant difference was identified between 
translocation status and the sub-group measuring ‘general symptoms’ from the Positive and 
Negative Symptoms Scale (PANSS) (t = 2.35, df = 27, p = .026) (equal variances assumed).  
This result became non-significant after controlling for age and gender using a general linear 
model univariate analysis of covariance. 
 
4.3 Clinical Symptom Rating Scales and Neuropsychological Assessments: DISC1 
Carriers and Non-Carriers as a Group 
 
Pearson bivariate correlational analyses were conducted between clinical ratings of symptom 
severity and neuropsychological assessments with the t(1;11) kindred (N=26).  Current IQ, 
simple and/or five-choice reaction time and motor speed were of particular interest and were 
all found to be significantly associated with measures from the Positive and Negative 
Symptoms Scale (PANSS) as well as the Scale for the Assessment of Negative Symptoms 
(SANS).  Pearson partial correlational analyses were conducted to control for age, gender and 
current IQ (premorbid IQ where current IQ was the variable of interest) and p values were 
corrected using the FDR procedure in which the majority of results remained significant (Table 
4.3).





t(1;11) Carriers and Non-Carriers: Correlational Analysis - Neuropsychological Assessments/Clinical Measures 
 




 r  (pFDR) r (pFDR) r (pFDR) r (pFDR) 
PANSS Total 
 
r = .71 (p = <.001)  r = .84 (p = <.001)  r = -.56 (p = .006)  r = -.63 (p = .001)  
PANSS Positive 
 
r = .53 (p = .010)  r = .75 (p = <.001)  r = -.55 (p = .007)  r = -.49 (p = .018)  
PANSS Negative r = .61 (p = .002) r = .70 (p = <.001) r = -.34 (p = .117) r = -.67 (p = <.001) 
PANSS General r = .66 (p = .001)  r = .73 (p = <.001)  r = -.60 (p = .003)  r = -.48 (p = .019)  
SANS 
 
r = .64 (p = .001)  r = .71 (p = <.001)  r = -.32 (p = .135)  r = -.67 (p = <.001)  
Table 4.3 – Correlational Analysis: Neuropsychological Assessments/Clinical Measures: DISC1 t(1;11) Translocation Carriers and Non-Carriers (N=26) 
 
- p-values have been controlled for age, gender and current IQ (premorbid IQ where current IQ is the variable of interest).  For all 
correlations, p values were corrected using the FDR procedure and considered significant when pFDR ≤ .05. 
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4.4 Polygenic Risk Profile Scores: DISC1 Carriers and Non-Carriers 
 
As DISC1 was originally identified as a direct result of this kindred and is primarily thought to 
increase risk for schizophrenia, we also examined the effects of polygenic risk for 
schizophrenia given that the t(1;11) translocation is not always associated with illness, let alone 
schizophrenia, and PGRSs is a risk factor for schizophrenia, bipolar disorder and depression 
that may interact with translocation status to influence diagnosis.  It was hypothesised that 
polygenic risk for schizophrenia would be significantly associated with current IQ and/or 
measures of processing speed and also with positive symptomology within the family and 
especially within t(1;11) carriers. 
 
Initial comparisons between translocation carriers and non-carriers using independent samples 
t-tests did not identify any significant differences between the polygenic risk profile scores for 
schizophrenia (p>.05) or major depressive disorder (p>.05) within the family (Table 4.4). There 
was, however, a significant difference between family carriers and non-carriers for polygenic 
risk for bipolar disorder (t = -2.202, df = 27, p = 0.036) (equal variances assumed) (Table 4.4 
and Figure 4.6).  This result remained significant using a general linear model univariate 
analysis of covariance (homogeneity of error variance met) to control for CNT (F(1,27) 4.847, 




N Mean Std. Deviation 
    
SCZ Score         T/L Carrier 







BP Score           T/L Carrier 







MDD Score       T/L Carrier 







    
Table 4.4 - Polygenic Risk Profile Scores: DISC1 t(1;11) Translocation Carriers and Non-Carriers (N=29) 
 
 




             
 
 
                       t(1;11) Carriers and Non-Carriers: Polygenic Risk for Bipolar Disorder 
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4.4.1 Polygenic Risk Profile Scores, Neuropsychology and Clinical Symptoms: DISC1 
t(1;11) Carriers and Non-Carriers as a Group 
 
No significant associations were identified between any of the polygenic risk profile scores and 
any of the neuropsychological measures (all p>.05) however as polygenic risk for 
schizophrenia was of particular interest - especially regarding neurocognitive function - it is 
worth noting that a weak association was identified between polygenic risk for schizophrenia 
and simple reaction time which marginally missed significance (r = .38, p = 0.052) (Table 4.5). 
 
For clinical measures, polygenic risk for schizophrenia was significantly associated with two 
sub-groups from the Positive and Negative Symptom Scale (PANSS), namely PANSS ‘total 
score’ (r = .37, p = 0.048) and PANSS ‘general symptoms’ (r = .42, p = 0.025) (Table 4.5). 
These results became non-significant after correcting using the FDR procedure and controlling 
for CNT (Table 4.6). 
 
No significant associations were identified between polygenic risk for either bipolar disorder 














 Simple Reaction Time* PANSS Total Score 
 
PANSS General Symptoms 
 r (pFDR) r (pFDR) r (pFDR) 
Polygenic Risk for 
Schizophrenia 
 
r = .38 
(p = .052)  
 
 
r = .37 
(p = .048) 
 
 
r = .42 
(p = .025) 
 
Table 4.5 – Correlational Analysis Results – Polygenic Risk for Schizophrenia – DISC1 t(1;11) Translocation Carriers and Non-








Simple Reaction Time* PANSS Total Score 
 
PANSS General Symptoms 
for CNT  r (pFDR) r (pFDR)  r (pFDR)  
Polygenic Risk for 
Schizophrenia 
 
r = .39 
(p = .056) 
 
 
r = .32 
(p = .093) 
 
 
r = .37 
(p = .054) 
 
Table 4.6 – Correlational Analysis Results (Controlling for CNT) – Polygenic Risk for Schizophrenia – DISC1 t(1;11) 
Translocation Carriers and Non-Carriers (N=29) *(N=26) 
 
 
For all correlations, p values were corrected using the FDR procedure and considered 
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4.4.2 Self-Reported Measures of Personality and Mood: DISC1 t(1;11) Carriers and Non-
Carriers 
 
As the self-report questionnaire data was found to deviate from normality, non-parametric 
Mann-Whitney U analyses were conducted between t(1;11) carriers and non-carriers. A 
significant difference was identified between the self-reported measure of ‘Anxiety’ as 
measured by the Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-
Questionnaire (TEMPS-A) (U = 0.18, p = .015) (exact significance result reported).  No other 
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4.5  DISC1 t(1;11) Carriers by Sub-Group Diagnoses: Premorbid I.Q., Current I.Q. and 
I.Q. Difference 
 
As per previous work by St. Clair et al., (1990) and Blackwood et al., (2001), thirteen t(1;11) 
carriers were sub-grouped according to diagnoses as follows: ‘psychotic disorder’ (n=3), 
‘major depressive disorder (recurrent)’ (n=3), ‘other diagnoses’ (n=7). 
 
4.5.1 Premorbid I.Q., Current I.Q. and I.Q. Difference; DISC1 t(1;11) Carriers by Sub-
Group Diagnoses 
 
An initial one-way analysis of variance (ANOVA) revealed significant differences (p<.05) in 
current IQ (F(2,10) 6.343  p=.017) and IQ difference (i.e. the difference between pre-morbid 
IQ scores and current IQ scores) (F(2,10) 5.911 p=.020).  Pairwise comparisons later identified 
current IQ as being significantly lower in family members with ‘psychotic disorder’ compared 
to those with ‘other diagnoses’ (p=.016).  IQ difference was also significantly greater in those 
with ‘psychotic disorder’ compared to those with ‘other diagnoses’ (p=.019).  A general linear 
model univariate analysis of covariance (homogeneity of error variance met) was then used to 
control for age and gender which remained significant for current IQ (F(2,8) 7.113 p=.017) and 
IQ difference (F(2,8) 6.452 p=.021) (Table 4.7 and Figure 4.7). 
IQ for DISC1 t(1;11) Translocation Carriers by Sub-Group Diagnoses 
 
IQ Measure t(1;11)  










Controlled for  
Age and Gender 
 M (SD) M (SD) M (SD) ‘F’ Sig 
Premorbid IQ 96.05 (3.99) 105.53 (4.13) 104.78 (2.49) - 
     
Current IQ 67.21* (6.32) 92.59 (6.59) 95.230* (4.25) F(2,8) 7.113, p = .017 
     
IQ Difference -29.14* (4.38) -13.05 (4.56) -10.49* (2.94) F(2,8) 6.452 p = .021 
Table 4.7 * Post-hoc analysis revealed significant between-group differences between ‘Psychotic Disorder’ and ‘Other 
Diagnosis’ controlling for age and gender 
  



























IQ Difference t(1;11) Carriers
Psychotic Disorder (N=3) MDD (Recurrent) (N=3) Other Diagnosis (N=7)
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4.5.2 Brief Assessment of Cognition in Schizophrenia (BACS): DISC1 t(1;11) Carriers by 
 Sub-Group Diagnoses 
 
Initial comparison of the t(1;11) carriers’ performance results from the six BACS assessments 
split by sub-group diagnoses revealed significantly reduced scores (p<.05) for verbal memory 
- as assessed by a list learning task (F(2,10) 8.264 p=.008), motor speed – as assessed by a 
token motor task (F(2,10) 4.620 p=.038) and attention and processing speed - as assessed by a 
symbol coding task (F(2,10) 6.921 p=.013) (Figure 4.8). 
 
A general linear model univariate analysis of covariance (homogeneity of error variance met) 
was then used to control for age, gender and current IQ.  Attention and processing speed 
remained significant (F(2,7) 5.211 p=.041) (Figure 4.9).  
 
Means and Standard Deviations for the raw scores for the performances for each of the tasks 
which make up the Brief Assessment of Cognition in Schizophrenia, together with both 















t(1;11) Carriers by Sub-Group Diagnoses - Means and Standard Deviations:  
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Table 4.8 – Brief Assessment of Cognition in Schizophrenia (BACS) and the Cambridge Neuropsychological Test Automated 
Battery (CANTAB) Means and Standard Deviations for DISC1 t(1;11) (N=13) Translocation Carriers by Sub-Group Diagnosis: 
Psychotic Disorder (N=3), Major Depressive Disorder (N=3) and Other Diagnosis  (N=7) 











































Psychotic Disorder (N=3) MDD (Recurrent) (N=3) Other Diagnosis (N=7)







t(1;11) Sub-Groups – Attention and Processing Speed 
 
    t(1;11) Carriers by Sub-Group Diagnosis 
 Psychotic Disorder        MDD (Recurrent)         Other Diagnoses 
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4.5.3 Cambridge Neuropsychological Test Automated Battery (CANTAB): DISC1 t(1;11)
 Carriers by Sub-Group Diagnoses 
 
Performances by DISC1 t(1;11) carriers split by sub-group diagnoses were also compared on 
two CANTAB reaction time tasks using a one-way analysis of variance (see Table 4.8 for raw 
scores means/standard deviations).  A significant between-groups difference was identified for 
simple reaction time (p > .05). Multiple comparison post hoc analysis identified a significantly 
reduced performance between family members with ‘psychotic disorder’ and those with ‘other 
diagnoses’.  This result was not robust, however, controlling for age, gender and current IQ 
when using a general linear model univariate analysis of covariance (homogeneity of error 
variance met) (Figure 4.10).  
 
Analysis of the five-choice reaction time task between DISC1 t(1;11) carriers by sub-group 
diagnoses was also non-significant (p>.05). 
 
 



















Simple Reaction Time t(1;11) Carriers
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4.6 Clinical Symptom Rating Scales: DISC1 t(1;11) Carriers by Sub-Group Diagnoses 
 
Initially, a one-way analysis of variance was conducted between symptom severity rating scales 
and t(1;11) translocation carriers split by diagnostic sub-group, revealing significant between-
group differences for ‘positive symptoms’ from the PANSS; overall functioning as assessed by 
the GAF and the Hamilton Rating Scale for Depression. These results remained significant 
after controlling for age and gender using a general linear model univariate analysis of 
covariance (p = .041, p = .046 and p = .008 respectively).  As expected, t(1;11) carriers with 
‘psychotic disorder’ had greater symptom severity than those with ‘other diagnoses’ and 
similarly, carriers with ‘major depressive disorder’ also had greater symptom severity than 
those with ‘other diagnoses’.  As the homogeneity of variance assumption was found to be 
violated in the ‘depression’ rating, a non-parametric Kruskal-Wallis H test was also conducted 
in which ‘depression’ - as assessed by the Hamilton Rating Scale for Depression (HDRS) 
remained significant (X²(2) = 9.91, p = .007) (Figure 4.11). 
 
     t(1;11) Sub-Groups: Hamilton Depression Rating Scale 
 
 
     Figure 4.11 – Hamilton Rating Scale for Depression/DISC1 t(1;11) Translocation Carriers by Sub-Group 
Diagnoses 
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4.6.1 Clinical Symptom Rating Scales and Neuropsychological Assessments: 
DISC1 t(1;11) Carriers as a Group 
 
Analyses were conducted between symptom severity rating scales and neuropsychological 
assessments for t(1;11) carriers (N=13).  In line with the main hypotheses, IQ and measures of 
processing speed were hypothesised to be significantly associated with symptom severity, in 
particular positive symptomology.  Current IQ, simple and/or five-choice reaction time and 
motor speed were of particular interest and as with the results for the family as a whole, these 
variables were also found to be significantly associated with measures from the Positive and 
Negative Symptoms Scale (PANSS) and the Scale for the Assessment of Negative Symptoms 
(SANS). 
 
Pearson partial correlational analyses were conducted to control for age, gender and current IQ 
(premorbid IQ when current IQ was the variable of interest) at which point the previously 
significant results for simple reaction time were lost, however significant associations remained 
between three of the variables of interest and measures from the PANSS (‘total score’, ‘positive 
symptoms’ ‘negative symptoms’ and/or ‘general symptoms’) and the Scale for the Assessment 
of Negative Symptoms (SANS). Not all associations were robust, however, after correcting 
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  r (pFDR)  r (pFDR) r (pFDR)  
PANSS Total 
 
r = .89 (p = .001)  r = -.72 (p = .018)  r = -.64 (p = .045)  
PANSS Positive 
 
r = .63 (p = .048)  r = -.70 (p = .023)  r = -.25 (p = .488)  
PANSS Negative 
 
r = .81 (p = .004) r = -.35 (p = .328) r = -.90 (p = <.001) 
PANSS General 
 
r = .72 (p = .020)  r = -.84 (p = .002) r = -.32 (p = .365) 
SANS 
 
r = .81 (p = .005)  r = -.33 (p = .345)  r = -.92 (p = <.001) 
Table 4.9 - Correlational Analysis: Neuropsychological Assessments/Clinical Measures: DISC1 t(1;11) Translocation 
Carriers (N=13) 
 
- p-values were controlled for age, gender and current IQ (premorbid IQ where current IQ is the 
variable of interest).  For all correlations, p-values were corrected using the FDR procedure 
and considered significant when pFDR ≤ .05. 
 
 
4.7 Polygenic Risk Profile Scores: DISC1 t(1;11) Carriers by Sub-Group Diagnoses 
 
Initial comparisons using one-way analysis of variance did not identify any significant 
differences between any of the polygenic risk profile scores (all p>.05) and any of the t(1;11) 
carrier diagnostic sub-groups, i.e. ‘psychotic disorder’, ‘major depressive disorder’ and/or 
‘other diagnoses’. 
 
4.7.1 Polygenic Risk: Neuropsychology and Clinical Symptoms – DISC1 t(1;11) Carriers as 
a Group 
 
As for all family, no significant associations were identified between any of the polygenic risk 
profile scores and any of the neuropsychological measures for t(1;11) carriers (all p>.05).  
There was, however, a significant association between t(1;11) carriers’ polygenic risk for 
schizophrenia and the Positive and Negative Symptom Scale (PANSS) ‘general symptoms’ 
which remained significant after controlling for CNT (r = .59, p = 0.035) however this result 
became non-significant after correcting using the FDR procedure (tables 4.10 and 4.11). 









 PANSS General Symptoms 
 r (pFDR) 
Polygenic Risk for 
Schizophrenia 
 
r = .59 
(p = .027) 







PANSS General Symptoms 
for CNT  r (pFDR)  
Polygenic Risk for 
Schizophrenia 
 
r = .59 
(p = .035) 
Table 4.11 – Correlational Analysis Results (Controlling for CNT) – Polygenic Risk for Schizophrenia – DISC1 t(1;11) 
Translocation Carriers (N=14) 
 
For all correlations, p-values were corrected using the FDR procedure and considered 
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4.8 Self-Reported Measures of Personality and Mood: DISC1 t(1;11) Carriers 
 
As the self-report questionnaire data was found to deviate from normality, non-parametric 
Kendall’s tau-b correlational analyses were conducted with a specific focus on 
neuropsychological measures and clinical symptoms with t(1;11) carriers.  No significant 
associations were found with any of the neuropsychological measures, however significant 
associations were identified between two sub-group measures from the Kings Schizotypy 
Questionnaire (KSQ), namely the KSQ ‘Total Score’ and ‘Total Negative’ scores (Table 4.12). 
 
 Kings Schizotypy Questionnaire 
(KSQ) 
 
 ‘Total Score’  ‘Total Negative’ 
 
Clinical Measure ‘p’ value/Kendall’s tau-b correlation co-efficient τb 
 
PANSS ‘Positive Symptoms’   p = .020, τb = .62  P = .020, τb = .64 
 
Table 4.12 – Correlational Analysis Results – Total Sub-Group Measures from the Kings Schizotypy Questionnaire (KSQ) and 
DISC1 t(1;11) Translocation Carriers (N=11) 
 
Strong positive associations were found between positive symptomology in t(1;11) carriers and 
self-reported negative measures from the Kings Schizotypy Questionnaire.  The KSQ ‘Total 














4.9.1 Neuropsychological Measures 
 
This is the first report of results from a full battery of neuropsychological assessments in 
individuals from the unique t(1;11) kindred. An obvious limitation is the unavoidably small 
sample sizes and possibility of Type II errors, but we have still been able to detect some effects 
of the t(1;11) balanced translocation on cognitive functions, especially reaction time, 
particularly in those individuals who have both the genetic risk factor (DISC1 t(1;11) balanced 
translocation) and psychotic disorder. Test results across all assessments reveal lower scores in 
all t(1;11) carriers, with the most severe seen in the group with psychotic disorders 
(schizophrenia, schizoaffective disorder and bipolar disorder).  It is also evident that 
individuals with recurrent major depressive disorder scored lower than those with other 
(usually minor) diagnoses, mainly cyclothymia, and that the t(1;11) carriers scored lower than 
their non-translocation carrying relatives across all measures. Where results did not meet 
significance, possibly due to a lack of statistical power, effect sizes revealed moderate to large 
effects in a number of areas. 
 
4.9.2 General Intelligence 
 
From t(1;11) carriers sub-group analyses, current IQ was significantly impaired in those with 
psychotic disorder, and a particularly large difference between pre-morbid and current IQ 
scores was found between individuals with psychotic disorder and those with other diagnoses 
within the DISC1 family. The mean pre-morbid IQ for t(1;11) carriers in this study (n=12) was 
103.67 and 104.54 for non-carriers (n=15). These scores are in line with those previously 
obtained from an overlapping group of t(1;11) carriers in 2001 by Blackwood et al., (2001).   
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Reduced premorbid and current intelligence is commonly found in schizophrenia, but the 
particularly marked change from premorbid to current IQ within this kindred - especially in 
psychotic disorder – suggests that DISC1 may increase the risk for major psychiatric disorder 
through a deterioration in general intelligence. 
 
In those with both the translocation and psychotic disorder, the combination could produce a 
‘double hit’ as the development of a psychotic illness would likely lead to a further negative 
impact on intelligence. 
 
Two t(1;11) family members were receiving anti-psychotic medication (one of whom was also 
receiving anti-depressant medication); one t(1;11) carrier was receiving anti-depressant 
medication and one non-carrier was also receiving anti-depressant medication.  Although 
antipsychotic medications have transformed the lives of those suffering from psychotic illness, 
they very often have negative effects and therefore come at a price. Antipsychotic medications 
target a key chemical brain transmitter – dopamine - which is also heavily involved with motor 
function (D Thomas & Dauner, 1992; Owens, D.C. 2014).  The most common extrapyramidal 
symptoms produced as side-effects of antipsychotic medications include tardive dyskinesia, 
dystonic reactions, akinesia and Parkinsonism.  As medication effects are known to have a 
deleterious effect on cognition, it is possible that this may have contributed to the marked 
change from premorbid to current IQ.  No associations were found, however, between 
neuropsychological measures and chlorpromazine equivalent (CPZ) during analysis, therefore 
although medication effects are considered to have a negative impact on cognition, it does not 
appear to be a contributory factor within this kindred. 
 
These results show that general intelligence (I.Q.) is impaired in t(1;11) family members with 
the translocation - especially those with a psychiatric diagnosis.   
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Although a high number of studies investigating DISC1 and cognition have been conducted, 
few have specifically investigated general intelligence. Most of these studies obtained a 
measure of either premorbid or current I.Q. however unfortunately, these data were not 
comparable due to the variety of methodologies employed (see Chapter 2 for a full review).  
As discussed, Blackwood et al., (2001) reported premorbid I.Q. to be within the normal range 
in a number of individuals from the t(1;11) kindred, however it can now be seen from these 
results that there is a marked difference between premorbid and current I.Q. in carriers 
(especially those with psychosis).  
 
DISC1 and general intelligence was also examined in two other studies and although no 
significant effects of DISC1 genotype and cognition were revealed, Thomson et al., (2005) 
revealed a significant effect of DISC1 genotype by sex interaction for older non-psychiatric 
females homozygous for the Cys allele of the DISC1 SNP Ser704Cys (rs821616).  This finding 
points to the possibility that variation in DISC1 may affect normal cognitive development, 
especially in females. 
 
More recently, Thomson and colleagues (2014) reported a nominal association between DISC1 
functional and putative regulatory variants and recurrent major depressive disorder and/or 
cognitive ability. 
 
4.9.3 Attention and Processing Speed 
 
It was also interesting to note that reaction time and, in particular, attention and processing 
speed were consistently found to be significantly reduced, as these results support the earlier 
auditory P300 ERP findings reported by Blackwood et al., (2001).   
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Further, these findings may also indicate the potential involvement of the t(1;11) balanced 
translocation in the development of structures within the temporal lobes which have previously 
been linked to abnormal P300 amplitude and latency in schizophrenia (McCarley, Nakamura 
et al. 2008). 
 
These findings support previous neuropsychological studies examining DISC1 and cognition, 
especially with regard to attention and processing speed. Visual attention has previously been 
reported to associate with a DISC1 haplotype (HEP3) (Hennah et al., 2005) and Liu et al., 
(2006) reported an association between DISC1 and impaired sustained attention. 
 
In addition to the abnormal P300 findings reported by Blackwood et al., (2001), DISC1 has 
also been associated with processing speed in several other studies including Burdick et al., 
(2005) in their study of schizophrenic patients.  In this study, DISC1 SNPs were associated 
with a rapid visual search task. 
 
Visual reaction time was found to be associated with a rare 4-SNP DISC1/TRAX haplotype 
(‘AATG’) in work by Cannon et al., (2005) and Palo and colleagues examined category fluency 
in a large study of Finnish families and reported association between a common DISC1 SNP, 
namely Ser704Cys (rs821616) and category fluency.  This study also identified a further 
association with psychomotor processing speed and the DISC1 SNP, rs980989.  Recently, 
category fluency was examined using a novel computational linguistic approach and was found 
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The ability to process information efficiently allows the successful execution of a range of 
other higher cognitive operations such as encoding and retrieval operations, decision processes, 
transformation of information held in active memory and perceptual processes, all of which 
rely on internal dynamics which are, to a certain extent, speed-dependent (Dickinson, Ramsey 
et al. 2007).  Dickinson et al., (2007) also point out that neuropsychological studies have tended 
to overlook measures of processing speed in favour of trying to tease out potentially localisable 
cognitive impairments.  Processing speed and other aspects of general intelligence are therefore 
promising performance dimensions worthy of further investigation in other genetic studies. For 
example, genetic variation in another gene - CADM2 – was very recently found to associate 
with individual differences in information processing speed (Ibrahim-Verbaas et al., 2015). 
 
4.9.4 Symptom Severity 
 
It is perhaps surprising that there were no significant differences between translocation status 
and symptom severity rating scales, however a number of non-carriers are known to suffer 
from anxiety and/or depression which may have resulted in higher scores for 
negative/depressive symptoms.  In this regard, a significant relationship was identified between 
translocation status for ‘Anxiety’ as measured by the Temperament Evaluation of the Memphis, 
Pisa, Paris and San Diego Auto Questionnaire (TEMPS-A) in which non-carriers reported 
greater anxiety than carriers, which may help to explain the non-significant clinical results. 
 
Although non-carriers reported experiencing greater anxiety than carriers, a strong positive 
association was found with t(1;11) carriers between positive symptomology (as measured by 
the Positive and Negative Symptoms Scale) and the sub-group ‘Total Negative’ from the Kings 
Schizotypy Questionnaire (KSQ).  The KSQ ‘Total Negative’ sub-group combines the self-
reported measures of social anxiety and social isolation. 
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4.9.5 Symptom Severity and Neuropsychological Measures 
 
In line with the main hypotheses, significant correlations were identified between symptom 
severity in the family (PANSS and SANS) and neuropsychological measures, particularly 
general intelligence (current IQ) and measures of attention and processing speed (simple and/or 
five-choice reaction time and motor speed). 
 
Several studies have reported that negative symptoms are most commonly associated with 
cognitive functioning (Andreasen et al., 1990; Addington et al., 1991; Basso et al., 1998; 
Nieuwenstein et al., 2001; Lewandowski et al., 2011) and the results of this study support these 
findings with significant correlations between measures from both the PANSS and SANS with 
general intelligence (current IQ) and attention and processing speed.  Executive function is 
most commonly associated with negative symptoms (Basso et al., 1998; Bozikas et al., 2004; 
Lewandowski et al., 2011;) which was not evident in this study, possibly due to the small 
sample size, however general intelligence has also been reported as being associated with 
negative symptoms (Basso et al., 1998; Berman et al., 1997; Addington et al., 1991) which 
concurs with the findings from this study.  Cognitive impairment is a strong predictor of 
outcome in patients with major mental illness and neurocognitive dysfunction is highly 
associated with negative symptoms, making this a key treatment target. 
 
4.9.6 Polygenic Risk Profile Scores 
 
Contrary to the main hypotheses, polygenic risk for schizophrenia (PGRs) was not significantly 
different between family t(1;11) carriers and non-carriers although the risk profile scores for 
schizophrenia were higher in t(1;11) carriers.  Polygenic risk for major depressive disorder 
(PGRmdd) was also non-significant but as with PGRs, the risk profile scores for depression 
were higher in t(1;11) carriers.   
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Polygenic risk for bipolar disorder (PGRbp), however, was significantly different between 
family t(1;11) carriers and non-carriers with higher risk scores seen in translocation carriers. 
 
Recent studies have confirmed a molecular genetic overlap in schizophrenia, bipolar disorder 
and/or major depressive disorder (Purcell at al., 2009; Hamshere et al., 2011; Schulze et al., 
2014).  Looking at the results for the t(1;11) family, these may be better accounted for by 
creating a cross-disorder polygenic risk profile score to measure the joint effects of risk for 
schizophrenia, bipolar disorder and major depressive disorder.  Similar studies have recently 
been conducted by Smoller et al (2013) and Whalley et al (2015) to investigate shared genetic 
aetiology and allow the examination of a broader set of common variants. 
 
It would be likely that a cross-disorder polygenic risk approach would account for a greater 
proportion of overall risk than a polygenic risk score for a single psychiatric disorder (Whalley 
et al., 2015). 
 
4.9.7 Polygenic Risk Profile Scores and Neuropsychological Measures 
 
Again, contrary to the main hypotheses, polygenic risk for schizophrenia was not found to be 
significantly associated with neuropsychological measures, however, as this was of particular 
interest, it is worth noting that polygenic risk for schizophrenia marginally missed the 
significance threshold for association with simple reaction time in the family as a whole. 
 
Recent studies have reported general intelligence as being highly polygenic (Davies et al., 
2011) and poorer cognitive ability in old age, as well as greater cognitive decline between 
childhood and old age has been reported as being associated with an increased polygenic risk 
for schizophrenia (McIntosh et al., 2013). 
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The first molecular genetic test to confirm the genetic overlap between cognitive ability and 
risk for schizophrenia was conducted by Lencz et al., (2014) who reported that cognitive 
polygenic scores for schizophrenia cases were significantly lower than controls, and similarly, 
they reported an association between poorer general cognitive ability and polygenic risk for 
schizophrenia.  Investigating polygenic risk profile scores and neurocognition is a promising 
area for future research as it could potentially shed light on the genetic risk of specific cognitive 
domains that may be impaired or unimpaired and help to establish risk for the later development 
of major mental illness.  
 
4.9.8 Polygenic Risk Profile Scores and Symptom Severity 
 
Again, contrary to the main hypotheses, polygenic risk for schizophrenia was not found to be 
significantly associated with symptom severity in the family.  Initial findings suggested that 
PGRs was significantly associated with two sub-groups from the positive and negative 
symptoms scale (PANSS) namely ‘total score’ and ‘general symptoms’ however these results 
were not robust after correcting using the FDR procedure. 
 
Investigating polygenic risk and symptom severity has the potential to provide important 
information that could be used clinically.  Recent work by Ruderfer et al., (2014) reported the 
identification of a polygenic component that significantly distinguished between bipolar 
disorder and schizophrenia, thereby implicating a difference in the underlying genetic 
architecture of these disorders (Ruderfer et al., 2014). 
 
Few studies could be found that specifically investigated polygenic risk and clinical symptoms 
which is a consideration for future work.  Derks et al., (2012) reported significant associations 
between polygenic risk for schizophrenia and five psychosis dimensions (positive, negative, 
disorganised, manic and depressed) in their case-control sample.  
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The significant results were only found in the combined case-control group and not when the 
schizophrenia cases and controls were compared separately.  Their study was unable to provide 
evidence of genetic risk for any specific symptom dimension of schizophrenia, however future 
collaborative work could help to elucidate the genetic risk of specific quantitative symptom 
dimensions by investigating the clinical symptom ratings of schizophrenia in combination with 
the clinical symptom ratings of bipolar disorder, major depressive disorder and unaffected 




Firstly, investigating the DISC1 t(1;11) balanced translocation was limited by the unavoidably 
low numbers of affected individuals and their non-translocation carrying relatives.  With this 
in mind, being able to recruit a total of 26 family members (carriers N=13, non-carriers N=13), 
each of whom completed all measures required for this work, enabled the identification of a 
large effect of the t(1;11) translocation. 
 
Secondly, a further limitation is the investigation of a single family with a single-gene locus as 
although these studies provide important information about a particular group of psychoses and 
help to ascertain whether any such single-gene locus has a major effect on the risk of illness, it 
could well be the case that findings may only relate to that particular family and remain unique 
(Blackwood et al., 2001).  In line with previous research by Blackwood et al., (2001) because 
of the rarity of the translocation it remains important to continue investigations with this family 
to identify any phenotypic differences between family members with and without the 
translocation, as well as between family members and unrelated individuals with major mental 
illnesses including schizophrenia, bipolar disorder and major depressive disorder which was 
the primary reason for recruiting a combined patients group. 
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A third limitation concerns medication status.  From the t(1;11) carriers, two individuals were 
taking antipsychotic medication together with a mood stabiliser, one individual was receiving 
a mood stabiliser only, and one was receiving an antidepressant only. Chlorpromazine 
equivalent scores were established and association analyses were conducted to identify 
associations between medication status and any of the clinical or cognitive measures.  The 
analyses proved to be non-significant and therefore CPZ scores were not included as covariates 
in the main analyses. This decision may have limited the results in view of the known 
extrapyramidal symptoms as side effects including Parkinsonism which could definitely have 
a negative impact on any measure that utilises fine motor function. 
 
Fourth – it is acknowledged that a power calculation should have been performed, however 
this wasn’t deemed appropriate due to the unique nature of the family and the fact that the aim 
was to recruit as many family members as possible.  This will be discussed further in Chapter 
6.  Another statistical consideration is the presence of outliers which can be seen in a number 
of graphs.  Outliers were not removed and are shown in the main graphs, however analyses 
were conducted with the main outlier removed in which the result remained significant.  It 
should also be noted that there were a large number of analyses conducted as part of the main 
a priori hypotheses and also as a result of additional exploratory analyses due to the fact that 
the family are so rare and opportunities to conduct investigations are limited. To reduce the 
chance of Type II errors, all analyses were corrected using the FDR procedure, however it is 
noted that some studies prefer not to correct for multiple comparisons due to the fact that 
mathematical corrections can substantially increase the risk of accepting the null hypothesis 
(Rothman, K. J. 1990).  These calculations reduce the statistical power which in turn can lead 
to problems interpreting the study results therefore in this study, both uncorrected and corrected 
results are shown. 
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A final limitation concerns the decision not to conduct direct statistical comparisons between 
the family groups (t(1;11) carriers and non-carriers) and the patient groups (schizophrenia and 
bipolar disorder) and/or unaffected control participants.  Research by Glahn et al., (2007b) has 
suggested that family members’ brains are anatomically very similar and that certain areas are 
highly heritable. Shared heredity within the family would significantly confound any direct 
comparisons between these family members and a group of unrelated individuals, which is the 
main reason the patient groups and unaffected control participants were recruited. By recruiting 
the patient and control groups we were able to conduct indirect comparisons on the effects of 
having a psychiatric illness in general to the effects of the t(1;11) translocation within the 
family without the need for direct statistical comparisons between the family and 
patients/control participants. In addition to the shared heredity, other confounding factors 




In line with the main hypotheses, IQ was reduced in translocation carriers compared to           
non-carriers and although not significant, there was a moderate to large effect size. For 
translocation carriers, however, IQ was significantly reduced between diagnostic groups, as 
was premorbid to current IQ difference. 
 
Measures of processing speed (reaction time and attention and processing speed) were also 
significantly reduced between translocation carriers and non-carriers. 
 
Sample sizes in this study are small, and it is possible that analyses did not reach significance 
due to the unavoidable lack of power.  
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However as can be seen from Table 4.5, measures of effect size were calculated in an effort to 
identify whether any lack of significance might indeed be an effect of the t(1;11) balanced 
translocation which didn’t reach significance purely due to the small numbers.  Focussing on 
t(1;11) translocation carriers compared with non-carriers, moderate to large effect sizes were 
revealed in a number of cognitive domains including IQ, especially the reduction between 
premorbid to current IQ - suggesting the t(1;11) translocation has a developmental effect, 
negatively impacting on intelligence.  Moderate to large effect sizes were also evident in 
measures of processing speed - particularly the symbol coding task which measures attention 
and processing speed, pointing to the potential involvement of the t(1;11) balanced 
translocation in the development of structures within the temporal lobes which have previously 
been linked to abnormal P300 amplitude and latency in schizophrenia. 
 
Simple and five-choice reaction time tasks were also found to have large effect sizes, however 
it is possible that reaction time may be more impacted by current symptoms and medication as 
opposed to being directly attributable to an effect of the t(1;11) translocation.  Although 
medication was not found to be significantly associated with any neuropsychological measures, 
it is possible that antipsychotic medication may have been a contributory factor in the 
significant associations identified between both measures of reaction time and symptom 
severity ratings by, for example, their known effects on fine motor function. 
 
Contrary to hypotheses, polygenic risk for schizophrenia was not significantly different 
between translocation carriers and non-carriers, however it was significantly associated with 
symptom severity and marginally associated with neuropsychological measures.  Polygenic 
risk for bipolar disorder was significantly different between translocation carriers and non-
carriers and may better describe the phenotype of this kindred which does appear to have more 
cases of depression. 




As previously mentioned, single family studies can be extremely helpful, especially when 
studying the psychoses. Although there is no doubt that the DISC1 t(1;11) kindred are truly 
unique - their rare genetic make-up providing the catalyst for over 40 years of progressive 
research into major psychiatric disorders - it remains a possibility that any findings could 
indeed be specifically related to their single lineage as opposed to potentially unravelling the 
common mechanisms in the universal population who develop major mental illness. 
 
Notwithstanding, these results support the literature and suggest that variation in DISC1 
(especially the rare t(1;11) balanced translocation) affects neurodevelopmental processes, 
impacts upon neurocognitive function and increases risk for the later development of 
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5. Patients and Control Participants 
 
5.1 Demographic Details 
 
The primary aim of having a combined patients group was to provide a positive control group 
for the DISC1 family in which there are mixed diagnoses. 
 
Sample demographics for all patients and control subjects are shown in table 5.1. 
 
 
Table 5.1 - Sample Demographics including Clinical Ratings – Patients and Control  





  Patients  
(N=48) 
 
 Controls  
(N=42) 






Age          39.65 (11.65)  38.24 (14.40) 
Premorbid IQ (NART)   110.42 (9.52)    111.29 (6.81) 
Current IQ (WASI)     103.79 (17.21)      113.98 (12.01) 
Premorbid to Current IQ Difference        -6.63 (11.52)        2.69 (9.83) 
PANSS Total Score       52.52 (19.13)  31.45 (4.17) 
PANSS Negative Symptoms     13.21 (7.26)       7.31 (1.40) 
PANSS Positive Symptoms   11.92 (4.58)  7.14 (0.65) 
PANSS General Symptoms   27.40 (9.52)  17.00 (3.51) 
SANS        25.96 (22.04)  1.43 (5.02) 
GAF        51.94 (17.49)  86.76 (8.07) 
YMRS 
HRSD 
Anti-psychotic medication (CPZ Equivalent)** 
  2.27* (3.03)* 
8.75* (7.99)* 
     475.14 (376.99) 
 0.13† (0.81)† 
0.78† (3.02)† 
0 (0) 
      
Table 5.1 – Sample demographics including Clinical Ratings for Patients and Control Participants.  
Positive and Negative Symptoms Scale (PANSS); Scale for the Assessment of Negative Symptoms 
(SANS); Global Assessment of Function (GAF); Young Mania Rating Scale (YMRS); Hamilton Rating 
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5.1.1 Age, Gender, Premorbid IQ, Current IQ and IQ Difference 
 
Patients (n=48) and controls (n=42) were compared using an independent samples t-test. No 
significant between-group differences were found for age (Figure 5.1), gender or premorbid 
IQ, however, as expected, current IQ was significantly reduced (t = -3.28, df = 83.9 p = .002) 
(equal variances not assumed) in patients compared with control subjects, as was IQ difference 
(i.e. the difference between premorbid and current IQ) (equal variances assumed) (t = -4.10, df 
= 88, p < .001) (Figure 5.2).  
 
        Mean Age for Combined Patients Group and Control Group 
 
 
                   Figure 5.1 – Mean and Median Age for Patient and Control Groups 
 

























Patients (N=48) Controls (N=42)
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5.1.2 Brief Assessment of Cognition in Schizophrenia (BACS) 
 
Initial analysis using independent samples t-tests (equal variances not assumed for digit 
sequencing and motor speed tasks) revealed significantly reduced performances for patients 
compared to controls in all six BACS assessments (Figure 5.3).  Controlling for age, gender 
and current IQ using a general linear model univariate analysis of covariance identified 
significantly poorer performances (p<.05) from the patient group for motor speed and attention 
and processing speed (using a symbol coding task). 
 
Brief Assessment of Cognition in Schizophrenia: Patients and Controls 
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5.1.3  Cambridge Neuropsychological Test Automated Battery (CANTAB) 
 
Initial comparisons using an independent samples t-test (equal variances not assumed) revealed 
significantly reduced performances (p<.05) from patients for both simple and five-choice 
reaction time tasks.  Further comparisons using a general linear model univariate analysis of 
covariance (homogeneity of error variance met) remained significant for the five-choice 
reaction time task controlling for age, gender and current IQ (F(1,81) 6.93, p = 0.010). (Figure 
5.4) 
Cambridge Neuropsychological Test Automated Battery (CANTAB) 
 
Simple and Five-Choice Reaction Time Tasks: Patients and Controls 
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Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
165 
  
5.2 Clinical Symptom Rating Scales 
 
Symptom severity was measured using a range of clinical rating scales including the Positive 
and Negative Symptoms Scale (PANSS), the Scale for the Assessment of Negative Symptoms 
(SANS), the Global Assessment of Functioning (GAF), the Young Mania Rating Scale 
(YMRS) and the Hamilton Rating Scale for Depression (HRSD).  Full details of these measures 
can be found in Chapter 3 (Methods).  
 
5.2.1 Clinical Symptom Rating Scales: Patients and Controls 
 
Direct comparisons of symptom severity were conducted between all patients (N=48) and 
control participants (N=42) using independent samples t-tests.  As expected, all symptom 
severity ratings were significantly different between these groups (p <.01).  As homogeneity 
of variance assumptions were violated, non-parametric Mann-Whitney U analysis were 
conducted which confirmed all significant results (p <.01). 
 
5.3 Clinical Symptom Rating Scales and Neuropsychological Assessments 
 
It was hypothesised that symptom severity, particularly positive and negative symptoms, would 
be significantly associated with measures of neuropsychology, in particular IQ and measures 
of processing speed.  Clinical rating scales were therefore investigated to establish whether 
symptom severity associated with cognitive function in the combined patients group and also 
in patients by diagnosis. 
 
5.3.1 Neuropsychological Assessments and Symptom Severity: Combined Patients Group 
 
Pearson bivariate correlational analysis identified significant associations between measures of 
neuropsychology and symptom severity in patients. 
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Not all results were robust controlling for age, gender and current IQ (premorbid IQ where 
current IQ was the variable of interest).  Current IQ was significantly associated with two 
measures from the positive and negative symptoms scale (PANSS), namely ‘total score’ and 
‘negative symptoms’ and current IQ was also significantly associated with negative symptoms 
as measured by the SANS. These results were robust controlling for age, gender and current 
IQ.  To reduce the possibility of Type II error, all significant p-values were corrected using the 









 r  (pFDR) r  (pFDR) 
PANSS Total r = -.33, p = .029 r = -.30, p = .041 
PANSS Positive r = -.27, p = .076 r = -.32, p = .030 
PANSS Negative r = -.39, p = .008 r = -.36, p = .014 
SANS 
 
r = -.47, p = .001 r= -.31, p = .039 
Table 5.2 – Correlational Analysis: Neuropsychological Assessments/Clinical Measures - Patients Group (N=48) 
 
p-values have been controlled for age, gender and current IQ (premorbid IQ where current IQ 
is the variable of interest).  For all correlations, p-values were corrected using the FDR 
 
5.4 Polygenic Risk Profile Scores: Patients and Control Participants 
 
It was hypothesised that polygenic risk for schizophrenia would be significantly associated 
with the combined patients group and particularly patients with schizophrenia.  It was also 
hypothesised that polygenic risk profile scores would be associated with measures of 
neuropsychology and symptom severity, in particular IQ, measures of processing speed and 
positive symptoms, especially in patients with schizophrenia. 
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5.4.1 Polygenic Risk Profile Scores: Patients and Control Participants 
 
Initial analysis between the combined patients group (N=41) and control participants (N=34) 
using an independent samples t-test (equal variances assumed) reached significance for 
polygenic risk for schizophrenia (p = .050) (Figure 5.5 and Tables 5.3 & 5.4).  No significant 
differences were identified between patients and controls for polygenic risk for bipolar disorder 
or polygenic risk for major depressive disorder. 
          Polygenic Risk Score for Schizophrenia: Patients and Controls 
 
          Figure 5.5 - Polygenic Risk for Schizophrenia: Combined Patients Group and Control Participants 
 




Mean Std. Deviation 
Schizophrenia 41 -.002040856 .0003146393 
Bipolar Disorder 41 .0012420535 .0005596922 
Major Depressive Disorder 41 .0083588015 .0007371641 
Table 5.3 - Polygenic Risk Profile Scores – Combined Patients Group (Schizophrenia & Bipolar Disorder Samples) 
 
Polygenic Risk  
Profile Score 
N Mean Std. Deviation 
Schizophrenia 34 -.002166094 .0002067250 
Bipolar Disorder 34 .0010939674 .0004490317 
Major Depressive Disorder 34 .0082641665 .0005667305 
Table 5.4 - Polygenic Risk Profile Scores – Control Participants  
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5.4.2 Polygenic Risk: Neuropsychological Assessments, Clinical Rating Scales and Self-
 Report Questionnaire Data – Combined Patients Group 
 
Pearson bivariate correlational analysis identified a number of significant associations between 
polygenic risk for schizophrenia, bipolar disorder and/or major depressive disorder in the 
combined patients group (schizophrenia (N=25) and bipolar disorder (N=16)) with several 
neuropsychological and/or clinical measures. 
 
(a) Polygenic Risk for Schizophrenia 
 
From the neuropsychological test battery, polygenic risk for schizophrenia was significantly 
associated with IQ difference (p = .048, r = -.31) and marginally missed the significance 
threshold for current IQ.  After controlling for CNT and correcting using the FDR procedure 
significance was lost (p = .051, r = -.31) (Tables 5.5 & 5.6).  No significant associations were 
identified between polygenic risk for schizophrenia and any of the clinical measures or self-
report questionnaires in the combined patients group. 
 
 Current IQ IQ Difference 
 r  (pFDR) r  (pFDR) 
Polygenic Risk for 
Schizophrenia 
 
r = -.30, p = .052 
 
r = -.31, p = .048 





Current IQ IQ Difference 
 r  (pFDR) r  (pFDR) 
Polygenic Risk for 
Schizophrenia 
 
r = -.30, p = .055 
 
r = -.31, p = .051 
   Table 5.6 – Correlational Analysis (Controlling for CNT): Polygenic Risk for Schizophrenia - Combined Patients Group (N=41) 
 
 
For all correlations, p-values were corrected using the FDR procedure and considered 
significant when pFDR ≤ .05. 
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(b) Polygenic Risk for Bipolar Disorder 
 
In the combined patients group, polygenic risk for bipolar disorder was significantly associated 
with simple reaction time (p = .033, r = .35) and attention and processing speed (as assessed 
by a digit sequencing task) (p = .041, r = -.32), however these results became non-significant 
after controlling for CNT and correcting using the FDR procedure. 
 
For clinical measures, polygenic risk for bipolar disorder was significantly associated with 
‘mania’ as measured by the Young Mania Rating Scale (YMRS) (p = .038, r = .34) and 
remained significant after controlling for CNT, however this later became non-significant after 
correcting using the FDR procedure (Tables 5.7 & 5.8). 
 
No significant associations were identified between polygenic risk for bipolar disorder and any 
self-report questionnaire data which is interesting as clinically rated mania but not self-rated 
mania was significantly associated with polygenic risk for bipolar disorder. 
 






 r  (pFDR) r  (pFDR) r  (pFDR) 
Polygenic Risk for 
Bipolar Disorder 
 
r = .35, p = .033 
 
r = -.32, p = .041 
 
r = .34, p = .038 













 r  (pFDR) r  (pFDR) r  (pFDR) 
Polygenic Risk for 
Bipolar Disorder 
 
r = .31, p = .060 
 
r = -.30, p = .060 
 
r = .34, p = .045 
Table 5.8 – Correlational Analysis (Controlling for CNT): Polygenic Risk for Bipolar Disorder - Combined Patients Group (N=41) 
 
 
For all correlations, p-values were corrected using the FDR procedure and considered 
significant when pFDR  ≤ .05. 
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(c) Polygenic Risk for Major Depressive Disorder 
 
The majority of results were found with polygenic risk for major depressive disorder which 
included IQ difference (p = .021, r = -.36), motor speed (p = .021, r = -.36), verbal fluency      
(p = .015, r = -.38) and executive function (p = .045, r = -.31) (Table 5.9).  All of these results 
remained significant after controlling for CNT and correcting using the FDR procedure (Table 
5.10). 
 
No significant associations were identified between polygenic risk for major depressive 
disorder and any of the clinical rating scales, however there was a significant association with 














 r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) 
 




r = -.36 
p = .021 
 
r = -.36 
p = .021 
 
r = -.38 
p = .015 
 
r = -.31 
p = .045 
 
r = -.44 
p = .023 














 r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) 
 




r = -.37 
p = .019 
 
r = -.38 
p = .017  
 
r = -.37 
p = .020 
 
r = -.33 
p = .035 
 
r = -.48 
p = .013 




For all correlations, p-values were corrected using the FDR procedure and considered 
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5.5 Sub-Group Comparisons: Schizophrenia and Bipolar Disorder 
 
5.5.1 Age, Gender, Premorbid IQ, Current IQ & IQ Difference 
 
Patients were sub-grouped according to diagnoses: schizophrenia (N=32), bipolar disorder 
(N=16).  Sample demographics are provided in Table 5.11.  Independent samples t-tests (equal 
variances assumed) did not identify any significant differences between patient groups for any 
of the demographic variables of age, gender, premorbid IQ, current IQ or IQ Difference (Figure 
5.6). 
Sample Demographics for Schizophrenia and Bipolar Disorder Samples 
Sample Size 
(N=48) 
  Schizophrenia 
(N=32) 
 
 Bipolar Disorder 
(N=16) 
Gender M/(F)   23/(9) 
 
     Mean (SD) 
     11/(5) 
 
       Mean (SD) 
Age            37.84 (9.97)      43.25 (14.12) 
Premorbid IQ (NART)   109.53 (10.28)       112.19 (7.80) 
Current IQ (WASI)   103.16 (16.70)  105.06 (18.88) 
Premorbid to Current IQ Difference          -6.38 (9.71)  -7.13 (14.84) 
PANSS Total Score   55.19 (20.53)  47.19 (15.14) 
PANSS Negative Symptoms          14.41 (7.80)         10.81 (5.50) 
PANSS Positive Symptoms          12.69 (4.89)         10.38 (3.52) 
PANSS General Symptoms          28.09 (9.84)         26.00 (9.00) 
SANS   28.88 (22.65)  20.13 (20.17) 
GAF   48.09 (17.31)  59.63 (15.65) 
YMRS 
HRSD 
Anti-psychotic medication (CPZ Equivalent)** 
  1.54* (1.91)* 
9.18* (8.43)* 
515.52 (397.88) 
           3.56 (4.11) 
          8.00 (7.38) 
    307.86 (223.08) 
      
Table 5.11 – Sample Demographics including Clinical Ratings for Schizophrenia and Bipolar Disorder Samples.  Positive and 
Negative Symptoms Scale (PANSS); Scale for the Assessment of Negative Symptoms (SANS); Global Assessment of Function 
(GAF); Young Mania Rating Scale (YMRS); Hamilton Rating Scale for Depression (HRSD), Chlorpromazine Equivalent 
(CPZ).*N=28 **N=29 (Scz) N=7 (BP) 
 
 






















Bipolar Disorder (N=16) Schizophrenia (N=32)
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5.5.2 Brief Assessment of Cognition in Schizophrenia (BACS): Schizophrenia and Bipolar 
Disorder 
 
Initial analyses using independent samples t-tests (equal variances assumed) did not identify 
any significant between-group differences for any of the six BACS assessments (see Table 5.12 
for raw score means and standard deviations). 
 
Controlling for age, gender and current IQ using a general linear model univariate analysis of 
covariance (homogeneity of error variance met) identified significantly poorer performances 
(p<.05) from patients with schizophrenia for verbal memory (as assessed by a list-learning 
task) (F(1,43) 4.98, p=.031) and motor speed (as assessed by a token motor task) (F(1,43) 5.14, 
p=.028).  Attention and processing speed (as assessed by a symbol coding task) marginally 
failed to reach the significance threshold (p=.052) (Figures 5.7 and 5.8). 
 
These results could, conceivably, be attributable to antipsychotic medication effects as 29 of 
32 patients with schizophrenia and 7 of 16 patients with bipolar disorder were receiving 
antipsychotic medication.  This is particularly relevant when considering the motor speed task 
and the powerful effects antipsychotics can exert on fine motor function.  An independent 
samples t-tests (equality of variances met), did not identify any significant differences in 
antipsychotic medication (CPZ Equivalent) between patient groups and further correlational 
analyses did not identify any significant associations between antipsychotic medication and 
any of the BACS assessments.  As a result of these findings, CPZ equivalents were not 
controlled for in the main analyses, however this omission may have limited these results and 
is a factor that should be addressed in future work. 
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Verbal Memory, Motor Speed, Attention & Processing Speed 
                         
              
Figure 5.7 - Error Bar Graphs for Verbal Memory (p = .031), Motor Speed (p = .028) and Attention & Processing Speed  




























Schizophrenia (N=32) Bipolar Disorder (N=16)




Sample Raw Scores for BACS and CANTAB 














 Mean (Standard Deviation) Mean (Standard Deviation) 
   
VERBAL MEMORY: 
(LIST LEARNING TASK) 
 
41.47 (16.20) 48.06 (15.85) 
WORKING MEMORY: 
(DIGIT SEQUENCING TASK) 
 
20.94 (5.28) 20.44 (7.52) 
MOTOR SPEED: 
(TOKEN MOTOR TASK) 
 
60.06 (17.70) 67.88 (23.44) 
PROCESSING SPEED: 
(VERBAL FLUENCY TASK) 
 
47.13 (14.11) 50.44 (17.54) 
ATTENTION & PROCESSING             
SPEED: 
(SYMBOL CODING TASK) 
 
47.56 (12.93) 52.25 (19.92) 
EXECUTIVE FUNCTION: 
(TOWER OF LONDON TASK) 
 
SIMPLE REACTION TIME 
(CANTAB) 
 

















Table 5.12 – Brief Assessment of Cognition in Schizophrenia (BACS) and Cambridge Neuropsychological Test Automated 
Battery (CANTAB) Raw Score Means and Standard Deviations for Schizophrenia (N=32) and Bipolar Disorder (N=16) Samples 
 
5.5.3 Cambridge Neuropsychological Test Automated Battery (CANTAB): Schizophrenia 
and Bipolar Disorder Samples 
 
No significant differences were identified between the schizophrenia and bipolar disorder 
samples for either simple or five-choice reaction time tasks (see Table 5.12 for raw score means 
and standard deviations). 
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5.6 Clinical Symptom Rating Scales 
 
Symptom severity was measured using a range of clinical rating scales including the Positive 
and Negative Symptoms Scale (PANSS), the Scale for the Assessment of Negative Symptoms 
(SANS), the Global Assessment of Functioning (GAF), the Young Mania Rating Scale 
(YMRS) and the Hamilton Rating Scale for Depression (HRSD). Full details of these measures 
can be found in Chapter 3 (Methods). 
 
5.6.1 Clinical Symptom Rating Scales: Patients by Diagnosis 
 
Direct comparisons of symptom severity were conducted between the schizophrenia and 
bipolar disorder samples using independent samples t-tests which identified a significant 
difference in overall functioning as assessed by the Global Assessment of Function (p<.05). 
As homogeneity of variance assumptions were violated, a non-parametric Mann-Whitney U 
test was conducted which confirmed significance (U=149.5, p = .020).  All other clinical rating 
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5.7 Clinical Symptom Rating Scales and Neuropsychological Assessments 
 
It was hypothesised that symptom severity, particularly positive and negative symptoms, would 
be significantly associated with measures of neuropsychology, in particular IQ and measures 
of processing speed.  Clinical symptom rating scales were therefore investigated to establish 
whether symptom severity associated with cognitive function in patients by diagnosis. 
 
5.7.1 Neuropsychological Assessments and Symptom Severity: Schizophrenia 
 
Current IQ in the schizophrenia sample was significantly associated with negative symptoms 
as measured by the Scale for the Assessment of Negative Symptoms (SANS)                                    
(r = -.41, p = .028) and was robust controlling for age, gender and premorbid IQ. 
 
5.7.2 Neuropsychological Assessments and Symptom Severity: Bipolar Disorder 
 
Current IQ in the bipolar disorder sample was also significantly associated with ‘negative 
symptoms’ as measured by both the Positive and Negative Symptoms Scale (PANSS)                  
(r = -.71, p = .007) and the Scale for the Assessment of Negative Symptoms (SANS)                     
(r = -.61, p = .025).  Both results were robust controlling for age, gender and premorbid IQ. 
 
Stronger correlations in bipolar disorder are unusual and analysis of polygenic risk profile 
scores may offer a more neurodevelopmental basis for these unexpected results which appear 
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5.8 Polygenic Risk Profile Scores: Schizophrenia and Bipolar Disorder Samples 
 
A significant difference (t(39) -3.33, p = .002) was identified using independent samples t-tests 
(equal variances assumed) between these patient groups for polygenic risk for bipolar disorder 
(Figure 5.10 and Tables 5.13 & 5.14).  There were no significant differences between patient 
groups with polygenic risk for schizophrenia or major depressive disorder. 
                    Polygenic Risk Score for Bipolar Disorder 
 
 
              Figure 5.10 - Polygenic Risk for Bipolar Disorder: Schizophrenia (N=25) and Bipolar Disorder (N=16) Samples 
Polygenic Risk Profile Score N Mean Std. Deviation 
Schizophrenia 25 -.002027400 .0003757594 
Bipolar Disorder 25 .001034114 .0004951135 
Major Depressive Disorder 25 .008339230 .0008024925 
Table 5.13 - Polygenic Risk Profile Scores: Schizophrenia Participants 
Table 5.14 – Polygenic Risk Profile Scores: Bipolar Disorder Participants 
Polygenic Risk Profile Score N Mean Std. Deviation 
Schizophrenia 16 -.002061881 .0001931551 
Bipolar Disorder 16 .001566959 .0005083912 
Major Depressive Disorder 16 .008389383 .0006458089 
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
179 
  
5.8.1 Polygenic Risk Profile Scores: Schizophrenia, Bipolar Disorder and Control 
Participants 
 
Finally, comparisons using a one-way analysis of variance were conducted between patients 
with schizophrenia, patients with bipolar disorder and control participants which identified a 
significant between-groups difference (F(2,72) 6.969, p = .002).  Post hoc tests revealed 
significant differences between polygenic risk for bipolar disorder in patients with bipolar 
disorder and both patients with schizophrenia (p = .003) and control participants (p = .005) 
(Figure 5.11 and Tables 5.4, 5.13 & 5.14). 
 
                         Polygenic Risk Score for Bipolar Disorder 
 
             Figure 5.11 - Polygenic Risk for Bipolar Disorder: Schizophrenia Sample (N=25), Bipolar Disorder Sample (N=16)    
and Control Participants (N=34) 
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5.8.2 Polygenic Risk: Neuropsychological Assessments, Clinical Rating Scales and Self-
 Report Questionnaire Data – Schizophrenia Patients 
 
Patients were split by diagnosis and their polygenic risk profile scores for each of 
schizophrenia, bipolar disorder and major depressive disorder were compared with 
neuropsychological, clinical and self-report measures. 
 
(a) Schizophrenia Patient Group: Polygenic Risk for Schizophrenia 
 
No significant results were identified for any of the neuropsychological or clinical measures in 
patients with schizophrenia. 
 
(b) Schizophrenia Patient Group: Polygenic Risk for Bipolar Disorder 
 
As with previous results, no significant associations were identified for any neuropsychological 
assessment, clinical measure and/or self-report questionnaire data. 
 
(c)  Schizophrenia Patient Group: Polygenic Risk for Major Depressive Disorder 
 
Again, there were no significant associations in the schizophrenic sample between any of the 
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5.8.3 Polygenic Risk: Neuropsychological Assessments, Clinical Rating Scales and Self-
 Report Questionnaire Data – Bipolar Disorder Patients 
 
There were a number of significant associations identified in the bipolar disorder sample for 
each of the polygenic risk profile scores and/or neuropsychological, clinical and self-report 
measures, the majority of which remained significant after controlling for CNT. 
 
(a)  Bipolar Disorder Patients: Polygenic Risk for Schizophrenia 
 
For neuropsychological assessments, current IQ and premorbid to current IQ difference were 
found to be significantly associated with polygenic risk for schizophrenia in patients with 
bipolar disorder (r = -.52, p = .039 and r = -.62, p = .011 respectively).  After controlling for 
CNT, premorbid to current IQ difference remained significant (r = -.58, p = .023).  
 
No significant associations were identified between polygenic risk for schizophrenia and any 
of the clinical measures in the bipolar disorder sample.  Self-report questionnaire data revealed 
a significant association between polygenic risk for schizophrenia and the sub-group measure 
‘irritable’ from the Temperament Evaluation of the Memphis, Pisa, Paris and San-Diego Auto-
Questionnaire (TEMPS-A) (r = -.62, p = .031), however this result became non-significant 
after controlling for CNT.   
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(b)  Bipolar Disorder Patients: Polygenic Risk for Bipolar Disorder 
 
For neuropsychological assessments, current IQ and premorbid to current IQ difference were 
significantly associated with polygenic risk for bipolar disorder (r = -.59, p = .016 and r = -.54, 
p = .031 respectively).  After controlling for CNT, current IQ remained significant                         
(r = -.61, p = .015 and r = -.51, p = .053 respectively). 
 
Premorbid IQ was significantly associated with polygenic risk for bipolar disorder after 
controlling for CNT (r = -.61, p = .005) but not before (r = -.39, p = .128).  All results remained 
significant after correcting using the FDR procedure. There were no significant associations 
between polygenic risk for bipolar disorder and any clinical or self-report measures. 
 
(c)  Bipolar Disorder Patients: Polygenic Risk for Major Depressive Disorder 
 
From the neuropsychological test battery, IQ, premorbid to current IQ difference, five-choice 
reaction time and motor speed were all found to be significantly associated with polygenic risk 
for major depressive disorder.  For symptom severity in the bipolar sample, negative symptoms 
as measured by the Positive and Negative Symptoms Sale (PANSS) and the Scale for the 
Assessment of Negative Symptoms (SANS) were also significantly associated with polygenic 
risk for major depressive disorder and remained significant after controlling for CNT and 
correcting using the FDR procedure (Tables 5.15 & 5.16). There were no significant 
associations between polygenic risk for major depressive disorder and any self-report 






















 r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) 
 




r = -.55 
p = .028 
 
r = -.65 
p = .006 
 
r = .54 
p = .030 
 
r = -.63 
p = .009 
 
r = .59 
p = .016 
 
r = .55 
p = .028 
























 r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) 
 




r = -.54 
p = .040 
 
r = -.67 
p = .006 
 
r = .47 
p = .074 
 
r = -.62 
p = .015 
 
r = .66 
p = .007 
 
r = .59 
p = .019 




For all correlations, p-values were corrected using the FDR procedure and considered 
significant when pFDR  ≤ .05. 
 
In additional exploratory analysis, neuropsychological measures of verbal memory, verbal 
fluency and executive function were found to be significantly associated with polygenic risk 
for major depressive disorder, as was the total score from the PANSS and a measure of overall 
function as assessed by the Global Assessment of Function (GAF).  The majority of these 
results remained significant after controlling for CNT and correcting using the FDR procedure 
(Tables 5.17 & 5.18).   
 
 


















 r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) 
 




r = -.57 
p = .020 
 
r = -.60 
p = .014 
 
r = -.55 
p = .028 
 
r = .54 
p = .032 
 
r = -.61 
p = .012 















 r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) r  (pFDR) 
 




r = -.52 
p = .049 
 
r = -.62 
p = .014 
 
r = -.51 
p = .053 
 
r = .55 
p = .035 
 
r = -.67 
p = .006 




For all correlations, p-values were corrected using the FDR procedure and considered 
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5.8.4 Polygenic Risk: Neuropsychological Assessments, Clinical Rating Scales and Self-
 Report Questionnaire Data – Control Participants 
 
Polygenic risk profile scores for control participants were also compared with 
neuropsychological assessments, clinical measures and self-report questionnaires. 
 
(a)   Polygenic Risk for Schizophrenia: Control Participants 
 
There were no significant associations between polygenic risk for schizophrenia with 
neuropsychological measures or clinical ratings.  Significant associations were identified, 
however with the self-reported questionnaire data in which two sub-group measures from the 
Kings Schizotypy Questionnaire (KSQ), namely ‘Recurrent Illusions 1’ and ‘Magical 
Thinking’ were both significantly associated with polygenic risk for schizophrenia. These 
results remained significant after controlling for CNT and correcting using the FDR procedure 
(Tables 5.19 & 5.20). 
 




 r  (pFDR) r  (pFDR) 
Polygenic Risk for 
Schizophrenia 
 
r = .45, p = .012 
 
r = .40, p = .027 









 r  (pFDR) r  (pFDR) 
Polygenic Risk for 
Schizophrenia 
 
r = .47, p = .010 
 
r = .42, p = .025 
Table 5.20 – Correlational Analysis (Controlling for CNT): Polygenic Risk for Schizophrenia - Control Participants (N=34) 
 
 
For all correlations, p-values were corrected using the FDR procedure and considered 
significant when pFDR  ≤ .05. 
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(b)  Polygenic Risk for Bipolar Disorder: Control Participants 
 
No significant associations were identified for any of the neuropsychological or clinical 
measures in this sample, however, as with previous results, a significant association was 
identified between polygenic risk for bipolar disorder and the ‘Recurrent Illusions 1’ sub-group 
from the Kings Schizotypy Questionnaire (KSQ) which remained significant after controlling 
for CNT and correcting using the FDR procedure (Tables 5.21 & 5.22). 
 
 
 Recurrent Illusions 1 (KSQ) 
 r  (pFDR) 
Polygenic Risk for 
Bipolar Disorder 
 
r = .51, p = .004 







Recurrent Illusions 1 (KSQ) 
 r  (pFDR) 
Polygenic Risk for 
Bipolar Disorder 
 
r = .51, p = .004 




For all correlations, p-values were corrected using the FDR procedure and considered 















Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
187 
  
(c)  Polygenic Risk for Major Depressive Disorder: Control Participants 
 
From the neuropsychological test battery, attention and processing speed (as assessed by a digit 
sequencing task) was significantly associated with polygenic risk for major depressive disorder                 
(r = -.45, p = .007) and remained significant after controlling for CNT and correcting using the 
FDR procedure (Tables 5.23 and 5.24). 
 
No significant associations were identified for any of the clinical rating scales in this sample, 
however, as with previous results, the sub-group ‘Recurrent Illusions 1’ from the Kings 
Schizotypy Questionnaire (KSQ) was significantly associated with polygenic risk for major 
depressive disorder and was robust controlling for CNT and correcting using the FDR 
procedure (Tables 5.23 and 5.24).   
 
 Attention & 
Processing Speed 
Recurrent Illusions 1 
(KSQ) 
 r  (pFDR) r  (pFDR) 




r = -.45, p = .007 
 
r = -.43, p = .017 











Recurrent Illusions 1 
(KSQ) 
 r  (pFDR) r  (pFDR) 




r = -.45, p = .008 
 
r = .44, p = .016 





For all correlations, p-values were corrected using the FDR procedure and considered 
significant when pFDR  ≤ .05. 
 





5.9.1 Neuropsychological Measures 
 
Overall, results were as expected and in line with hypotheses, with the combined patients group 
underperforming in all cognitive domains compared to control participants. Individuals with 
schizophrenia scored lower than those with bipolar disorder in the majority of 
neuropsychological tasks and in turn, patients with bipolar disorder scored lower than control 
participants. To reduce the risk of Type II errors, significant p-values were corrected using the 
FDR procedure and considered significant when pFDR ≤ .05.  As it is possible some results 
could be attributable to the effects of medication, association analysis was conducted which 
did not identify any significant association between antipsychotics (CPZ equivalent) and any 
neuropsychological measure.  Although association analysis was conducted and there were no 
significant differences identified between medication and patient groups, CPZ equivalents 
were not included as covariates which may have limited these findings.  This is an important 
consideration for future work, especially in view of the fact that medication, particularly first 
generation antipsychotics such as chlorpromazine, can result in movement disorders, including 
Parkinsonism, which could confound measures utilising fine motor function (D Thomas & 
Dauner, 1992; Owens, D.C. 2014). 
 
5.9.2 General Intelligence 
 
In line with hypotheses, current IQ for the combined patients group (schizophrenia and bipolar 
disorder) was significantly reduced compared to control participants, as was IQ difference, i.e. 
the difference between premorbid and current IQ.   
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Prior to controlling for variables known to impact on cognitive function (current IQ, age and 
gender), test results for the main group comparisons as well as for additional exploratory 
analyses were significantly lower in patients compared to controls across all 
neuropsychological measures. As previously, it should be noted that antipsychotic medication 
may have played a part in these results and CPZ equivalents should be included as covariates 
in future work. 
 
This is also in line with hypotheses, as constructs such as reasoning and problem solving, 
attention, memory and processing speed highly correlate with general intelligence (Kahn & 
Keefe, 2013). 
 
Comparing schizophrenia and bipolar disorder groups separately, current IQ was lower in 
individuals with schizophrenia than those with bipolar disorder, however a direct comparison 
did not reach significance.  This was unexpected as cognition is known to be most impaired in 
schizophrenia, however, five individuals from the schizophrenia sample were first episode 
psychosis cases which may have contributed to minimising the overall deficit, as the IQ 
measure for these individuals was captured prior to them experiencing any ongoing cognitive 
decline which may occur as the illness progresses (Johnstone et al., 2010).  Additionally, this 
result may be sensitive to environmental factors such as years of education, as the majority of 
individuals with schizophrenia in this sample had completed ‘post-secondary education’ 
(N=18) with a further 6 completing ‘more than compulsory education’ compared to 8 who 
completed ‘compulsory education’. Palmer (1997) reported that 27% of all schizophrenia 
patients wouldn’t be classed as cognitively impaired by clinical neuropsychological assessment 
(also applies to the general population = 85%).  This is believed to be as a result of these 
individuals having higher premorbid functioning.   
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Although their performance would not warrant them being classed as impaired, it would, 
however, still be much lower than would have been expected based on their premorbid function 
and their parents level of education (Palmer et al., 1997).  
 
In the bipolar disorder sample, 8 individuals had completed ‘post-secondary education’, 4 had 
completed ‘more than compulsory education’ and 4 completed ‘compulsory education’.  
 
Overall, IQ is impaired in the schizophrenia sample, however years of education, parents’ 
education and higher premorbid functioning may help to account for the non-significant 
difference in current IQ between the schizophrenia and bipolar disorder patient groups.  
 
IQ Difference, i.e. the difference between premorbid and current IQ was reduced (although not 
significantly) in both the schizophrenia (-6.38) and bipolar disorder (-7.13) samples.  As can 
be seen however, the greatest reduction between premorbid to current IQ was identified for 
individuals with bipolar disorder. This was again an unexpected result, as IQ is generally 
preserved in bipolar disorder (Lewandowski et al., 2011). As with the unexpected result for 
current IQ, this difference may be accounted for by the five first-episode psychosis cases in the 
schizophrenia sample and the fact that there were two particularly impaired individuals in the 
bipolar disorder sample, both of whom had >30 points difference between measures of their 
premorbid and current IQ.  Also of note is the fact that the bipolar disorder sample were older 
(M=44 years) than the schizophrenia sample (M=38 years) and that as a group, the bipolar 
disorder sample had high polygenic risk profile scores for bipolar disorder, possibly making 
them an especially ‘genetic’ or developmental group. 
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Overall, these results support the literature which has consistently reported impaired general 
intelligence in schizophrenia (Aylward et al., 1984; Heinrichs et al., 1998; Johnstone et al., 
1999; Caspi et al., 2003; McIntosh et al., 2005; Osler et al., 2007; Woodberry et al., 2008; 
Joyce et al., 2013). 
 
Global impairments in IQ have been reported to pre-date psychosis onset, and studies have also 
reported significantly poorer performances in tasks assessing general intelligence in people 
who later develop schizophrenia as far back as primary school (Caspi et al., 2003, Osler et al., 
2007).  
 
General intelligence is strongly genetic and highly heritable (McIntosh et al., 2005; 
Toulopoulou et al., 2007; Deary et al., 2009) although no single genetic locus has as yet been 
identified as being unequivocally associated with intelligence (Deary et al., 2009).  Cognitive 
ability has, however, been reported as being a true endophenotype for susceptibility to 
schizophrenia (Lencz et al., 2014) and as such, warrants further investigation - especially with 
regard to identifying the genes associated with intelligence and it’s high heritability. 
 
Associations have been found between certain genes and measures of cognitive ability, in 
particular, older healthy females carrying the Cys allele from the DISC1 gene were found to 
have poorer cognitive ability in old age (Thomson et al., 2005). 
 
IQ generally remains intact in bipolar disorder, at least until the experience of a first episode 
of illness, and levels of impairment are not as severe as those seen in schizophrenia, however 
impaired cognition is a core feature of the illness (Bora et al., 2009).   
 
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
192 
  
It is also now becoming more evident that general cognitive ability does not necessarily return 
to premorbid levels during periods of euthymia as previously believed, and that individuals 
with bipolar disorder continue to suffer cognitive impairment during all phases of the illness 
as a result of residual symptoms of hypomania and/or depression (Angst & Sellaro, 2000; 
Thompson et al., 2005; Kurtz & Gerraty., 2009; Bora et al., 2010).  At the time of testing, this 
sample were assessed as euthymic, however it is evident from the results that their current IQ 
is lower than their premorbid IQ which supports the fact that cognitive impairment is still 
present. 
 
5.9.3 Attention and Processing Speed 
 
From the Brief Assessment of Cognition in Schizophrenia (BACS) and the Cambridge 
Neuropsychological Test Automated Battery (CANTAB), main group comparisons and 
additional exploratory analyses identified significant differences in all cognitive domains.  
Three measures of attention and/or processing speed were robust controlling for current IQ, 
age and gender. Significantly reduced performances were identified in the combined patients 
group compared to control participants for motor speed and attention and processing speed 
(from the BACS) and five-choice reaction time (from the CANTAB). 
 
These results are in line with the hypotheses and also support previous findings in which 
processing speed produced the largest group difference effect size in a meta-analysis between 
patients with schizophrenia and control groups in a large battery of neuropsychological 
assessments (Dickinson et al., 2007).  A study by McIntosh et al., (2005) found evidence that 
genetic liability to schizophrenia was related to intellectual abnormalities including 
psychomotor performance and that all patient groups were significantly impaired compared to 
controls.   
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
193 
  
Patients with schizophrenia and/or bipolar disorder, as well as their non-affected family 
members were also found to be impaired on measures of psychomotor performance.  In a later 
study, Glahn et al., (2010) postulated information processing speed as being a candidate 
endophenotype for bipolar disorder and suggested it could be one of the main causes of 
cognitive impairment in both schizophrenia and bipolar disorder. 
 
Looking specifically at patient groups, a significant difference was identified, after controlling 
for current IQ, age and gender, for motor speed as assessed by the token motor task from the 
BACS. 
 
These findings could be attributable to the effect of medication, as at the time of testing, 29 of 
32 patients with schizophrenia and 7 of 16 patients with bipolar disorder were receiving 
antipsychotics.  To minimise this possibility, correlational analysis was conducted between 
antipsychotic dose (CPZ Equivalent) (Gardner et al., 2014) and each neuropsychological 
assessment with no significant results.  CPZ equivalents were also directly compared between 
patient groups, again with no significant results.  Although medication effects were considered, 
future work would benefit by including CPZ equivalents as covariates in the main analysis, 
particularly when investigating measures utilising fine motor function. This is especially 
important with first generation antipsychotics such as chlorpromazine, which commonly 
produce extrapyramidal symptoms as side effects, including Parkinsonism (D Thomas & 
Dauner, 1992; Owens, D.C. 2014). 
 
These findings support hypotheses with poorer performances from individuals with 
schizophrenia compared to those with bipolar disorder.   
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Results are also in line with previous findings which have reported impaired attention and 
processing speed in both schizophrenia and bipolar disorder (Fleming et al., 2004; McIntosh et 
al., 2005; Dickinson et al., 2007; Glahn et al., 2010; Lewandowski et al., 2011; Joyce, 2013) 
with the greatest deficits identified in schizophrenia. 
 
No group differences were identified between individuals with schizophrenia and individuals 
with bipolar disorder for either of the simple or five-choice reaction time tasks which is in 
keeping with rationale 1 and further suggests that the earlier reported DISC1 effect identified 
between family translocation carriers and non-carriers is an effect of the translocation. 
 
5.9.4 Symptom Severity and Neuropsychological Measures 
 
Symptom severity, particularly positive and negative symptoms, were hypothesised to be 
significantly associated with neuropsychology - particularly general intelligence (IQ) and 
measures of processing speed. 
 
In line with hypotheses, negative symptoms - as measured by both the Positive and Negative 
Symptoms Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS) - 
were significantly associated with general intelligence (current IQ) in the schizophrenia 
sample; bipolar disorder sample and with both patient groups combined.  These results support 
previous findings in which negative symptoms were reported as being significantly associated 
with impaired general intellectual ability (IQ) in both schizophrenia and bipolar disorder 
(Andreasen et al., 1990; Addington et al., 1991; Strauss, 1993; Berman et al., 1997; Basso et 
al., 1998; Nieuwenstein et al., 2001; de Gracia Dominguez et al., 2009; Leeson et al., 2009; 
Bowie et al., 2010; Lewandowski et al., 2011). 
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As no study investigated general intelligence (current IQ) as a specific outcome measure, 
results could not be directly compared with previously reported findings. Overall however, as 
general intelligence is measured from the summed performances from a variety of tasks tapping 
a number of specific cognitive domains, i.e. memory, attention and processing speed, executive 
function etc., results from this study are in support of previous findings. 
 
Studies investigating clinical symptoms and cognitive function in both schizophrenia and 
bipolar disorder include Krishnadas et al., (2014) who reported that residual negative 
symptoms (as measured by the SANS) mediated a difference in the cognitive performance of 
those with schizophrenia and those with bipolar disorder.  In line with the results from this 
study, both of their patient groups performed worse than healthy controls.  
 
General psychotic symptoms and antipsychotic medication were investigated, however neither 
of these explained this relationship.  A limitation of this study is that a measure of premorbid 
IQ was not gathered which may have been able to help explain differences in cognitive 
performance and is a consideration for future work. 
 
Studies investigating measures of processing speed have reported mixed findings.  A visual 
backward-masking study by Braff (1989) reported impaired visual identification thresholds in 
schizophrenic patients with negative and/or mixed symptomology compared to patients with 
positive symptomology and healthy control participants. Following these findings, Strauss 
(1993) posited that positive and negative symptoms represented different underlying processes, 
with positive symptoms more related to auditory processing deficits and negative symptoms 
more related to visual and/or motor impairments. Buchanan et al., (1997) focussed on 
schizophrenia and negative symptomology. Their participants were split into two groups - those 
with and those without the deficit syndrome (negative symptoms).   
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Participants undertook the Continuous Performance Test (CPT) and the study reported finding 
attentional impairments in those with the deficit syndrome but not in those without. 
 
Cornblatt et al., (1997) failed to find a significant relationship between attention using the CPT 
and either positive or negative symptomology. Their study went on to suggest that attention 
and clinical symptoms were independent and remained independent even after illness onset. 
 
In 2001, Nieuwenstein et al., undertook a meta-analysis of CPT and Wisconsin Card Sorting 
Task (WCST) studies to investigate the relationship between neurocognitive functioning and 
symptom dimensions in schizophrenia and reported a significant relationship between negative 
symptoms and poorer performances on both the CPT and the WCST.  
 
A further meta-analysis conducted by Cohen et al., (2007) investigated the neuropsychology 
of the deficit syndrome in schizophrenia and reported that patients with the deficit syndrome 
(negative symptoms) were globally more neuropsychologically impaired than patients without 
the deficit syndrome. 
 
A recurring limitation in the majority of these studies is the effect of antipsychotic medication 
on task performance. Medication effects were considered from an improvement/recovery 
perspective in one study (Cornblatt et al., 1997) but were not accounted for in any study which 
may have impacted on the reported results. In the meta-analyses the authors reported that most 
of the included studies did not find significant group differences between these variables and 
therefore determined that the impact of these, if any, would be relatively small. Nonetheless, 
antipsychotics commonly produce extrapyramidal symptoms including Parkinsonism which 
can negatively impact fine motor function (D Thomas & Dauner, 1992; Owens, D.C. 2014).   
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Fine motor function is required for the successful completion of a number of 
neuropsychological tasks including the CPT, therefore fully investigating medication effects is 
an important issue to consider. 
 
Negative symptoms are known to correlate in severity with impaired cognition in cross-
sectional assessments and the severity of cognitive impairment and negative symptoms are 
known to be accurate predictors of real-world functional outcome, so much so that if negative 
symptoms are experienced early into illness, the outcome would be expected to be much worse 
(Harvey et al., 2005).  It is also known that negative symptoms can be extremely debilitating 
and their management has proved to be challenging, however negative symptoms are now 
considered as being a separate dimension of psychopathology rather than as a neurochemical 
or structural abnormality (Mitra et al., 2016).  
 
From this study, general intellectual ability (current IQ) was found to be significantly 
associated with negative symptoms, supporting the hypotheses and concurring with the wider 
literature. Future work investigating negative symptoms and specific cognitive domains may 
lead to the identification of new treatment targets, improved management and ultimately 
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5.9.5 Polygenic Risk Profile Scores 
 
In line with hypotheses, polygenic risk for schizophrenia was greater in patients (schizophrenia 
and bipolar disorder together) than control participants with analyses reaching the significance 
threshold.  All analyses controlled for CNT (the number of non-missing SNPs used for 
scoring).  Schizophrenia is highly heritable (Harrison & Owen, 2003; O’Donovan et al., 2009) 
and genetic risk for the later development of schizophrenia is believed to be conferred by a 
large number of alleles – some of which are common alleles which have a small effect (Ripke 
et al., 2014).   It has also been suggested that as much as a half to one third of the genetic risk 
of schizophrenia is linked by common alleles (Ripke et al., 2014).  The result from this study 
was fairly weak (p = .05), however this may be due to the small sample size (schizophrenia 
N=25, bipolar disorder N=16, control participants N=34).  Overall these results are in line with 
the literature and the view from The International Schizophrenia Consortium (2009) that there 
is a substantial polygenic component – made from thousands of common alleles of very small 
effect - which increases the risk of schizophrenia (Purcell et al., 2009). 
 
No differences were identified for either polygenic risk for bipolar disorder or polygenic risk 
for major depressive disorder between the combined patients’ group and control participants. 
However when investigating patients by diagnosis, although not significant, there was a greater 
genetic loading for polygenic risk for schizophrenia within the bipolar disorder sample than 
the schizophrenia sample which was an unexpected finding.  This may be accounted for by the 
fact that the schizophrenia sample included first episode cases, some of whom may since have 
received a diagnosis of bipolar disorder and further, as is the nature of psychiatric nosology, 
some original schizophrenia diagnoses may have changed over the course of this study.   
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Polygenic risk for bipolar disorder was found to be significantly higher in those with bipolar 
disorder compared to those with schizophrenia as well as between the bipolar disorder sample 
and control participants which is in the expected direction. 
 
5.9.6 Polygenic Risk Profile Scores and Neuropsychological Measures – Combined 
 Patients Group 
 
Prior to controlling for CNT, polygenic risk for schizophrenia was found to be significantly 
associated with premorbid to current IQ difference in the combined patients group. Measuring 
the difference between an individuals estimated premorbid IQ and their current IQ is useful 
because although poor cognitive function is known to be a key symptom of major mental illness 
- particularly in schizophrenia - we are able to quantify the extent to which general intelligence 
has reduced (or not) on an individual basis. Although not significant, polygenic risk for 
schizophrenia was also found to be weakly associated with current IQ as well as verbal fluency. 
 
These results are in general supportive of previous findings that suggest polygenic risk for 
schizophrenia is associated with lower general intelligence, for example, Lencz et al., (2014) 
provided molecular genetic evidence of an overlap between risk for schizophrenia and 
cognitive ability.  Their large study reported that individuals with schizophrenia had lower 
cognitive polygenic scores than control participants and that polygenic risk for schizophrenia 
was significantly associated with lower general cognitive performance.  An earlier study by 
Davies et al., (2011), was the first study to show biologically that human intelligence is highly 
polygenic and they also reported that intelligence could be predicted using genetic (SNP) 
information (single nucleotide polymorphism). 
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The combined patients group also revealed a number of associations between polygenic risk 
for major depressive disorder and several cognitive assessments including premorbid to current 
IQ difference, motor speed, verbal fluency and a measure of executive function. To our 
knowledge, this is the first report of a relationship between polygenic risk for major depressive 
disorder and measures of neuro- cognition. Very recently, a large mixed model study by 
Liebers et al., (2016) failed to find any significant relationships between polygenic risk for 
major depressive disorder and any cognitive measure in a sample of healthy older adults. 
 
Although not an observable behavioural study, a significant relationship was previously 
reported between polygenic risk for major depressive disorder and reduced white matter 
integrity in the superior longitudinal fasciculus (SLF) (Whalley et al., 2013).  This region is 
believed to be involved in a number of higher-order cognitive functions including memory, 
motor function and attention (Whalley et al., 2013; Makris et al., 2005), and may relate to a 
range of cognitive deficits often seen in patients as well as unaffected family members who 
carry more common, risk-associated genetic variants for major depressive disorder. 
 
5.9.7 Polygenic Risk Profile Scores and Neuropsychological Measures – Patients by 
 Diagnosis and Control Participants 
 
Looking at the schizophrenia sample, no significant associations were identified between 
measures of cognition and any of the polygenic risk profile scores which was contrary to 
hypotheses.  These results disagree with positive findings reported between general intelligence 
and polygenic risk for schizophrenia (Lencz et al., 2014; McIntosh et al., 2013; Davies et al., 
2011; Hubbard et al., 2015), however studies by Fowler et al., (2012) and van Scheltinga et al., 
(2013) also resulted in non-significant associations between polygenic risk for schizophrenia 
and general intelligence.   
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
201 
  
The negative results here could be due to sample size as the significant associations were 
detected in much larger studies, more likely to be able to detect effects. 
 
Significant relationships were identified in the bipolar disorder sample between polygenic risk 
for schizophrenia and both current IQ and premorbid to current IQ difference.  These results 
are in line with hypotheses and support previous findings which suggest that higher polygenic 
risk for schizophrenia is related to lower general cognitive ability over the lifespan (McIntosh 
et al., 2013). 
 
Increased polygenic risk for schizophrenia has also been reported as being able to predict 
fluctuations in neurocognition in the general population (Hatzimanolis et al., 2015). 
 
Significant associations were also identified in the bipolar disorder sample between polygenic 
risk for bipolar disorder and both current IQ and premorbid to current IQ difference. 
 
Polygenic risk for major depressive disorder, however, was found to significantly associate 
with current IQ, premorbid to current IQ difference, five-choice reaction time and motor speed 
which was an unexpected finding.  As part of additional exploratory analyses, verbal memory, 
verbal fluency and executive function were also found to be significantly associated with 
polygenic risk for major depressive disorder. These results are in line with the previously 
reported results from the combined patients group which also found the majority of significant 
relationships between measures of neuropsychology and polygenic risk for major depressive 
disorder. 
 
For control participants, no significant associations were identified between any cognitive 
assessments and either polygenic risk for schizophrenia or polygenic risk for bipolar disorder. 
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Polygenic risk for major depressive disorder however, was significantly associated with 
attention and processing speed which is in disagreement with the findings from a study by 
Liebers et al., (2016) who found no association between cognition and polygenic risk for major 
depression, however this result does appear to be in line with the findings already reported 
from this study. 
 
Research to identify depression genes has so far failed to identify any genome-wide significant 
SNPs, however recent work by de Moor et al., (2015) reported a genome-wide significant SNP 
located at a novel locus on 3p14 located in MAGI₁ which was found to significantly predict 
neuroticism as well as major depressive disorder. 
 
This gene has previously been associated with schizophrenia, bipolar disorder and episodicity 
in major depressive disorder (de Moor et al., 2015) and may prove to be fruitful for future work. 
 
In this study, polygenic risk for major depressive disorder has been found to correlate with 
impaired IQ and slowed reaction time in patients who are not currently depressed, suggesting 
there may be genetic risk markers in this population which are impacting on cognition. This is 
a novel finding as there is currently no precedent in the literature. These results are not likely 
to be attributable to the effects of medication and suggest there may be a biological component 
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5.9.8 Polygenic Risk Profile Scores: Symptom Severity and Self-Report Questionnaire 
 Data – Combined Patients Group 
 
Polygenic risk profile scores were investigated with clinical symptoms - in particular positive 
and negative symptomology – and additional exploratory analysis investigated data from     
self-report mood questionnaires. 
 
Polygenic risk for bipolar disorder was significantly related to self-reported mania in the 
combined patients group and polygenic risk for major depressive disorder was found to be 
significantly associated with paranoid ideation as measured by the Kings Schizotypy 
Questionnaire (KSQ). 
 
5.9.9 Polygenic Risk Profile Scores: Symptom Severity and Self-Report Questionnaire 
 Data – Patients by Diagnosis and Control Participants 
 
Investigating patients by diagnosis revealed a significant relationship between psychoticism as 
measured by the Eysenck Personality Questionnaire (EPQ) and polygenic risk for major 
depressive disorder in the schizophrenia sample. 
 
Polygenic risk for major depressive disorder was also found to be significantly associated with 
negative symptoms as measured by both the PANSS and the SANS in the bipolar disorder 
sample. 
 
A number of interesting relationships were identified in the control sample. Recurrent illusions, 
a measure captured by the KSQ, was found to be significantly associated with all three 
polygenic risk profile scores.   
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Magical thinking - also measured by the KSQ - was significantly associated with polygenic 
risk for schizophrenia, and although non-significant, magical thinking was also found to be 
weakly associated with polygenic risk for major depressive disorder. 
 
A search of the literature failed to identify any studies that investigated polygenic risk with 
either clinical symptoms or self-reported personality/mood data, therefore we were unable to 
compare these results. 
 
Looking at the individual polygenic risk profile scores in participants who reported 
experiencing recurrent illusions and magical thinking suggests that increasing polygenic risk 
for major psychiatric disorder (schizophrenia, bipolar disorder and major depressive disorder) 
in general is associated with an increased risk of the experience of schizotypal symptoms, in 
particular recurrent illusions and magical thinking. Schizotypy is more commonly identified in 
family members of probands with schizophrenia who have been found to have higher 
schizotypal scores than controls without a family history of schizophrenia (Heron et al., 2003).  
Although it is not uncommon for control participants to report experiencing various schizotypal 
symptoms, it is interesting that significant associations between these ratings and polygenic 




It is acknowledged that when designing a research study, a power calculation should be 
performed to determine an appropriate sample size.  Power calculations allow researchers to 
establish the minimum number of participants they will need to recruit to obtain sufficient 
power for their study (which is usually 80%) (Cohen, J. 1992).   
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Power calculations also help to prevent time wasting and help to save money by identifying 
studies that are potentially underpowered. Power calculations can also prevent too many 
participants from being recruited (Whitley & Ball, 2002).  Retrospectively, a power calculation 
should have been performed for this study, however as discussed previously, due to the nature 
of the DISC1 family, it was necessary to recruit as many family members as possible and 
therefore a power calculation wasn’t performed. For the patient and control groups, sample 
sizes were higher than the DISC1 kindred, having a combined patients group of n = 48 and a 
control group of n = 42 which is similar or higher than comparative studies and as such, any 
effect would hopefully be similar, if not greater without running an actual power analysis. 
 
It is also acknowledged that the patient cases recruited for this study included schizophrenia 
and bipolar disorder only, however this may not have been the best mix of psychiatric 
diagnoses as there are a wide range of diagnoses in the t(1;11) kindred.  Diagnoses include 
schizophrenia, bipolar disorder, schizoaffective disorder, recurrent major depressive disorder, 
single episode depression, cyclothymia and adult conduct disorder therefore including patients 
with major depressive disorder would have been very beneficial and is a consideration for 
future work. 
  
As previously mentioned, a further limitation concerns medication.  29 out of 32 schizophrenia 
cases and 8 out of 16 bipolar disorder cases were taking antipsychotic medication.  Combining 
the various types of antipsychotic medications and their varying doses as chlorpromazine 
equivalents provides a very useful way to examine antipsychotic medications together (Gardner 
et al., 2010).  Direct comparisons were conducted between medication and patient groups with 
no significant results.  Correlational analyses were also conducted to look for any significant 
relationships between medication and any of the clinical or cognitive measures again with no 
significant results. 
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As a result of these preliminary analyses, chlorpromazine equivalents were not included as a 
covariate which in hindsight may have limited the results.  As such, chlorpromazine equivalent 
values should be included as a co-variate in any future work to ensure all potential confounding 
factors are controlled for. This is particularly important when investigating measures that rely 
on fine motor function in view of the commonly produced extrapyramidal symptoms as side 
effects, specifically movement disorders such as Parkinsonism. 
 
An unexpected limitation concerns the patient and control participants themselves, as they may 
not be as representative of these samples as originally intended. Schizophrenic cases appear to 
be relatively cognitively intact which may be as a result of greater premorbid function and 
greater number of years of education/parent’s education. The majority of schizophrenic cases 
were recruited locally from outpatient clinics and from the case loads of psychiatrists at the 
Royal Edinburgh Hospital and they were happy to take part in research, having participated in 
previous studies. The bipolar disorder sample was surprisingly genetic and a number of 
unaffected control participants reported they had experienced schizotypal symptoms.  A 
number of control participants had also previously suffered from depression, however this is 
in line with the prevalence of depression expected in Scotland’s general population (Fernandez-




This is one of the first studies to relate cognition and clinical symptomology to polygenic risk 
profile scores and is also the first study to compare the cognitive and/or clinical effects of 
having a psychiatric illness in general to the cognitive and/or clinical effects of the t(1;11) 
balanced translocation within the DISC1 family without the need for direct statistical 
comparisons between the family, patient and/or control groups. 
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Schizophrenia and bipolar disorder cases were compared using standardised measures as 
provided by the Brief Assessment of Cognition in Schizophrenia (BACS) (Keefe et al., 2008) 
of which to date only four studies could be found (Cholet et al., 2014; Caletti et al., 2013; 
Kuswanto et al., 2013; Hill et al., 2013).  Three of these studies reported robust deficits in 
cognitive function with the greatest cognitive impairment seen in schizophrenia cases, followed 
– where investigated - on a continuum by depressed schizoaffective, manic schizoaffective, 
psychotic bipolar disorder and bipolar disorder. Verbal memory, together with attention and 
processing speed sub-scores were reported to be most severely impaired in schizophrenia, 
however one study (Kuswanto et al., 2013) reported no significant differences in cognitive 
performance between their schizophrenia and bipolar disorder samples, reporting that both 
patient groups suffered a similar degree of cognitive impairment. 
 
Direct comparisons between schizophrenia and bipolar disorder samples in this study for the 
six tasks which make up the BACS identified significantly poorer performances from the 
schizophrenia sample for motor speed (as assessed by a token motor task) and although not 
significant, attention and processing speed (as assessed by a digit symbol coding task) 
marginally missed the significance threshold. These results are in line with previous findings 
using this test battery and provide support for the use of a standardised battery of 
neurocognitive tasks to allow the comparison of future studies assessing cognition in 
schizophrenia and bipolar disorder. 
 
Cognitive impairment is known to be an important predictor of functional outcome (Kahn & 
Keefe, 2013) and has been found to correlate more with functional outcome than symptoms 
(Joyce, 2013), therefore lending itself as a potential treatment target. 
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This notion is gaining momentum, especially as psychological interventions are beginning to 
show that general cognition can be improved in schizophrenia (Joyce, 2013), making it a 
promising and important area for future work. 
 
Polygenic risk for schizophrenia (PGRS) was, as expected, significantly greater for the 
combined patients group compared to control participants and PGRS was also significantly 
associated with measures of neuropsychology in the bipolar disorder sample, particularly 
premorbid and current IQ. For control participants, PGRS was significantly associated with 
schizotypal symptomology, i.e. recurrent illusions and magical thinking – this is an interesting 
finding as it only occurred in control participants suggesting increased polygenic risk for major 
mental illness in general increases the risk of experiencing schizotypal symptoms. 
 
Polygenic risk for bipolar disorder (PGRBD) was significantly greater in bipolar disorder cases 
than schizophrenia or control samples and PGRBD was significantly associated with both 
current IQ and premorbid to current IQ difference in the bipolar disorder sample. 
 
Self-reported measures of personality, together with self-reported and clinically rated measures 
of mood – particularly negative symptoms - were found to significantly associate with 
polygenic risk.  A search of the literature failed to find any similar studies, therefore results 
could not be compared. 
 
Negative symptomology has consistently shown strong correlations with neuropsychological 
dysfunction and is known to be a strong outcome predictor making it a logical target for 
treatment, however future work may also benefit from investigating polygenic risk and clinical 
symptoms. 
 
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
209 
  
Polygenic risk for major depressive disorder (PGRMDD) produced the largest number of 
associations with measures of neurocognition, clinical symptomology and self-reported 
measures of personality. In the combined patients group, PGRMDD was significantly 
associated with premorbid to current IQ difference, motor speed, verbal fluency and executive 
function, while PGRMDD was found to be significantly associated with current IQ, premorbid 
to current IQ difference, five-choice reaction time and motor speed in the bipolar disorder 
sample and with attention and processing speed in the control sample. 
 
Impaired attention and/or measures of processing speed may be pre-existing risk markers for 
the later development of major depressive disorder (Sarapas et al., 2012) and may have a 
biological link to PGRMDD which has been found to be significantly related to measures of 
attention and processing speed across all groups and as such, warrants further investigation. 
 
These novel findings could be accounted for by the fact that schizophrenia, bipolar disorder 
and major depressive disorder are believed to share genetic architecture, therefore future 











































This chapter provides a summary of the aims and key results from this thesis together with 
discussions in relation to the implications of these findings, evidence for and against the DISC1 
gene and the t(1;11) balanced translocation, strengths and limitations of the study, 
considerations for future work and final conclusions. 
 
6.1 Summary of Aims 
 
The primary aims of this thesis were to compare the cognitive, clinical and polygenic profiles 
of family members with and without psychosis to establish the effect, if any, of a rare genetic 
abnormality, believed to increase the risk of major mental illness; the DISC1 t(1;11) balanced 
translocation.  Following the results from previous work, it was firstly hypothesised that 
general intelligence and measures of processing speed would be significantly reduced in t(1;11) 
carriers compared to non-carriers.  It was also hypothesised that clinical symptoms, in 
particular positive and negative symptomology, would be significantly related to 
neurocognition in t(1;11) carriers and finally, it was hypothesised that polygenic risk for 
schizophrenia would be significantly related to measures of cognition as well as clinical 
symptomology, particularly positive and negative symptoms in t(1;11) carriers. 
 
Parallel investigations were conducted between participants with schizophrenia, bipolar 
disorder and unaffected controls.  These samples were recruited to facilitate the comparison of 
the effect of having a major psychiatric disorder in general, to the effect of having the t(1;11) 
translocation without the need for direct statistical analyses.  Direct comparisons were not 
conducted between the t(1;11) kindred and patients primarily due to the potential problem of 
confounders such as shared heredity, age and gender as well as a number of environmental 
factors including geographical location, education and socio-economic status (see 6.6). 
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6.2 Summary of Results: t(1;11) Carriers and Non-Carriers 
 
As seen in the narrative literature review (Chapter 2), a number of studies have investigated 
DISC1 and cognition, but few specifically investigated general intelligence as an outcome 
measure.  Most studies gathered a measure of either premorbid or current I.Q. however 
unfortunately, these data were not comparable due to the variety of methodologies employed.  
Blackwood et al., (2001) reported premorbid I.Q. to be within the normal range in a number of 
family members from the t(1;11) kindred, and it can now be seen from these results that general 
intelligence (current IQ), is particularly impaired in t(1;11) carriers compared to non-carriers.  
This could, of course, be as a result of medication, although correlation analysis did not identify 
any significant associations between general intelligence and CPZ equivalent (antipsychotic 
medication).  Three t(1;11) carriers were also receiving sodium valproate which has been 
reported as having a negative impact on verbal intelligence (Haddad et al., 2009), however the 
points difference in the most impaired t(1;11) case is circa 32 which is unlikely to be the result 
of valproate alone. 
 
These results support an effect of the DISC1 gene firstly by increasing the risk for the later 
development of a major psychiatric disorder by negatively impacting on general intelligence 
developmentally, and secondly, those who carry the rare genetic risk factor (DISC1 t(1;11) 
balanced translocation) could be subjected to a ‘double hit’ on their general intellectual ability 
as not only will their intelligence already have been compromised developmentally, the later 
development of a major mental disorder brings with it the potential of experiencing psychosis 
which, it is known, can result in a further insult on intelligence. 
  
Studies investigating DISC1 and neuropsychology have proved inconclusive.   
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The majority of studies measuring aspects of cognitive function have been genetic in nature, 
designed to identify relationships between relatively common single nucleotide 
polymorphisms (SNPs) or haplotypes with specific cognitive domains. As concluded in 
Chapter 2, DISC1/DISC1 SNPs and/or DISC1 (DISC1/TRAX) haplotypes have shown 
association with a number of cognitive domains, the majority of which utilise a working 
memory component, supporting the neurodevelopmental hypothesis of schizophrenia (Owen 
et al., 2011).  Impaired working memory is likely to have a knock-on effect on other cognitive 
processes, which in turn, are likely to have a negative impact on measures of general 
intelligence (I.Q.).  
 
Reaction time and, in particular, attention and processing speed were consistently found to be 
significantly reduced in this study, which supports the earlier auditory P300 ERP findings 
reported by Blackwood et al., (2001).  In addition to the abnormal P300 findings, these results 
are also in general support of a number of other studies investigating DISC1 and measures of 
cognition including Burdick et al., (2005) in which DISC1 SNPs were associated with a rapid 
visual search task. Visual attention has also previously been reported to associate with a DISC1 
haplotype (HEP3) (Hennah et al., 2005) and Liu et al., (2006) reported an association between 
DISC1 and impaired sustained attention. 
 
Cannon et al., (2005) reported an association between visual reaction time and a rare 4-SNP 
DISC1/TRAX haplotype (‘AATG’) and Palo and colleagues reported an association between 
category fluency and a common DISC1 SNP, namely Ser704Cys (rs821616).  A further 
association was identified in their study with psychomotor processing speed and the DISC1 
SNP, rs980989.  More recently, Nicodemus and colleagues (2014) examined category fluency 
using a novel computational linguistic approach which they reported as being negatively 
associated with the DISC1 SNP, rs12133766. 
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It can be seen from this study that the DISC1 t(1;11) translocation appears to impact upon 
general intelligence and attention and processing speed which are significantly reduced in 
family translocation carriers.  These results support all earlier findings, however as it is known 
that the DISC1 t(1;11) translocation reduces DISC1 protein expression in carriers by 
approximately 50% (Miller et al., 2005), it was not considered appropriate to investigate 
measures of cognition with SNP status.  The marked reductions evidenced in all cognitive 
tasks, however, supports an effect of the t(1;11) balanced translocation and therefore the DISC1 
gene, for increasing the risk of major mental illnesses, in particular schizophrenia, bipolar 
































Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
215 
  
6.3 Summary of Results: Patients and Unaffected Control Participants 
 
Significant cognitive deficits were evident across all tasks between patients (combined patients 
group) and unaffected control participants and a similar pattern of cognitive impairment was 
seen between schizophrenia and bipolar disorder samples.  These results are in line with the 
literature and although a significant difference was not identified between individuals with 
schizophrenia and those with bipolar disorder for general intelligence (current IQ), it could be 
seen that IQ for the schizophrenia sample was most impaired and was lower than in those with 
bipolar disorder which, in turn, was lower than unaffected control participants.  It was also 
noted that the patient samples recruited for this study may not be representative in that the 
majority of individuals with schizophrenia had completed more years of full-time education 
and had better socio-economic backgrounds than most which will be revisited in section 6.6. 
 
A significant difference was identified for psychomotor speed using a token motor task and 
although not significant, a digit symbol coding task to measure attention and processing speed 
marginally missed the significance threshold.  Individuals with schizophrenia demonstrated 
poorer performances for both of these tasks which is as expected and in line with the literature.  
 
This is one of the first studies to relate polygenic risk to measures of neuropsychology and of 
particular interest is the finding that polygenic risk for major depressive disorder was found to 
significantly correlate with impaired IQ and slowed reaction time in patients who were not 
currently depressed.  This suggests there may be genetic risk markers in this population which 
are impacting on cognition. This is a novel finding.  These results are not likely to be 
attributable to the effects of medication and suggest this IQ effect may be one biological 
component related to the genetics of depression. 
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Measures of information processing were found to be significantly related to polygenic risk for 
major depressive disorder in both patient groups as well as with healthy control participants 
suggesting that polygenic risk for major depressive disorder may be a risk factor for impaired 
processing speed as well as the later development of major psychiatric disorder.  Efficient 
information processing has been reported as being a “prerequisite of higher cognitive abilities” 
and is robustly associated with intelligence (Jensen, A. R. 2006).   
 
Research has also proposed that processing speed is associated with white matter integrity and 
polygenic risk for major depressive disorder has also been found to be significantly associated 
with reduced white matter integrity in individuals at high risk of mood disorder (Whalley et 
al., 2015). Polygenic risk for major depressive disorder has also been significantly associated 
with variability in amygdala-medial prefrontal circuitry, and found to be significantly 
associated with impaired social functioning (Holmes et al., 2013). 
 
Further research examining polygenic risk for major depressive disorder with cognitive 
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6.4 Observational Comparison of Results Between t(1;11) Kindred, Schizophrenia and 
Bipolar Disorder Cases 
 
General intelligence (current IQ) was found to be particularly impaired in t(1;11) carriers with 
psychotic disorder (M = 67, SD = 6.2) compared to patients with schizophrenia (M = 103, SD 
= 16.7) and bipolar disorder (M = 105, SD = 18.9).  This observation supports the earlier 
reported family results for an effect of the DISC1 balanced translocation having a negative 
developmental impact on intelligence. These findings could also, however, be the result of the 
effect of medication, as 29 of the 32 schizophrenia cases and 8 of the 16 bipolar disorder cases 
were receiving antipsychotic medication. Although direct comparisons and correlational 
analyses did not identify any significant associations between general intelligence and 
antipsychotic medication (CPZ equivalent), sodium valproate has also been reported to have a 
negative impact on verbal intelligence (Haddad et al., 2009) which may have had an effect on 
these results.  Taking this into consideration, the most cognitively impaired t(1;11) case had an 
I.Q. points difference of circa 32 which is unlikely to be the result of valproate alone.  Overall, 
the indirect comparison of general intellectual ability between the DISC1 t(1;11) carriers with 
psychotic disorder and both patient groups supports an effect of the DISC1 t(1;11) balanced 
translocation negatively impacting on intelligence. 
 
Measures of processing speed were also found to be impaired - more so than the level of 
impairment evident in patients with schizophrenia.  It was interesting to note that contrary to 
the family results, no group effect was evident for patients’ reaction time tasks, suggesting the 
DISC1 effect seen within the family results is an effect of the t(1;11) translocation.  
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These results are also in line with recently published imaging findings from a parallel study 
which reported that the t(1;11) translocation was significantly associated with reduced white 
matter integrity in t(1;11) carriers (Whalley et al., 2015). 
 
Polygenic risk for bipolar disorder was found to be significantly different between DISC1 
family members (t(1;11) carriers and non-carriers) as well as between patients (schizophrenia 
and bipolar disorder samples).  As expected in the patients group, higher polygenic risk profile 
scores for bipolar disorder were evident in those with bipolar disorder. 
 
Within the family, higher polygenic risk profile scores for bipolar disorder were evidenced in 
t(1;11) carriers, suggesting that DISC1 may increase risk for major mental illness, in particular 
schizophrenia, bipolar disorder and major depressive disorder.  It is worth noting that the 
patients included in the bipolar disorder sample in this study were found to be a particularly 
highly genetically loaded group and additionally, the majority of diagnoses within the t(1;11) 
family are affective in nature. 
 
Polygenic risk for schizophrenia, although not significantly different, was higher in t(1;11) 
carriers than non-carriers and similarly in patients, polygenic risk for schizophrenia was also 
higher in cases of schizophrenia compared to bipolar disorder.  These results also support a 
role for DISC1 increasing the risk for major psychiatric illness and with reports that major 
psychiatric disorders, i.e. schizophrenia, bipolar disorder and major depressive disorder, have 
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6.5 DISC1 Challenges 
 
There is a wealth of evidence in support of the DISC1 gene and the DISC1 pathway (Porteous 
et al., 2014).  Additionally, recent work has also re-confirmed the importance of the DISC1 
t(1;11) balanced translocation (Whalley et al., 2015; Thomson, Duff et al., 2016) however, 
DISC1 has not been without its’ challenges – even the name ‘disrupted-in-schizophrenia’ has 
been suggested as being a ‘misnomer’ and ‘prone to misinterpretation’ (Sullivan et al., 2013). 
 
One of the reasons this concern has arisen is because of the range of psychiatric diagnoses 
evident in the DISC1 kindred which range from cyclothymia to schizophrenia.  On the contrary, 
however, this phenotypic pleiotropy of the t(1;11) translocation is precisely what makes the 
DISC1 kindred unique as it has been evident from the first report of the family.  As such, the 
family have provided evidence for genetic and biological overlap between the major 
psychiatric disorders, i.e. schizophrenia, bipolar disorder and major depressive disorder 
(Smoller et al., 2013).  Recent GWAS-derived estimates of co-heritability have estimated 
schizophrenia/bipolar disorder at 0.68; bipolar disorder/major depressive disorder at 0.47 and 
schizophrenia/major depressive disorder at 0.43 (Consortium C-D., 2013) and these estimates 
are entirely consistent with the spectrum of diagnoses seen in the t(1;11) family. 
 
The relevance of the biology of DISC1 to psychiatry and the wider significance of the original 
t(1;11) findings were also challenged (Sullivan et al., 2013).  Their concern revolved around 
the fact that DISC1 fell short in genome-wide association studies (GWAS) – the assumptions 
of which are based on the ‘common disease; common variant’ hypothesis, however DISC1, 
(and other rare variants such as APP, PSEN1 and PSEN2 in relation to Alzheimer’s Disease) 
are all prime examples of the ‘common disease; rare variant’ hypothesis.   
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APP, PSEN1 and PSEN2 are all rare family-based variants which have provided important 
insights into Alzheimer’s disease however, these would have been ignored had the GWAS 
criteria been applied (Porteous et al., 2014). 
  
A further challenge surrounds investigating unique and rare variants and/or mutations in single 
families as they may ultimately be private to the particular family being studied and not to the 
disorder itself, therefore lacking generalisability.  However, as mentioned above, single family 
studies have provided important insights into diseases such as Alzheimer’s (Porteous et al., 
2014). Whalley et al., (2015) have also posited that rare genetic family-specific variants such 
as the DISC1 t(1;11) balanced translocation could be especially useful by helping to explain 
the neurobiology of major psychiatric disorders such as schizophrenia as the result of a less 
complex genetic architecture within families and an increased penetrance at the endophenotype 
level.  Investigating rare mutations and variants such as DISC1 and the DISC1 t(1;11) balanced 
translocation offers an opportunity to help identify specific disease pathways mediated by 
DISC1, and the potential to identify and develop novel pharmacological treatment options 
which could ultimately, effectively reduce the symptoms of psychiatric disorders and greatly 












Investigating the DISC1 t(1;11) balanced translocation was limited by the unavoidably low 
numbers of affected individuals and their non-translocation carrying relatives.  With this in 
mind, being able to recruit a total of 26 family members (carriers N=13, non-carriers N=13), 
each of whom completed all measures required for this work, enabled the identification of a 
large effect of the t(1;11) translocation.  This kindred are unique in nature and research 
opportunities with the family are rare.  A full neuropsychological assessment has never been 
investigated or reported and the findings from this study are novel.  These results provide 
evidence that the t(1;11) balanced translocation effects general intelligence and attention and 
processing speed.  It is hoped that these important factors provide justification for this 
methodological limitation. 
 
Another limitation concerns the investigation of a single family with a single-gene locus as 
although these studies provide important information about a particular group of psychoses and 
help to ascertain whether any such single-gene locus has a major effect on the risk of illness, it 
could well be the case that findings may only relate to that particular family and remain unique 
(Blackwood et al., 2001).  In line with previous research by Blackwood et al., (2001) because 
of the rarity of the translocation it remains important to continue investigations with this family 
to identify any phenotypic differences between family members with and without the 
translocation, as well as between family members and unrelated individuals with major mental 
illnesses including schizophrenia, bipolar disorder and major depressive disorder which was 
the primary reason for recruiting a combined patients group. 
 
A third limitation concerns medication status.   
Cognition in t(1;11) Translocation Carriers and Patients with Psychotic Disorders 
222 
  
From the t(1;11) carriers, two individuals were taking antipsychotic medication together with 
a mood stabiliser, one individual was receiving a mood stabiliser only, and one was receiving 
an antidepressant only. From the patient groups, 29 out of 32 schizophrenia cases and 8 out of 
16 bipolar disorder cases were taking antipsychotic medication. 
 
Combining the various types of antipsychotic medications and their varying doses as 
chlorpromazine equivalents provides a very useful way to examine antipsychotic medications 
together (Gardner et al., 2010).  Direct comparisons were conducted between medication and 
translocation status in the family and between patient groups with no significant results.  
Correlational analyses were also conducted to look for any significant relationships between 
medication and any of the clinical or cognitive measures.  As a result of these preliminary 
analyses, chlorpromazine equivalents were not included as a covariate which in hindsight may 
have limited the results.  Future work should consider including chlorpromazine equivalent 
values as co-variates to ensure all potential confounding factors are controlled for. This is 
particularly important when investigating measures that rely on fine motor function in view of 
the commonly produced extrapyramidal symptoms as side effects, specifically movement 
disorders such as Parkinsonism (Owens, D.C. 2014).  A further consideration concerns the 
potential overlap between negative symptomology and the risk of adverse effects of 
antipsychotic medication.  Although negative symptom ratings were low for the DISC1 family 
(M = 9.6) and also for the patients group (M = 13.2) it should be noted that the benefits of 
antipsychotic medication in relieving the positive symptoms of psychosis can sometimes have 
negative consequences by way of adverse effects such as sedation and movement disorders 
which is another consideration for future work (Arango et al., 2004; Upthegrove, R. 2009; 
Muench et al., 2010). 
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Fourth – it is acknowledged that a power calculation was not performed as this wasn’t deemed 
to be appropriate due to the unique nature of the family and the fact that the aim was to recruit 
as many family members as possible.  It is acknowledged that when designing a research study, 
a power calculation should be performed to determine an appropriate sample size.  Power 
calculations allow researchers to establish the minimum number of participants they will need 
to recruit to obtain sufficient power for their study (which is usually 80%).  Power calculations 
also help to prevent time wasting and help to save money by identifying studies that are 
potentially underpowered and can also prevent too many participants from being recruited 
(Cohen, J. 1992; Whitley & Ball, 2002). Retrospectively, a power calculation should have been 
performed for this study, however as discussed previously, due to the nature of the DISC1 
family, it was necessary to recruit as many family members as possible and therefore a power 
calculation wasn’t performed.  
 
For the patient and control groups, sample size numbers were higher than those for the DISC1 
kindred, having a combined patients group of n = 48 and a control group of n = 42 which is 
similar or higher than comparative studies and as such, any effect would hopefully be similar, 
if not greater without running an actual power analysis. 
 
Another statistical consideration is the presence of outliers.  Outliers were not removed due to 
the low number of cases included in each analysis and they are shown in the main results, 
however analyses were conducted with the main outlier removed in which the result remained 
significant. 
 
It has been noted that the family sample was limited by low numbers and as such, non-
parametric tests were initially considered for the main analyses.   
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As the data were found to be normally distributed and the low sample size prevented the use 
of more rigorous statistical methods, parametric independent samples t-tests, Analysis of 
Variance (ANOVA) and Analysis of Covariance (ANCOVA) were considered to be the most 
appropriate. Non-parametric tests were used where homogeneity of variance was found to be 
violated and also for analysis of the self-reported personality and mood questionnaire data 
which were found to violate assumptions of normality. 
 
A large number of analyses were conducted as part of the main a priori hypotheses and also as 
a result of additional exploratory analyses due to the fact that the family are so rare and 
opportunities to conduct investigations are limited. To reduce the chance of Type II errors, all 
analyses were corrected using the FDR procedure, however it is noted that some studies prefer 
not to correct for multiple comparisons due to the fact that mathematical corrections can 
substantially increase the risk of accepting the null hypothesis (K. J. Rothman, 1990).  These 
calculations reduce the statistical power which in turn can lead to problems interpreting the 
study results therefore in this study, both uncorrected and corrected results are shown. 
 
It has also been noted that the combined patients group, recruited to act as a ‘positive control’ 
group for the t(1;11) family, consisted of individuals with schizophrenia and bipolar disorder 
which, considering a number of family members have diagnoses of major depressive disorder, 
may not have been the best diagnostic split of psychiatric disorders. Diagnoses in the family 
include schizophrenia, bipolar disorder, schizoaffective disorder, recurrent major depressive 
disorder, single episode depression, cyclothymia and adult conduct disorder, therefore in 
hindsight, including patients with major depressive disorder would have been very beneficial 
and is a consideration for future work.  
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A further limitation was the decision not to conduct direct statistical comparisons between the 
family groups (t(1;11) carriers and non-carriers) and the patient groups (schizophrenia and 
bipolar disorder) and/or unaffected control participants.  Research by Glahn et al., (2007b) has 
suggested that family members’ brains are anatomically very similar and that certain areas are 
highly heritable. Shared heredity within the family would significantly confound any direct 
comparisons between these family members and a group of unrelated individuals, which is the 
main reason the patient groups and unaffected control participants were recruited. In addition 
to the shared heredity, other confounding factors include age, geographical location, socio-
economic status, education and employment. Recruiting the patient and control groups allowed 
us to compare the effects of having a psychiatric illness in general to the effects of the t(1;11) 
translocation within the family without the need for direct statistical comparisons.  
 
An unexpected limitation concerns the patient and control participants themselves, as they may 
not be as representative of these samples as originally intended. Schizophrenic cases appear to 
be relatively cognitively intact which may be as a result of greater premorbid function and 
greater number of years of education/parent’s education. The majority of schizophrenic cases 
were recruited locally and were happy to participate in research, having taken part in previous 
studies. The bipolar disorder sample was surprisingly genetic and a number of unaffected 
control participants reported they had experienced schizotypal symptoms. A number of control 
participants had also previously suffered from depression, however this is in line with the 
prevalence of depression expected in Scotland’s general population (Fernandez-Pujals et al., 
2015).  
 
Finally, not having a standardised battery of neuropsychological assessments prevents the 
comparison of results across studies which, if these were able to be compared, may identify 
new treatment targets. 
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6.7 Future Work 
 
Going forward, future studies of the t(1;11) translocation could extend the findings from this 
study in the domains of attention and processing speed and general, especially fluid, 
intelligence.  Being able to administer a non-verbal measure of IQ such as the Ravens Matrices 
(Raven, 1958) or the Culture Fair (Cattell, 1959) would provide a measure of current IQ not 
dependent on language based tasks.  
 
The geographical locations of t(1;11) family members are particularly rural and not 
surprisingly, the majority of family members did not continue education beyond secondary 
school with the majority of occupation categories being either unemployed, manual or skilled 
manual. 
 
Genetic studies may benefit from the creation of a cross-disorder polygenic risk profile score 
as it is becoming more and more evident that the major psychiatric disorders have a shared 
genetic hierarchy.  A cross-disorder risk profile score could then be related to measures of 
neuropsychology within the family which may result in more robust findings. 
 
Future work with patient groups would benefit from the continued investigation of polygenic 
risk with a particular focus on polygenic risk for major depressive disorder which to date has 
not been investigated as much as polygenic risk for schizophrenia or bipolar disorder. Relating 
polygenic risk for major depressive disorder to measures of neuropsychology may replicate the 
findings from this study and/or identify further associations. As no studies investigating 
polygenic risk with clinical symptoms and/or self-reported personality and mood could be 
found, these are areas which may prove to be highly beneficial.   
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Future such studies could also benefit from the creation of a cross-disorder polygenic risk 
profile score in view of the evidence for a shared genetic aetiology for major psychiatric 
disorders.  
 
A recent imaging study by Whalley et al., (2014) reported an impact of cumulative genetic risk 
using a cross-disorder risk profile score generated from the shared genetic effects of five major 




















This first full neuropsychological assessment of the unique DISC1 t(1;11) kindred has provided 
evidence that DISC1 impacts upon general intelligence and attention and processing speed, 
supporting earlier work by Blackwood et al., (2001).  Premorbid to current IQ difference is 
significantly reduced in carriers and current IQ is also particularly impaired in individuals who 
have both the t(1;11) translocation and psychotic disorder, suggesting that DISC1 may increase 
the risk for major psychiatric disorder through an impact on general intelligence and further, 
those who carry the rare genetic risk factor (DISC1 t(1;11) balanced translocation) may be 
subject to a ‘double hit’ as the development of a psychotic disorder would likely result in a 
further insult on intelligence.  Overall these results support the role of DISC1 as a risk factor 
for the development of major psychiatric disorders, in particular schizophrenia, bipolar disorder 
and major depressive disorder. 
 
Polygenic risk for major depressive disorder was found to be significantly associated with 
impaired general intelligence (current IQ) and slowed reaction time in patients who were not 
currently depressed suggesting there may be genetic risk markers in this population which 
impact on cognition.  This is a novel finding and further suggests the possibility of a biological 
component related to the genetics of depression. 
 
This is the first full investigation of the DISC1 t(1;11) translocation and also one of the first 
studies to relate polygenic risk profile scores to measures of cognition.  Results confirm the 
importance of DISC1 for increasing risk of major mental illness and identify promising new 
areas for future research with regard to polygenic risk for major depressive disorder and 
cognition which may aid understanding and help to identify and create new treatment targets 
to improve outcomes for those living with major mental illness. 
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Genotypes of common nonsynonymous variants in DISC1 were extracted from whole genome 
sequencing data. Whole genome sequencing was performed by W. Richard McCombie at The 
Stanley Institute for Cognitive Genomics, Cold Spring Harbor Genomics Centre under an NIH 
grant awarded to W. Richard McCombie and David J. Porteous (CGE, IGMM, University of 
Edinburgh; NIH award R01MH102088). 
 
Briefly, whole genome sequencing of whole blood-derived DNA, or lymphoblastoid cell     
line-derived DNA, was performed on an Illumina HiSeq 2000 at an average read depth of >30x. 
Sequence reads from the Illumina HiSeq 2000 runs were aligned to human genome assembly 
hg19 using the BWA aligner 1, allowing 2 mismatches in the 30-base seed. Alignments were 
then paired, imported to binary (bam) format, sorted and indexed using SAMtools1. Picard was 
then used to fix any mate pair information altered by the sorting. Bamtools2 was used to filter 
alignments to retain only properly paired reads (reads aligned with appropriate insert size and 
orientation). PCR duplicates were removed using Picard. Bamtools2 was then used to select 
alignments with a minimum mapping quality score of 20. Target coverage for each NimbleGen 
exome capture was assessed using Picard’s HSmetrics utility, and both depth and breadth of 
coverage were reviewed for each sample. The Genome Analysis Toolkit3 GATK was used for 
local read realignment around indels, and for base quality score recalibration using corrections 
for base position within the Illumina read, for sequence context, and for platform-reported 
quality.  Variants were filtered for a minimum confidence score of 30, and minimum mapping 
quality of 40.  
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Additional filters were applied for base quality score, strand bias and homopolymer stretches. 
SNP clusters (>3 SNPs per 10 bp window) were excluded. SNPs falling within called indel 
regions were also masked. 
 
Genotypes were checked using Merlin4 to identify errors in Mendelian segregation. Pedigree 
relationships were verified between samples by calculation of identity by state matrices 
between all individuals using a linkage disequilibrium pruned dataset of >100,000 variants in 
PLINK5. 
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Polygenic Profile Scores 
 
Polygenic profiles scores were generated from the whole genome sequencing data using the 
latest Psychiatric Genomics Consortium summary GWAS reference data (SCZ21, BP22, 
MDD13) following Purcell et al. 20094, with the following adjustments. Polygenic profiling 
was performed using PLINK, and as scoring was performed on a single family, no pruning for 
linkage disequilibrium was performed. This is unlikely to have a major effect (see Purcell et 
al., 20094 Supplementary Information).  As recommended by Dudbridge (2013), no p-value 
threshold was applied to the summary data, maximising the information retained. Scores were 
standardise with a mean of 0 and a standard deviation of 1. Higher positive scores represent a 
higher polygenic risk of psychiatric illness. The number of variants scored in each individual 
was retained and used as a covariate in all analyses. 
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